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Abstract
Abstract
The ability of Mycobacterium tuberculosis (Mtb) to be transmitted from host to host is not well 
understood. Previous molecular epidemiology studies have shown that while some clinical strains of 
Mtb are able to cause infection and disease in a large number of individuals exposed to them, others 
are confined in their transmission, despite the ample chance for the spread of the infection. Since 
preventing transmission of Mtb is the key to a continued decline in tuberculosis cases, understanding 
the host and bacterial factors that are associated with transmissibility could be useful in developing 
strategies to prevent transmission.
Previous work has focused on cluster size as a measurable proxy for transmissibility, and several 
studies have found that host risk factors are associated with clustering and cluster size. This thesis 
set out to explore if and what bacterial factors, such as phylogenetic lineage and genomic markers, lie 
behind an increased transmissibility phenotype. We describe a novel approach, called the Propensity 
to Propagate (PPP), with which to adjust for host risk factors when quantifying transmissibility. Using 
this method, we found no significant differences to propagate between four different lineages within 
the Netherlands, as measured by molecular-typing defined cluster sizes. When looking more specifically 
at infectivity (as defined by mean number of positive contacts around each patient) and number of 
secondary cases within two years after diagnosis of an index case sharing the same fingerprint, we 
found evidence of phylogenetic lineage influencing these two indicators, namely, a decreased ability to 
infect and a lower secondary case rate in ancient phylogenetic lineages (Mycobacterium africanum and 
EAI) compared to their modern counterparts (Euro-American, Beijing, and CAS). 
One simple approach to discovering more specific genetic regions behind transmissibility involves 
checking the absence/presence of mutations in the genes of interest between transmissible and non-
transmissible phenotypes. In one of our studies, a multivariate logistic regression-based analysis of 
patient-, microorganism- and disease-related factors failed to reveal any significant association between 
frameshift-causing indels in Mycobacterium cyclase/LuxR-like genes (mclxs) and transmissibility. 
Abstract
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Finally, using a large, well-characterized, complete data set of typed strains to identify strains found 
in large clusters as a proxy for a transmission phenotype as well as related strains that have not been 
transmitted, we selected 100 bacterial isolates after controlling for epidemiologic and host factors 
that may influence transmission. After whole genome sequencing, we subjected them to evolutionary 
convergence analysis. We identified six bacterial DNA regions - espE, PE-PGRS33, PE-PGRS56, Rv0197, 
Rv2813-14c and Rv2815-16c - to be associated with Mtb transmission and validated these regions by 
studying the response of human white blood cells to extracts from a subset of the tuberculosis bacteria 
that carried or did not carry mutations in these DNA regions. We show that there are differences in the 
immune response – as reflected by in vitro monocyte and T-cell cytokine production, reactive oxygen 
species release and neutrophil apoptosis - that associate with these genetic changes.
These findings not only contribute to our understanding of the interplay of bacterial factors in creating 
more successful strains at transmitting, but also have implications in the future of disease surveillance 
and curbing of transmission, by providing for instance tools with which to flag patients carrying 
particularly transmissible strains.
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Resumo
A forma com que a bacteria Mycobacterium tuberculosis (Mtb) é transmitida de um hospedeiro para 
outro não está ainda bem estudada. Estudos de epidemiologia molecular têm demonstrado que, 
enquanto que algumas estirpes de Mtb tendem a  causar infecção e doença num grande número de 
indivíduos, sugerindo uma grande capacidade de transmissão entre estes, outras apresentam uma 
propagação restrita, independentemente de terem elevadas oportunidades de disseminação. Uma vez 
que a prevenção da transmissão da Mtb é fundamental para o declínio continuado da tuberculose, 
o estudo dos fatores bacterianos que estão associados à transmissibilidade poderá ser útil para o 
desenvolvimento de novas estratégias de controlo da tuberculose.
Trabalhos anteriores focaram-se no tamanho dos clusters como medida de transmissibilidade, e vários 
estudos demonstraram uma associação entre os fatores de risco do hospedeiro e o agrupamento 
e tamanho dos clusters. Nesta foi explorada a existência de fatores bacterianos, tais como 
linhagem filogenética ou marcadores genéticos, responsáveis por um fenótipo de maior ou menor 
transmissibilidade. Descrevemos assim uma nova abordagem, chamada propensão para propagar 
(PPP), com a qual é possível corrigir o viés dos factores de risco do hospedeiro na quantificação 
da transmissibilidade de uma estirpe. Ao aplicar este método não foi possível detectar diferenças 
significativas de propagação - considerando o tamanho de clusters definidos por tipagem molecular - 
entre quatro linhagens diferentes presentes na Holanda. Mas uma análise específica da capacidade 
de infetar (definida pelo número médio de contatos positivos de cada doente) e do número de casos 
secundários, no espaço de dois anos após o diagnóstico de um caso índice com o mesmo perfil 
genético, determinou que a linhagem filogenética influencia estes dois indicadores. Concretamente, 
as linhagens filogenéticas mais antigas (Mycobacterium africanum e EAI) apresentam uma menor 
capacidade de infectar e um menor número de casos secundários quando comparadas com as suas 
equivalentes modernas (Euro-Americano, Beijing, e CAS).
Resumo
Resumo
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Uma abordagem simples para identificar regiões genéticas específicas responsáveis pelas diferenças 
na transmissibilidade das estirpes envolve a análise da distribuição de mutações nos genes de 
interesse entre o fenótipo transmissível e o não-transmissível. Neste sentido uma análise baseada em 
regressão logística multivariada de fatores relacionados com o doente, o microorganismo ou a doença, 
não revelou qualquer associação significativa entre frameshift-causing indels (a presença de inserções 
ou deleções nucleotídicas causando a interrupção precoce da grelha de leitura dos genes) em genes 
Mycobacterium ciclase / LuxR-like (mclxs) e a transmissibilidade.
Finalmente, uma grande coleção de isolados bem caracterizados e sujeitos a tipagem molecular foi 
usada para identificar estirpes pertencentes a clusters grandes - representativas de um fenótipo de 
transmissão elevada - bem como estirpes com propagação limitada. Selecionamos 100 estirpes tendo 
em consideração os factores epidemiológicos do hospedeiro com influência na transmissibilidade 
da estirpe. Após sequenciação do genoma, estas estirpes foram submetidas a uma análise de 
convergência evolutiva. Identificamos seis genes/regiões intergénicas - Espe, PE PGRS33, PE PGRS56, 
Rv0197, e Rv2815-16c Rv2813-14c - como estando associados com a transmissão de Mtb, e 
validamos estes resultados através da análise da resposta de leucócitos a extractos de bactérias com 
ou sem as mutações nos seis genes/regiões intergénicas mencionados. Demostramos que existem 
diferenças na resposta imunitária – em termos da produção in vitro de citoquinas pelos monócitos e 
células T, espécies reativas de oxigénio e apoptose de neutrófilos - associadas às alterações genéticas 
estudadas.
As conclusões desta tese não só contribuem para a melhor compreensão da interação de fatores 
bacterianos no estabelecimento de linhagens com uma maior transmissibilidade, como têm 
implicações para o futuro da vigilância e contenção da transmissão, providenciando, por exemplo, 
as ferramentas necessárias para a identificação de doentes portadores de estirpes particularmente 
transmissíveis.
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General Introduction

3General Introduction
1.1 OVERALL INTRODUCTION
Although a largely curable disease, tuberculosis (TB) remains a major cause of morbidity and mortality 
worldwide, with over 8.7 million new cases and 1.4 million deaths in 2011 (World Health Organization 
2015). Caused by Mycobacterium tuberculosis (Mtb), an acid-fast, intracellular bacillus, it is a disease 
predominantly of the lungs (approximately 70% of cases), although Mtb can disseminate to other 
organs, including lymph nodes, bone and meninges (Harisinghani et al. 2000). Following infection, one 
can either spontaneously clear the infection, progress to disease, or remain asymptomatic (latent), a 
result of the inability of the host to eliminate the bacteria but to at least control it’s growth (Stewart et 
al. 2003). Only 5-10% of such latent cases will develop active TB disease in their lifetimes.
The control of the global TB epidemic has been thwarted by the lack of sensitive and rapid diagnostics, 
given that clinical data, albeit important, is insufficient for diagnoses. X-rays cannot exclude 
extrapulmonary TB and may not even be available in countries where resources are limited. Smear 
microscopy of sputum is inexpensive, simple, and results are available within hours, but the sensitivity 
is only about 50-60%, or even lower in countries with a high prevalence of both pulmonary TB and 
HIV infection (Siddiqi et al. 2003). The Tuberculosis Skin Test (TST), in use since 1910, is based on a 
protein–purified derivate resulting from a culture filtrate of tubercle bacilli containing over 200 antigens 
common both in bacilli Chalmette-Guerin vaccine (BCG) and in most non TB bacteria. As such, the test 
specificity is low and also the ability to distinguish latent infections is limited, decreasing its usefulness 
in a high prevalence setting. Newer tests, such as the Interferon gamma release assays (IGRAs), work 
by measuring the interferon gamma cytokine, a proxy of the person’s immune response to the bacteria. 
Even though results are available within 24 hours, and prior BCG vaccination does not cause false 
positive results, IGRAs are most often used in low prevalence resource rich settings due to its high cost 
and necessary laboratory facilities. Discordance between TST and IGRA occurs in 10-20% of individuals, 
but the underlying mechanisms are poorly understood (Jones-Lopez et al. 2015; Ribeiro-Rodrigues et al. 
2014). 
4Chapter I 
Treatment of TB spans four to nine months on a cocktail of various first- and second-line antibiotics, 
depending on whether the disease is active or latent, and on the drug-resistance profile of the strain. 
Treating drug-resistant TB, which does not respond to the main drugs used for TB, requires people to 
endure a longer treatment course of up to twenty pills a day, and in the early stages of treatment, a 
daily injection. The side effects of such treatment are severe and some of the drugs are very expensive.
1.2 THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS  TRANSMISSION
Mtb is transmitted almost exclusively by inhalation of droplet nuclei bearing Mtb particles released 
from the lungs of patients with pulmonary or laryngeal disease. Bacteria that traverse the mouth or 
nasal passages, upper respiratory tract, and bronchi to reach the alveoli of the lung are phagocytised 
by macrophages, where they can initiate rounds of intracellular replication and cell lysis (O’Garra et al. 
2013).
Macrophages are key effector cells in mycobacterial killing, evoking a vigorous host cellular immune 
response involving cytokines and a large number of chemokines. But, they can also provide a niche 
for bacterial multiplication. Dendritic cells then engulf bacteria, or bacterial components, circulate to 
the draining lymph nodes and prime T cells, which then return to the lungs to orchestrate control of 
the infection (Orme et al. 2014). T cells enhance the antibacterial activity of macrophages by releasing 
cytokines, such as interferon-γ, which generally results in arrest or clearance of the infection. If the 
immune response is insufficient to control the initial infection, clinical symptoms and associated 
pathology, including tissue necrosis and cavitation, will develop within ~1 year in the form of primary 
progressive disease. Individuals with cavitary TB are especially infectious (Rodrigo et al. 1997), since 
lung tissue destruction leads to the formation of macroscopic open spaces that contain numerous Mtb 
bacilli and connect to large airways, facilitating efficient expectoration of the bacteria (Kaplan et al. 
2003). 
Several lines of evidence indicate that — in addition to their widely known roles in protecting an infected 
individual from rapidly lethal TB — human T cell responses actually contribute to the lung tissue 
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destruction underlying cavitary TB, thereby enhancing to host-to-host TB transmission. Multiple studies 
have revealed that individuals with TB who are co-infected with HIV have a lower frequency of cavitary 
TB, and a recent systematic review revealed a linear correlation between the number of circulating 
CD4+ T cells and the frequency of cavitary TB (Kwan & Ernst 2011). Indeed, HIV-infected people 
transmit TB less efficiently than do HIV-uninfected people (Kwan & Ernst 2011). It is unclear 
whether the effect of CD4+ T cells on the promotion of cavitary TB is direct or indirect, and the 
mechanisms by which CD4+ T cells contribute to lung tissue damage and cavitary TB are not well 
characterized. 
Compared with many other diseases, the timescales involved in TB are long and there is large variation 
between different individuals. Most individuals in fact develop a T-cell response in the absence of any 
clinical symptoms, which is defined as a latent infection, indicated by a positive TST or IGRA. In latent 
patients, bacteria can persist within infected tissues, such as granulomas, as well as in other sites that 
function to contain bacterial spread (Ramakrishnan 2012). Transmission from latent patients is only 
possible if there is reactivation of the initial infection (Silva Miranda et al. 2012). Isoniazid preventive 
therapy – the use of isoniazid monodrug therapy to interrupt progression from latent infection to active 
TB – helps in avoiding patients from transmitting in the future (Churchyard et al. 2014; World Health 
Organization 1982).
In most instances, patients respond to antibiotic treatment by clearance of the bacilli from tissues, 
partial reversal of the granulomatous process, and clinical cure. As such, starting appropriate therapy 
as early as possible not only contributes towards more timely curing of the patient, but also makes it 
less likely for drug resistance to develop and for the bacteria to be transmitted. 
Prior vaccination with BCG, a live attenuated strain that is closely related to Mtb, establishes a primed 
population of T cells and protects against severe childhood forms of disease, including milliary and 
extrapulmonary TB and the often fatal TB meningitis (Roy et al. 2014). It also confers protection 
against leprosy. With a long-established safety profile and inexpensive cost, it remains the most widely 
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used vaccine in the world, currently compulsory in ≥64 countries and administered in >167 countries 
(Zwerling et al. 2011). However, the level of protection conferred by BCG is extremely variable, differing 
by target population given to, form of pulmonary TB and whether there is HIV co-infection. The reason 
for this remains a topic of active research — one of the hypotheses gleaned from newer genomic 
evidence points to differences between the BCG strains themselves, which have evolved from the 
original variant used in 1921 (Behr 2002). Meanwhile, a vaccine with reliable efficacy in preventing 
transmission of the infection does not yet exist (Franco-Paredes et al. 2006).
1.3 DETERMINANTS OF TRANSMISSION
An extensive crosstalk between internal (bacterial) and external (host and environmental) factors may 
influence the success of the bacteria in transmitting.  
1.3.1 ENVIRONMENTAL
For centuries, TB has been linked anecdotally with environmental risk factors that go hand-in-hand 
with poverty, such as crowded housing and inadequate ventilation (Beggs et al. 2003; Schmidt 2008), 
associations that have been confirmed even in more developed settings (Baker et al. 2008; Wanyeki 
et al. 2006). Both factors increase the likelihood of transmission by either increasing exposure to the 
bacteria or by insufficient dilution and removal of infectious droplet nuclei from the air. Factors reflective 
of the level of healthcare accessibility, such as delay in diagnosis or ineffective treatment (either due 
to non-compliance or sub-optimal drug regimen), are also responsible for prolonging the period of 
infectiousness of the host, thus increasing potential exposure to others.
1.3.2 HOST
Comorbid conditions that dampen the host immune system, such as HIV co-infection, anti-TNF 
treatment, diabetes mellitus and malnutrition, have all been identified as risk factors for transmission 
(Kwan & Ernst 2011; Ali 2013; Qu et al. 2012; Cegielski & McMurray 2004). Demographic factors and 
risky social behaviors engaged by hosts, such as smoking or alcohol/drug addiction, have also been 
shown to contribute towards increasing the likelihood of transmission (Godoy et al. 2013; Nava-Aguilera 
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et al. 2009; Boum et al. 2014). Even in the absence of any of the above, various lines of evidence 
indicate that genetic factors partly determine differences in host susceptibility to mycobacterial 
infection (Schurr 2011). A family-based study in a hyperendemic area for TB with a sub-population that 
shows persistent lack of TST reactivity (thus appearing to be naturally resistant to infection by Mtb) 
has identified major loci in different chromosomal regions purported to influence T cell-dependent 
responses to tuberculin (Cobat et al. 2009). Gene expression analyses performed in TB patients versus 
uninfected healthy controls have also defined biomarkers predictive of susceptibility (Bellamy et al. 
1998; Milano et al. 2016; Maertzdorf et al. 2011). Furthermore, gene expression levels in ex vivo Mtb-
stimulated macrophages have revealed two cytokine genes (IL17 and IL6) associated to pulmonary 
manifestation of disease, rather than the meningeal or latent forms (Thuong et al. 2008).
1.3.3 BACTERIAL
Some strains may be inherently more transmissible than others, perhaps because they are particularly 
likely to give rise to sputum smear–positive disease, they are associated with a more insidious onset 
of clinical symptoms (so patients are infectious for longer), or the strains are more virulent and are 
therefore more likely to give rise to secondary cases within the period studied. A strain’s overall 
propensity to transmit can be broken down into further components, such as infectivity (the ability 
of the bacteria to survive its aerosolized stage and reach the alveoli of the host) and breakdown to 
disease (also referred to as pathogenicity or virulence). 
There have been studies suggesting that certain differences in the apparent virulence of specific 
Mtb strains can be explained by the genetic variability of the organism, such as by Rhee et al., which 
looked for associations between three katG-463 and gyrA-95 genotypes and the epidemiologically 
and clinically measured properties of infectivity and pathogenicity in a population-based sample of 
TB patients (Rhee et al. 1999). There have only been a couple of other studies aimed at identifying 
genomic markers for overall increased transmissibility. In 2007, Talarico et al. showed that PE_PGRS33 
alleles that would result in a significant change to the PE_PGRS33 protein due to large insertions/
deletions or frameshift mutations were significantly associated with clustering based on genotype 
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and absence of cavitations in the lungs, compared to isolates having PE_PGRS33 alleles that would 
result in no or minimal change to the PE_PGRS33 protein. A later study by the same author comparing 
the genomic content of one strain from a large cluster to that of a non-clustered strain from the same 
community identified 25 genes that differed between the two strains, potentially contributing to the 
observed differences in transmission (Talarico et al. 2007; Talarico et al. 2011).
Phylogenetic lineages, a form of bacterial variation reflecting adaption to populations from different 
parts of the world, have also been shown to have epidemiological and clinical implications. Based 
on the genotype, Mtb has seven lineages: three ‘ancient’ (lineage-1 and two Mycobacterium 
africanum lineages), and three ‘modern’ (lineages-2, 3, 4) (Comas et al. 2009) and one intermediate 
(lineage-7), recently described in Ethiopia (Firdessa et al. 2013). Several population-based studies have 
used genotypic clustering as a proxy for transmissibility between different phylogenetic lineages (Buu 
et al. 2012; J. Anderson et al. 2013; Toungoussova et al. 2003; Hanekom et al. 2007). As an example 
selected from many others, particular sublineages of lineage 4 (Euro-American) have been shown to 
have an increased ability to cause secondary cases as determined by genotypic clustering (J Anderson 
et al. 2013). Other lineages have been associated to a particular site of disease, such as the East 
African Indian and Indo-Oceanic lineages, both associated to extrapulmonary manifestation (Click et al. 
2012). Eighty percent of strains from modern Beijing sublineages, but not from ancient sublineages, 
have been found to synthesize relatively high quantities of phenolic glycolipid (PGL), which suppresses 
proinflammatory cytokines. While this is suggestive that modern sublineages are more pathogenic, 
molecular epidemiologic studies on the transmissibility of the Beijing lineage have been contradictory 
so far. 
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1.4 IMPLICATIONS ON TUBERCULOSIS CONTROL EFFORTS
Continued investigations of the association between bacterial genotypes (be it phylogenetic lineages, or 
presence/absence of genetic variations) and epidemiologically defined phenotypes (i.e. transmissibility, 
infectivity, pathogenicity) may: 
1. Contribute to our understanding of the interplay of bacterial factors in creating more successful 
strains at transmitting.
2. Provide tools for disease surveillance and curbing of transmission in a population by flagging 
patients carrying particularly transmissible strains:
• Intensifying contact tracing efforts around such patients. 
• Offering specific preventive measures to such patients i.e. patients with cavitary 
pulmonary TB receiving anti-TB medications supplemented with nebulized interferon-
gamma have been found to have fewer bacilli in the lungs and less inflammation, thereby 
reducing the transmissibility of Mtb in the early phase of treatment (Dawson et al. 2009). 
1.5 METHODS USED TO MEASURE AND MAP TRANSMISSION 
1.5.1 MOLECULAR TYPING METHODS 
Molecular epidemiology of TB emerged in the early 1990s thanks to the development of DNA 
fingerprinting techniques, such as restriction fragment length polymorphism (RFLP) of the insertion 
sequence (IS) 6110 and variable number of tandem repeats (VNTR). In the former, the number of 
IS6110 copies, a repetitive, mobile insertion sequence element of 1.35 kb (McAdam et al. 1990), 
varies from zero to about 25 per strain. This variation in insertion sites means IS6110 typing yields 
thousand of different banding patterns. VNTR typing utilizes locus-specific primers to amplify an 
unknown number of tandem repeats at 24 different sites, resulting in varying amplicon lengths for 
each. Since specificity seems to be comparable to IS6110 RFLP (de Beer et al. 2013), and it is faster 
and cheaper to perform (Allix-Béguec et al. 2008), VNTR typing has become the new standard in public 
10
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health applications of Mtb in the USA, Europe, and other parts of the world. Spoligotyping, a rapid, 
polymerase chain reaction (PCR)-based method that detects the presence of 43 unique DNA sequences 
interspaced between 36-base pair repeats in the DR (direct repeat) locus of Mtb complex isolates, is 
also widely used and highly reproducible (Driscoll 2009).
Based on comparisons of these markers of Mtb isolates from different patients, the resultant 
fingerprints can be classified as being either ‘clustered’ or ‘unique’. Individuals with identical or similar 
fingerprint patterns (i.e. up to 1 site with a different amplicon length in VNTR) are considered to be 
‘clustered’. Clustered TB patients are believed to be involved in recent transmission chains, while 
patients with unique isolates are more likely to have reactivated TB acquired in the past.
Genotypic tools can therefore provide novel insight into Mtb transmission by identifying clusters of 
active cases and getting a sense via clustering rates (% of isolates that are clustered out of the total 
number of isolates) of how much transmission is occurring in a particular setting and over time (Adams 
et al. 2012; Tuite et al. 2013; Ferdinand et al. 2013). In the Netherlands, genotypic clustering has been 
shown to have steadily decreased over the years, from above 40% in 1993 to around 30% in 2008 
(unpublished data). Clustering rates can also highlight increased transmission in specific higher –risk or 
immigrant sub-populations (Rossi et al. 2012; Iñigo et al. 2007).
Several population-based studies have used genotypic clustering as a proxy for transmissibility between 
different phylogenetic lineages (Buu et al. 2012; J. Anderson et al. 2013; Toungoussova et al. 2003; 
Hanekom et al. 2007). Findings from these studies have been varied and non-conclusive so far, most 
likely reflecting differences in other factors affecting transmission between different settings.
1.5.2 CONTACT TRACING
Genotyping of Mtb is also used to support contact tracing and source case finding, a form of active 
case detection (via interviews) entailing the systematic evaluation of the contacts of known TB patients 
to identify active disease or latent TB infection. Traditional contact tracing focuses on smear-positive 
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(defined by the presence of at least one acid fast bacilli (AFB+) in at least one sputum sample) adult 
index TB cases, as these are the most infectious. The primary goal is the early diagnosis and treatment 
of contacts with disease, both interrupting ongoing transmission and reducing morbidity and mortality 
in affected individuals. This strategy may be worthwhile in contacts (i.e. household) of patients with TB 
because they are at higher risk of TB (having had prolonged exposure and shared environmental risk 
factors with the index case) than members of the general population (Greenaway et al. 2003; Fox et 
al. 2013). Contact investigation has been widely implemented in high-income countries for decades 
(Erkens et al. 2010). Recently there has been a growing interest in it also being performed in resource-
limited settings, as national programs seek new methods for improving case detection (Fox et al. 
2012; Shapiro et al. 2012). Used as a parallel tool to fingerprinting data by confirming or disputing the 
epidemiologic link between two patients (Lambregts-Van Weezenbeek et al. 2003), it helps by pointing 
towards potential secondary cases whose recent infection may be subsequently confirmed via the 
application of immunological tests, such as TST and IGRAs.
1.5.3 IMMUNOLOGICAL MARKERS OF TRANSMISSION
TST and IGRAs are ‘indirect tests’ designed to detect latent TB infection, that is, they do not detect the 
actual bacilli but instead an immune response that suggest past or present exposure to Mtb bacilli. 
TST conversion – where a result changes from “negative” (typically 0-4mm diameter induration) to 
“positive” (typically equal to or >10mm diameter induration) within a 24 month period - may therefore 
be used as a proxy measure of infection, by calculating the proportion of contacts that started with a 
negative result and converted to positive during a determined follow-up period. This method has been 
used to find out whether transmission has taken place in certain settings i.e. health-care associated 
workplaces (Reynolds et al. 2006; Lee et al. 2005) as well at to identify populations that are at highest 
risk for being infected (Sherman et al. 2011). Both tests are however better suited to low prevalence 
settings where BCG vaccination, which may give a false positive result on the TST, is not routinely used.
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1.5.4 WHOLE GENOME SEQUENCING
More recently, the exponentially falling cost of whole genome sequencing (WGS) has turned it into 
an increasingly accessible tool in epidemiologic studies. Since it monitors all variation in a bacterial 
genome it therefore has the highest level of discriminatory power that is possible at the DNA level. 
For example, in an investigation of a crack cocaine related outbreak in Vancouver, Canada, Gardy et 
al. demonstrated the value of performing WGS on all the Mtb isolates in the outbreak.  While MIRU-
VNTR grouped the isolates into a single genotype, WGS showed that there were really two concomitant 
outbreaks with two distinct strains that had evolved from a common ancestor and kept the same 
MIRU-VNTR genotype (Gardy et al. 2011). More recently, a threshold number (i.e. below five) of single 
nucleotide polymorphisms (SNPs) between strains has been shown to translate into an epidemiological 
link, whilst stains differing by more than 12 SNPs reflect unlinked cases (Walker et al. 2013). In a 
subsequent study of transmission epidemiology, Walker et al used WGS to analyze all available isolates 
from Mtb cases in Oxfordshire, UK from 2007 – 2012.  Although they used a cut-off of 12 or fewer 
SNP differences to define clustered strains, the differences within the clusters ranged from zero to 
just 7 SNPs, with a median of 1 SNP difference (Walker et al. 2014). Tracing outbreaks by genome 
analysis of SNPs is therefore more discriminative than any of the more traditional methods (IS6110 
RFLP, spoligotyping and MIRU-VNTR), but the process is still poorly standardized, and because each 
lab can use one of several available bioinformatics program, it is hard to compare results from studies 
performed in different labs.  
1.6 THE NETHERLANDS: A SETTING CONDUCIVE TO STUDYING TRANSMISSION
Since 1993, patient epidemiological data and DNA fingerprints of virtually all Mtb complex isolates have 
been stored in a database at the National Institute for Public Health and the Environment (RIVM; Bilthoven) 
and the National Tuberculosis Register (NTR) of the Netherlands. Both IS6110 restriction fragment length 
polymorphism (RFLP) and 24-locus variable-number tandem-repeat (VNTR) typing are routinely performed, 
the discriminatory power and agreement of findings between both methods of which were evaluated in 2013 
(de Beer et al. 2013). Systematic contact investigations around source cases are also routinely performed by 
the TB Public Health Services, and the TST test used to investigate presumably exposed contacts.
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Given this wealth of data, multiple studies on the epidemiology of TB in the Netherlands have 
been generated. The observed declining incidence over the past decade, for example, has been 
attributed to older birth cohorts with high infection prevalence being replaced by those with lower 
infection prevalence (Borgdorff et al. 2005). Prevalence among immigrants has been associated with 
immigration figures (numbers of incoming people), (Borgdorff et al. 2010) and host risk factors, such 
as young age (<35 years) and geographic origin of first patients in a DNA fingerprint cluster, have been 
shown to be predictors of outbreaks (Kik et al. 2008).
WGS has also featured in more recent publications, such as in an outbreak investigation of over 100 
cases beginning in the Dutch city of Harlingen in 1992 and extending through 2008. Most of the 
strains had identical IS6110 RFLP patterns, making it impossible to identify the sources of infection or 
routes of transmission. WGS of three of these isolates identified eight polymorphic SNPs specific for 
the Harlingen strains. By tracing the evolution of the nucleotide changes in these eight positions, the 
isolates of the Harlingen cluster could be divided into five SNP clusters, with the earliest isolate in each 
cluster defined as the index case, defined as the earliest isolate in each SNP cluster, from which the 
subsequent chains of transmission events could be delineated (Schürch et al. 2010).
The low TB prevalence setting of the Netherlands presents itself as an advantage in the study of 
the role of genotype on transmission, since it is less likely to be confounded by a high background 
infection pressure, where a TST result is more likely to fail at distinguishing recent from past infection. 
Furthermore, in the Netherlands there is no routine BCG vaccination program that could affect the 
interpretation of TST results, making TST a suitable tool for the detection of Mtb infection in contact 
investigations, particularly amongst the native population. The importance of a bacteriological 
component in TB transmission was first addressed in a study from 2011, where it was found that large 
clusters were independently associated with an increased number of TST positive contacts, suggesting 
that the spread of Mtb also depends on bacteriological factors (Verhagen et al. 2011).
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1.7 RESEARCH QUESTIONS
The discovery of genotypic markers associated with increased transmissibility in Mtb would represent 
an important step in advancing mycobacterial virulence studies. In contrast to our understanding of 
host and environmental influences on infection and disease, there is a lack of systematic information 
on the influence of the genetic diversity of the pathogen itself that may provide important clues 
for basic and applied research on TB and its relation with the human host. This thesis focuses on 
addressing some of the gaps in our knowledge of bacterial factors behind transmissibility, such as: 
• How can we control for host-related factors in measuring the “transmissibility” of Mtb, 
and are there any differences between phylogenetic lineages once these factors are 
adjusted for?
• Are there any differences in the infectivity and pathogenicity of different phylogenetic 
lineages of Mtb?
• Do variations in Mycobacterium cyclase/LuxR-like (mclx) genes play a role in virulence-
related fitness and host adaptation ability to the host?
• Can we identify SNPs and genes associated to transmissibility? And if so, do we find 
biological correlates of their interaction with the human immune system?
1.8 THESIS OVERVIEW
Chapter 2 describes a new method to improve proxy measures of “transmissibility” by adjusting for 
patient-related factors, thus strengthening the causal association found with bacterial factors. 
Chapter 3 looks more closely at the “transmissibility” phenotype, breaking it down into the bacteria’s 
ability to spread or progress to disease, and explores any differences in these by phylogenetic lineage.
The study in chapter 4 aims at correlating genetic variation (in mclx genes) with phylogenetic and 
epidemiological characteristics, including transmissibility, of Mtb strains. 
Chapter 5 describes the application of evolutionary convergence analysis to identify SNPs/genes 
associated with “transmissibility” in Mtb. 
In chapter 6, the general discussion chapter, the implications of these studies are discussed.
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Introduction
Transmission of Mycobacterium tuberculosis (MTB) occurs through
aerosol droplets. Subsequent cases in transmission chains result in
‘‘clusters’’ of patients who share Mtb strains of the same genotype
or molecular fingerprint [1]. Cluster sizes vary widely, which may
reflect the fact that strains do not spread equally or that they differ
in their rate of progression to active TB disease. The identification
of strains that cause large tuberculosis (TB) outbreaks, such as
CDC1551 or Harlingen [2,3], has lead to studies on the virulence
of such strains. Indeed molecular epidemiologic studies have
suggested that some strains are more successfully transmitted than
others [4–6]. The mechanisms however governing this variability
remain largely unknown, with much research focused on the
contribution of host risk factors. In the Netherlands for example,
age, sex, homelessness, alcohol or drug abuse, living in an urban
area and smear positivity have all been associated to increased
transmissibility [7]. There is substantial evidence however to
suggest that bacterial factors also contribute to variability in cluster
size and the extent of transmission of TB. For example, Verhagen
and colleagues showed that newly diagnosed index cases in a
larger cluster infected more people than did newly diagnosed cases
in smaller clusters [8]. This implies that clusters not only grow over
time because of well-known patient risk factors for TB transmis-
sion, but also because the strain itself generates an increased
number of tuberculin skin test-positive contacts, and spreads more
effectively than other strains.
Phylogenetic lineages reflect evolutionary divergence associated
with different geographical regions [9]. Beijing lineage strains, for
example, are predominantly found in Asia, yet are widely
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Introduction
Transmission of Mycobacterium tuberculosis (MTB) occurs through
aerosol droplets. Subsequent cases in transmission chains result in
‘‘clusters’’ of patients who share Mtb strains of the same genotype
or molecular fingerprint [1]. Cluster sizes vary widely, which may
reflect the fact that strains do not spread equally or that they differ
in their rate of progression to active TB disease. The identification
of strains that cause large tuberculosis (TB) outbreaks, such as
CDC1551 or Harlingen [2,3], has lead to studies on the virulence
of such strains. Indeed molecular epidemiologic studies have
suggested that some strains are more successfully transmitted than
others [4–6]. The mechanisms however governing this variability
remain largely unknown, with much research focused on the
contribution of host risk factors. In the Netherlands for example,
age, sex, homelessness, alcohol or drug abuse, living in an urban
area and smear positivity have all been associated to increased
transmissibility [7]. There is substantial evidence however to
suggest that bacterial factors also contribute to variability in cluster
size and the extent of transmission of TB. For example, Verhagen
and colleagues showed that newly diagnosed index cases in a
larger cluster infected more people than did newly diagnosed cases
in smaller clusters [8]. This implies that clusters not only grow over
time because of well-known patient risk factors for TB transmis-
sion, but also because the strain itself generates an increased
number of tuberculin skin test-positive contacts, and spreads more
effectively than other strains.
Phylogenetic lineages reflect evolutionary divergence associated
with different geographical regions [9]. Beijing lineage strains, for
example, are predominantly found in Asia, yet are widely
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disseminated and present in more countries than any other lineage
strain. This suggests that this evolutionary lineage may have
evolved unique properties leading to its successful clonal expansion
[10,11]. To date, studies examining the association between
phylogenetic lineages of MTB and transmissibility have typically
used DNA fingerprinting clustering rates as measures of transmis-
sibility, with very few adjusting for host-related factors.
Since preventing transmission of MTB is key to a sustained
decline in TB incidence, understanding the genetic variations
between strains with differential ability to transmit would be a
major step forward. In order to distinguish bacterial factors
associated with transmission from those that pertain to the host
however, the influence of host-related factors needs to be
addressed. In the Netherlands, a nationwide surveillance of TB
including structural DNA fingerprinting of all M. tuberculosis
isolates has been in place since 1993. Patient information is
available for all registered TB cases, of which there are
approximately one thousand per year. Here, we describe a
method to complement and extend the conventional use of cluster
size and proportion of cases in a cluster as proxy measures of
transmissibility by adjusting for patient related factors, thus
strengthening the causal association found with bacterial factors.
Since cluster size may reflect both the propensity of a strain to be
transmitted and to cause disease given an infection, we have
chosen to use the term ‘‘propagation’’ instead of transmissibility as
a more accurate description of cluster growth.
Methods
Data Collection and DNA Fingerprinting
The National Institute for Public Health and the Environment
(RIVM) in Bilthoven, The Netherlands, serves as a reference
laboratory for the secondary laboratory diagnosis of all TB cases in
The Netherlands, offering identification, drug susceptibility
testing, and molecular typing. DNA fingerprints of all nationwide
MTB complex isolates and their cluster status have been stored in
Figure 1. Flow-diagram of exclusion criteria applied to dataset.
doi:10.1371/journal.pone.0097816.g001
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a RFLP database since 1993. The Registration Committee of the
Netherlands Tuberculosis Register (NTR) approved this retro-
spective study and provided demographic and clinical information
for patients. Because these data are de-identified by name, DNA
fingerprinting results from the RIVM were linked on the basis of
sex, date of birth, year of diagnosis and postal code. All notified
MTB culture-positive cases between 1993 and 2011 were included
in the study. In case of patients with multiple isolates, only the
isolate with the earliest date of diagnosis was included. Contam-
inated isolates were excluded from the database.
Isolates recovered from patients between 1993 and 2009
underwent IS6110 and polymorphic GC-rich sequence (PGRS)
restriction fragment length polymorphism (RFLP) typing
(n = 15,073), and those from 2004 onward to variable number of
Table 1. Host risk factors for clustering of MTB in the Netherlands, 1993–2011.
No. (%) in clustering state:
Category and case group Clustered Non-clustered OR (95% CI)
Adjusted OR (95%
CI)
Sex Males 5385 (60.8) 3474 (39.2) 1 (Ref) 1 (Ref)
Females 3200 (53.5) 2779 (46.5) 0.74 (0.70–0.79) 0.87 (0.81–0.93)
Age at diagnosis (years) 0–15 366 (69.2) 163 (30.8) 1.28 (1.11–1.56) 1.05 (0.86–1.29)
16–30 3383 (63.7) 1929 (36.3) 1 (Ref) 1 (Ref)
31–45 2485 (60.9) 1593 (39.1) 0.89 (0.82–0.97) 0.86 (0.78–0.94)
46–60 1254 (59.5) 852 (40.5) 0.84 (0.76–0.93) 0.77 (0.69–0.86)
61–75 715 (45.1) 871 (54.9) 0.47 (0.42–0.52) 0.40 (0.35–0.45)
76–90 370 (31.6) 800 (68.4) 0.26 (0.23–0.30) 0.19 (0.17–0.23)
.90 12 (21.1) 45 (78.9) 0.15 (0.08–0.29) 0.12 (0.06–0.22)
Disease Classification Pulmonary 5107 (61.6) 3187 (38.4) 1 (Ref) 1 (Ref)
Extrapulmonary 2465 (51.2) 2347 (48.8) 0.66 (0.61–0.70) 0.76 (0.69–0.83)
Pulmonary-extrapulmonary 1013 (58.5) 719 (41.5) 0.88 (0.79–0.98) 0.90 (0.80–1.01)
Smear-positivity No 5068 (54.7) 4205 (45.3) 1 (Ref) 1 (Ref)
Yes 3517 (63.2) 2048 (36.8) 1.43 (1.33–1.53) 1.17 (1.07–1.27)
Alcohol consumption No 8426 (57.6) 6200 (42.4) 1 (Ref) 1 (Ref)
Yes 159 (75.0) 53 (25.0) 2.20 (1.61–3.01) 1.29 (0.92–1.80)
Drug-use No 8213 (57.0) 6193 (43.0) 1 (Ref) 1 (Ref)
Yes 372 (86.1) 60 (13.9) 4.67(3.55–6.15) 2.75 (2.05–3.67)
Homelessness No 8362 (57.4) 6198 (42.6) 1 (Ref) 1 (Ref)
Yes 223 (80.2) 55 (19.8) 3.0 (2.23–4.04) 1.58 (1.15–2.18)
Health-care worker No 8463 (57.8) 6187 (42.2) 1 (Ref) 1 (Ref)
Yes 122 (64.9) 66 (35.1) 1.35 (1.00–1.83) 1.00 (0.73–1.38)
Traveler to endemic areas No 8423 (58.0) 6090 (42.0) 1 (Ref) 1 (Ref)
Yes 162 (49.8) 163 (50.2) 0.72 (0.58–0.90) 0.58 (0.46–0.73)
Origin Native Dutch 2343 (58.4) 1667 (41.6) 1 (Ref) 1 (Ref)
Foreign-born (Asia) 1247 (39.0) 1949 (61.0) 0.41 (0.37–0.45) 0.28 (0.25–0.31)
Foreign-born (Africa) 3253 (65.0) 1749 (35.0) 1.18 (1.09–1.29) 0.76 (0.69–0.84)
Foreign-born (America) 704 (72.1) 273 (27.9) 1.64 (1.41–1.91) 1.06 (0.90–1.25)
Foreign-born (Europe) 415 (53.1) 366 (46.9) 0.72 (0.62–0.84) 0.43 (0.37–0.51)
Total cases 8585 (57.9) 6253 (42.1)
OR, odds ratio; CI, confidence interval; Statistically significant OR are highlighted in bold.
doi:10.1371/journal.pone.0097816.t001
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tandem repeat (VNTR) typing (n= 5,870) [12,13], In the period of
2004–2008 both RFLP and VNTR typing were performed [14].
In addition, 4,433 randomly selected isolates were spoligotyped.
We defined a cluster as groups of patients who shared TB isolates
with identical RFLP or VNTR patterns or, if strains had fewer
than five IS6110 copies, identical PGRS RFLP patterns [15].
Classification into phylogenetic lineages
The phylogenetic label of a spoligotyped isolate was used to
infer the lineage of isolates belonging to the same RFLP or VNTR
cluster as the spoligotyped isolate. Following this, the MIRU-
VNTRplus online tool was used to perform MIRU Best Match
Analysis (stringent cut-off of 0?17) followed by MIRU Tree-based
identification to identify the phylogenetic lineages of strains with
MIRU patterns [16]. Resulting matched phylogenetic lineages
from clustered isolates were extrapolated to the remaining isolates
of the respective clusters. Remaining strains without an inferred
lineage were assigned one on the basis of RFLP similarity ($80%)
to a reference dataset of pre-identified strains with RFLP patterns
in a tree generated by the neighbor-joining method with the
Kimura 2 parameter on BioNumerics software for Windows
(version 6?6, Applied Maths). The same procedure was repeated
for strains with RFLP PGRS patterns. Finally, any remaining
MIRU-typed strains without an inferred lineage were subjected to
MIRU Best Match Analysis (relaxed cut-off of 0?3). This was
purposely left as the last in the series of steps for the classification of
lineages as it is the least optimized for minimizing fine-tuned
mismatching that can occur as an exception among strains
belonging to the Euro-American family [17].
Four major phylogenetic lineages were identified: Euro-Amer-
ican, Central Asian Strain (CAS), East-African-Indian (EAI) and
Beijing (Table S1). Strains not assigned a phylogenetic lineage or
assigned more than one major phylogenetic family per cluster were
excluded from analysis. Strains classified as either ‘‘T’’ or ‘‘U’’
(Unknown) were also excluded due to the ambiguity of these
classifications (Figure 1).
We considered the possibility that the use of spoligotyping,
MIRU- or RFLP-typing for inferring phylogenetic lineages in this
study may have resulted in misclassification of lineage, due to the
propensity of these markers for convergent evolution and resulting
homoplasies [18]. To assess this, we compared the inferred
phylogenetic lineages with those determined using single nucleo-
tide polymorphisms (SNP) markers in a subset of strains (n = 248)
that were also whole-genome sequenced [19].
Statistical Analysis
We used a logistic regression model to determine independent
host risk factors including demographic, behavioral, and sputum
smear status, for clustering. Variables with p-values ,0?20 were
entered into a multivariate model. Crude and adjusted odds ratios
(OR) are presented with 95% confidence intervals (CI). Estimates
for the adjusted ORs were each multiplied as weights to calculate
each patient’s propensity to propagate (PPP). The geometric mean
of PPP values belonging to a cluster was taken as the overall
measure of a cluster’s propensity to propagate (CPP). Confidence
intervals for the median CPP by phylogenetic lineage were
calculated using nonparametric bootstrapping methods based on
10,000 replicates. An analysis of variance (ANOVA) with
Bonferroni correction was performed to determine CPP compa-
rability among the four phylogenetic lineages. We repeated this
step on a validation subset of strains (n = 2,136) whose lineages
were determined using the highly reliable MIRU Best Match
Analysis (stringent cut-off) and SNP markers [9]. We also explored
the variability of CPP by phylogenetic lineage stratified by host
region of origin, by repeating the ANOVA on a subset of clusters
composed of patients of a particular region only (Europe versus
Asia). In a sensitivity analysis, we checked the consequences of
excluding extra-pulmonary cases from the dataset. Finally, the
proportion of clustered isolates was calculated for each phyloge-
netic lineage. Mean and median cluster size (plus interquartile
ranges and 95% CI, respectively) were calculated for three
increasing CPP categories (,0?5, 0?5–0?8 and .0?8) for each of
the four phylogenetic lineages. SAS software for Windows, version
9?3, was used for statistical analyses.
Results
During the period January 1993 to December 2011, 18,294
isolates were collected from 18,274 notified TB cases in the
Netherlands and their clustering status ascertained, of which
15,601 (85%) were successfully matched with the NTR data. Of
these, 14,838 (94%) were non-contaminated MTB cultures with
completely ascertained information on host risk factors (Figure 1).
The mean age of MTB positive TB cases was 41 years (SD, 20);
8,859 (60%) were male; and 10,005 (67%) were foreign-born.
Host-related factors for clustering
Of the 14,838 strains with both DNA fingerprinting and host-
related data, 8,585 were clustered (57?9%) and 6,253 were non-
clustered (42?1%). Table 1 shows that patients were more likely to
be in a cluster if they were smear-positive, had a pulmonary
manifestation and were younger, male, alcohol or IV drug users,
homeless, a health-care worker, native Dutch or foreign-born from
Africa or the Americas. Patients were less likely to be in a cluster if
they had travelled to an endemic area in the past two months or
were foreign-born from Asia or Europe. In the multivariate model,
all risk factors for clustering remained significant with the
exception of alcohol consumption, being a health-care worker or
being a foreign-born from the Americas. Being a foreign-born
from Africa turned into a protective factor against clustering after
adjustment in multivariate analysis. Resulting values for PPP and
CPP ranged from 0 (a low risk profile for clustering, i.e. an elderly
female patient with extra-pulmonary, smear-negative TB and no
Figure 2. Distribution of Propensity to Propagate values.
doi:10.1371/journal.pone.0097816.g002
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behavioral risk factors) to 3?9 (a high risk profile i.e. a young (,30
years) male patient with pulmonary, smear-positive TB and at
least one behavioral risk factor), with the distribution of CPP
values skewed to the right of PPP values from patients with unique
isolates (Figure 2).
Host-related factors by phylogenetic lineage
Of the 10,389 M. tuberculosis isolates which had both a CPP and/
or PPP value and an assigned phylogenetic lineage, 6,595 were
classified as Euro-American (63?5%), 1,327 as CAS (12?8%), 1,422
as EAI (13?7%) and 1,045 as Beijing (10?0%). The excluded 15%
of strains that were not matched with the NTR data fall into a
similar lineage distribution. Lineage misclassification was estimat-
ed at 19%, with 200 out of 248 strains in this study having
concordant lineage classifications to SNP-based inferences. Of the
10,389 strains, 4,491 (43?2%) were non-clustered and the
remainder consisted of 1,505 clusters, representing 175 CAS
clusters, 972 Euro-American, 202 EAI and 156 Beijing. Median
values for CPP were 0?64 (95% CI: 0?57–0?67), 0?76 (95% CI:
0?73–0?77), 0?75 (95% CI: 0?71–0?76) and 0?72 (95% CI: 0?70–
0?73) for Beijing, Euro-American, CAS and EAI strains. CPP
values from strains of the Euro-American lineage were on average
higher than those of Beijing and EAI strains, and CAS strains were
also on average higher than EAI strains at a 0?05 level of
significance (Figure 3). CPP values of strains belonging to the
validation subset of strains classified using high reliability markers
showed a similar trend, with the median CPP of strains of the
Euro-American lineage remaining on average higher than those of
Beijing and EAI strains at a 0?05 level of significance. Repeating
the ANOVA on clusters composed of patients of European origin
only (n = 277) showed a significantly lower mean CPP in clusters of
the Euro-American strain (0?73; 95% CI: 0?70–0?76) compared to
that of in clusters of Beijing (0?89; 95% CI: 0?80–0?98) or CAS
(0?86; 95% CI: 0?77–0?96) strains, at a 0?05 level of significance.
In the subset of clusters composed of patients of Asian origin only
(n = 57), mean CPP values were 0?46 (95% CI: 0?43–0?49), 0.40
(95% CI: 0?32–0?48), 0?40 and 0?43 (95% CI: 0?39–0?47), for
Beijing, Euro-American, CAS (n = 1) and EAI strains, respectively.
Excluding extra-pulmonary cases (n = 4,812) from the dataset and
logistic regression model resulted in Beijing strains maintaining the
lowest median CPP (0?71, 95% CI: 0?65–0?78) compared to that
of Euro-American (0?85, 95% CI: 0?82–0?85), CAS (0?84, 95%
CI: 0?80–0?85) and EAI (0?83, 95% CI: 0?75–0?86) strains.
Propagation by phylogenetic lineage
The proportion of clustered isolates was 60?7% (95% CI, 59?5–
61?9) for Euro-American strains, 49?2% (95% CI, 46?5–51?9) for
CAS strains, 51?1% (95% CI, 48?5–53?7) for EAI strains and
49?4% (95% CI, 46?4–52?4) for Beijing strains. Both minimum
and average PPP/CPP per cluster size increased with rising
cluster size (Figure 4). Likewise, mean and median cluster size
grew with increasing CPP category (Figure 5). There were no
significant differences between the mean and median values of
cluster size between the four phylogenetic lineages within each
CPP category.
Figure 3. Distribution of Cluster Propensity to Propagate by 4
Phylogenetic Lineages. * 0.05 Level of Significance. Q1 – Lower
Quartile; Q3 – Upper Quartile.
doi:10.1371/journal.pone.0097816.g003
Figure 4. Distribution of Propensity to Propagate by Cluster Size.
doi:10.1371/journal.pone.0097816.g004
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Discussion
In this long-term Netherlands-based study, we compared the
propensity to propagate of four major MTB lineages using a novel
method designed to differentiate host and bacterial factors
associated with strain transmissibility and progression. We found
that although Euro-American strains were more likely to be found
in clusters in an unadjusted analysis, no significant differences
among the four different lineages persisted after we controlled for
host factors.
The range of host factors associated with clustering that we
identified in this study include demographic (age, gender and
geographic origin), clinical (pulmonary manifestation and smear-
positivity) and behavioral (drug-use, homelessness) determinants
that have been identified in previous studies in this (and other)
settings [7,20]. The clearly skewed distribution of cluster CPP
values to the right of PPP values from patients with unique isolates
confirms the role of host-related factors in propagation. The
method described in this study to correct for host-related factors in
transmission enables the identification of highly propagating
strains (i.e. belonging to a larger than average cluster size for its
CPP score) from non-propagating ones (i.e. non-clustered isolates
with a high PPP). This selection process is useful to hone in on a
crisp phenotype that is necessary to study bacterial factors
associated with transmission, by means of genomic comparison
in future whole-genome sequencing studies [21]. It would for
example be interesting to subject the CDC1551 outbreak to our
new approach in order to separate host risk factors from the true
bacteriological component.
Our finding that the distribution of Cluster Propensity to
Propagate scores was not equal across the Euro-American, Beijing,
CAS and EAI lineages supports the notion that host-related factors
need to be controlled for in order to attain comparability in
measuring the ability of different phylogenetic lineages to
propagate. Other previous studies in low prevalence settings such
as Montreal and San Francisco have found the EAI lineage to be
associated with lower rates of transmission [22], and the Euro-
American lineage three times more likely to cause a secondary case
[23]. The former adjusted their OR for clustering for age, whilst
the rate measure used in the latter did not adjust for host-related
factors. Discrepancies between results from studies measuring
transmissibility between phylogenetic lineages may therefore partly
be due to differences in how and if host-related factors are
controlled for at all. This also seems important in the light of
studies on co-evolution between bacteria and hosts; to facilitate a
meaningful interpretation such studies should take patient risk
factors for transmission and breakdown to disease into consider-
ation [24]. In high prevalence settings this may be especially
challenging.
A major strength of our study was the use of a large sample size
over a long time period to accurately quantify the contribution of
host-related factors in clustering within this setting. With 69% of
patients being foreign-born from 159 different countries, our study
sample is also globally representative; given the phylogeographic
diversity of the major MTB lineages this is crucial to perform
comparative analyses to identify associations between strain
lineages and transmissibility. There is also an advantage in
conducting this analysis in a low prevalence setting such as the
Netherlands where the majority of people are susceptible and not
vaccinated with BCG. This means that cluster sizes more closely
reflect the biological underpinning of increased transmissibility
rather than the proportion of the population that is still susceptible
to MTB. Finally, our use of mean and median cluster size
(therefore excluding non-clustered strains) across CPP categories
instead of clustering rates decreases possible bias from the over-
representation of foreign-born patients, associated with non-
clustered strains from reactivation of latent TB infections acquired
before immigration, among non-Euro-American strains (74?3%,
95% CI: 73?0–75?6) versus Euro-American strains (53?3%, 95%
CI: 52?2–54?4).
Although our results contrast with those from studies carried out
in other populations where Beijing has been associated with
greater virulence and transmissibility [25–27], they are consistent
with those from other low incidence immigrant-receiving settings
such as the United States and Canada where it was concluded that
Beijing strains do not pose more of a public health threat than
non-Beijing strains [23,28]. The successful spread of this genotype
in Asia and other parts of the world may therefore be related to a
higher ability to withstand exposure to antituberculosis drugs and
BCG vaccination, rather than a higher ability to propagate
[11,29].
Figure 5. Distribution of Cluster Propensity to Propagate by Cluster Size and 4 Phylogenetic Lineages.
doi:10.1371/journal.pone.0097816.g005
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It has also been hypothesized that lineages that are rare in a
specific human population are not adapted to transmit and cause
secondary cases [23]. In Sweden for example, despite the close
proximity to Russia and the Baltic states, Beijing was found to
have a lower clustering rate, no absolute increase in number over
time and very little observed transmission from immigrants to
indigenous population [30]. In our study, there was no statistically
significant difference between the median and mean cluster sizes of
Beijing versus Euro-American strains after taking host propensity
to propagate factors into account. This was also found to be the
case for EAI and CAS strains, which suggests that imported strains
in the Netherlands are not necessarily less adapted to the native
host population and are just as likely to propagate as locally
occurring strains of the Euro-American lineage. A lower mean
CPP of Euro-American versus non-Euro-American strains found
in clusters of European origin only suggests the possibility of co-
evolution between phylogenetic lineages to their sympatric host
population, as has been previously reported [23]. No significant
differences were found however between CPP of phylogenetic
lineages in clusters of Asian origin only, which may reflect the
smaller sample size and reduced power to detect such an
association.
The inclusion of M. africanum isolates, which have been
associated with a lower rate of disease transmission compared to
other MTB strains [31], for comparison in our study was not
possible due to the very small number of patients infected with this
strain. A differential representation of lineages amongst the native
Dutch (who are not BCG vaccinated or previously exposed) versus
the foreign-born population also represents a possible source of
bias. In this dataset, the percentage of lineages circulating in the
native Dutch were 7.6%, 10.4%, 25.3% and 36.7% in the CAS,
EAI, Beijing and Euro-American lineages, respectively. It should
also be noted that the weights used to calculate each patient’s
propensity to propagate (PPP) in this study depended on the
clustering status given by molecular epidemiology data (RFLP-
and VNTR-typing) alone, whose accuracy is limited.
In sum, this study demonstrates the importance of controlling
for host-related factors in measuring the transmissibility of strains
and describes a method to do so in order to identify bacterial
factors in future studies. It also shows that there are no significant
differences in the ability to propagate of four main phylogenetic
lineages in the Netherlands, which is indicative that the spread of
imported strains (most often of the EAI, CAS and Beijing lineages)
is not necessarily curbed by a lack of adaptation to the native host
population.
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The aim of this study was to determine if mycobacterial lineages affect infection risk, clustering, and disease progression among
Mycobacterium tuberculosis cases in The Netherlands. Multivariate negative binomial regression models adjusted for patient-
related factors and stratified by patient ethnicity were used to determine the association between phylogenetic lineages and in-
fectivity (mean number of positive contacts around each patient) and clustering (as defined by number of secondary cases within
2 years after diagnosis of an index case sharing the same fingerprint) indices. An estimate of progression to disease by each risk
factor was calculated as a bootstrapped risk ratio of the clustering index by the infectivity index. Compared to the Euro-Ameri-
can reference,Mycobacterium africanum showed significantly lower infectivity and clustering indices in the foreign-born popu-
lation, whileMycobacterium bovis showed significantly lower infectivity and clustering indices in the native population. Signifi-
cantly lower infectivity was also observed for the East African Indian lineage in the foreign-born population. Smear positivity
was a significant risk factor for increased infectivity and increased clustering. Estimates of progression to disease were signifi-
cantly associated with age, sputum-smear status, and behavioral risk factors, such as alcohol and intravenous drug abuse, but
not with phylogenetic lineages. In conclusion, we found evidence of a bacteriological factor influencing indicators of a strain’s
transmissibility, namely, a decreased ability to infect and a lower clustering index in ancient phylogenetic lineages compared to
their modern counterparts. Confirmation of these findings via follow-up studies using tuberculin skin test conversion data
should have important implications onM. tuberculosis control efforts.
Curbing tuberculosis (TB) transmission is a challenge in high-burden countries. However, even in low-prevalence settings,
controlling TB is an important requirement due to humanmigra-
tion from higher-incidence areas to Western countries (1). In
Western countries, studies on transmission are more feasible, as
all cases undergo extended diagnostic algorithms and all clinical
and demographic data are recorded. Current molecular typing
methods, such as variable number of tandem repeat (VNTR) typ-
ing and restriction fragment length polymorphism (RFLP) typing,
allow identification of clusters of Mycobacterium tuberculosis iso-
lates with identical genotypes that, in population-based studies,
reveal recent transmission (2, 3). Spoligotyping and VNTR typing
can identify the genotype family of the isolate, revealing bacterial
variation via the identification of phylogenetic lineages (4, 5).
While many studies have elucidated the variation in the dis-
ease’s spread and outcome attributable to host and environmental
factors, there is also evidence that bacterial factors may affect the
spread of tuberculosis (6). In The Netherlands, for example, one
study showed that the number of positive contacts around a case
increases with growing cluster size (7). In a subsequent study in
the same setting, cluster size growth was not different between
phylogenetic lineages after controlling for host risk factors (8).
However, this study could not distinguish between transmission
rates and progression to disease. There are, however, indications
that progression to disease is partly dependent on bacterial varia-
tion. It has, e.g., been postulated that someMycobacterium africa-
num strains might transmit equally well as other M. tuberculosis
complex strains but might be less associated with progression to
disease (9). We will refer to these two properties that affect the
degree of clustering as infectivity (the bacterium’s ability to estab-
lish an initial infection in the human host) and progression to
disease (the bacterium’s capacity to produce disease) (10).
In the low-incidence context of The Netherlands, with a glob-
ally representative cohort of patients, we aim to determine dif-
ferences in indices of infectivity, clustering, and estimated pro-
gression to disease of different mycobacterial lineages using
fingerprinting data and contact investigation. This will provide
insights into the role of bacteriological factors in TB transmission,
which itself may affect future TB control measures.
MATERIALS AND METHODS
Data collection andDNAfingerprinting.TheNational Institute for Pub-
lic Health and the Environment (RIVM) is a reference laboratory for
secondary laboratory diagnosis of all TB cases in The Netherlands, offer-
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ing identification, drug susceptibility testing, and molecular typing for
each TB case. DNA fingerprints of all nationwideM. tuberculosis complex
isolates and their cluster statuses have been stored in an RFLP/VNTR
database since 1993. The registration committee of The Netherlands Tu-
berculosis Register (NTR) approved this retrospective study and provided
anonymized demographic and clinical information for patients. Because
these data are deidentified by name, DNA fingerprinting results were
matched by sex, date of birth, year of diagnosis, and postal code. All
notified culture-positive cases of M. tuberculosis between 1993 and 2011
were included in the study. For patients with multiple isolates sharing
identical fingerprints, only the isolate with the earliest diagnosis date was
included. Contaminating isolates were excluded.
Isolates recovered from patients between 1993 and 2009 underwent
IS6110 typing and polymorphic GC-rich sequence (PGRS) RFLP typing
(n ! 15,073), and those from 2004 onward were subjected to VNTR
typing (n! 5,870) (11, 12). In the period of 2004 to 2008, both RFLP and
24-locus VNTR typing were performed to obtain a smooth transition in
typing methods and to evaluate VNTR typing performance (3). In addi-
tion, 4,433 randomly selected isolates were spoligotyped (n! 4,433). We
defined a cluster as a group of patients who sharedM. tuberculosis isolates
with identical RFLP or VNTR patterns or, if strains had fewer than five
IS6110 copies, identical PGRS RFLP patterns.
Conventional contact investigation. Systematic contact investigation
by TB Public Health Services in The Netherlands is conducted per the
stone-in-the-pond principle, in which the decision to extend conven-
tional contact investigation to the next ring of contacts is based on the
prevalence of infection in the investigated ring (13). Contacts are defined
by the frequency and intimacy of their contacts with the TB index case.
The tuberculin skin test (TST) is used to investigate presumably exposed
contacts. If the number of TST-positive contacts in the first ring suggests
a high spread of tuberculosis, a larger ring of contacts is investigated. We
have defined positive contacts as contacts with a TST induration!10mm
and/or contacts who received a diagnosis of TB disease. If contact inves-
tigations become very large, identified TB infections and secondary cases
are less likely to be related to the index case. To minimize the probability
that positive contacts in our research were unrelated to the defined index
case, we only included contacts in the first ring around the index patient.
First-ring contacts are defined as contacts that are physically close to the
index patient, considering environmental factors, such as room size, ven-
tilation, air purification, and air circulation. In addition, the patient and
the contact must be able to indicate where they met and must have a
long-standing relationship to qualify as a first-ring contact. Examples of
first-ring contacts are household members, close work colleagues, and
close friends.
Classification into phylogenetic lineages. The phylogenetic lineages
of isolates were determined using a combination of spoligotyping, the
MIRU (mycobacterial interspersed repetitive unit) best match analysis
offered by the MIRU-VNTRplus online tool, and RFLP similarity, as de-
scribed in a previous study using the same data set (8, 14). Three species
(M. africanum,Mycobacterium bovis, andM. tuberculosis) and four major
phylogenetic lineages ofM. tuberculosis were identified: the Euro-Ameri-
can, Central Asian strain (CAS), East African Indian (EAI), and Beijing
genotypes. Strains not assigned a phylogenetic lineage or assigned tomul-
tiple major phylogenetic families per cluster were not analyzed. Strains
classified as either T or U (unknown) also were excluded due to the am-
biguity of these classifications.
Definitions. For our infectivity index, we took the mean number of
positive contacts around each patient who underwent contact investiga-
tion. We excluded patients with missing data on contact investigation or
those who had zero contacts investigated, as well as those for whom we
lacked ethnicity information. Because TB transmission almost exclusively
results from patients with pulmonary TB, we also excluded patients with
extrapulmonary TB, leaving us with a total of 2,809 cases (Fig. 1).
For our clustering index, we used the number of secondary cases oc-
curring within 2 years of the index case diagnosis. The 2-year cutoff has
been shown to best reflect recent transmission as opposed to disease re-
activation (1, 15).We defined index cases as patients who had strains with
RFLP or VNTR patterns not seen in other patients in the previous 2 years.
We searched for index cases based onRFLP-typing data from1995 to 2007
and for index cases based on VNTR typing from 2007 to 2009. We ex-
cluded RFLP-defined index cases from 1993 and 1994 and VNTR-defined
index cases from 2005 and 2006 (n! 2,684), because we could not deter-
mine whether the strains of these index cases were unobserved in the
previous 2 years. Similarly, we excluded RFLP-defined index cases occur-
ring after 2007 and VNTR-defined index cases occurring after 2009 (n!
950), because we could not follow these index cases for a full 2 years.
Secondary cases from these index cases (included in the counts) were also
excluded. Finally, we excluded cases between 1995 and 2007 occurring"2
years after a previous patient with the same RFLP fingerprint yet diag-
nosed #2 years after a cluster’s start (n ! 722) and cases occurring be-
tween 2007 and 2009 that occurred"2 years after a previous patient with
the same VNTR fingerprint yet #2 years after a cluster’s start (n ! 40).
After excluding extrapulmonary cases, 4,432 patients remained: 2,881
nonclustered index patients, 607 index patients who were the first
patient of a cluster, and 944 secondary cases within 2 years of a cluster’s
start (Fig. 1).
Finally, estimates of progression to disease were calculated as risk ra-
tios (RR) of the population risk of disease given exposure to a risk factor by
the population risk of infection given exposure to the same risk factor
(dividing the clustering odds ratios [ORs] by the infectivity ORs).
Statistical analysis. We used a multivariate negative binomial re-
gression model to determine the association between phylogenetic lin-
eages and the infectivity and clustering indices. Since TST is poorly
specific among Mycobacterium bovis BCG contacts and positive TSTs
may represent old infections, we divided our data sets into native and
foreign-born (FB) cohorts in order to address important differences
between the two: FB patients are often BCG vaccinated (in contrast to
native Dutch patients, who are not), while the prevalence of infection
is higher among FB patients. Second-generation patients (born to FB
patients) were included in the native cohorts, given that, like native
patients, they are not BCG vaccinated and they have already been born
in a setting of lower prevalence of infection. Studies carried out in The
Netherlands have also previously demonstrated that contact investiga-
tion practices vary by demographic characteristics of the index patient
(16). As such, in both analyses, we adjusted for index patient-related
factors, including demographic, behavioral, and sputum smear status.
In addition, the logarithm of the number of investigated contacts
around a source case was used as an offset in the multivariate model
assessing the association between phylogenetic lineages and the spread
index, since the greater number of contacts around a source are inves-
tigated, the likelier it is to detect TST positive contacts. Variables with
P values of"0.20 were entered into the multivariate model. Crude and
adjusted ORs are presented with 95% confidence intervals (CIs). Esti-
mates of TB progression were calculated for any risk factor that was
significant in either multivariate regression model. To calculate the
variance for the estimate of TB progression, we performed a bootstrap-
ping procedure, running our multivariate negative binomial regres-
sion models 10,000 times on bootstrapped data sets. The median of the
resulting 10,000 RRs was used as the estimate of TB progression, while
the 2.5th and 97.5th percentiles were used as the 95% cutoffs for the
estimate CI. All analyses were conducted using SAS (Windows version
9.3), SPSS program for Windows version 20.0 (SPSS Inc., Chicago, IL,
USA) and R (version 3.1.2 for Windows).
RESULTS
Between January 1993 and December 2011, 18,294 isolates were
collected from the same number of notified TB cases in TheNeth-
erlands, and their clustering statuses were ascertained, of which
15,601 (85%) were successfully matched with the NTR data. Of
these, 15,224 (98%) were noncontaminated M. tuberculosis cul-
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tures with completely ascertained information on host risk fac-
tors. After phylogenetic lineage assignment, there were 10,738 iso-
lates that were M. bovis, M. africanum, or M. tuberculosis of the
Euro-American, Beijing, CAS, or EAI lineages (Fig. 1). The mean
age of the patients carrying these strains was 41 years (standard
deviation, 20 years); 6,394 (60%) were male; and 7,762 (72%)
were foreign born.
Mycobacterial genotypes. The Euro-American lineage was
predominant in both the infectivity (78% in native cohort; 56% in
FB cohort) and clustering (79% in native cohort; 64% in FB co-
hort) data sets. In contrast, both M. africanum and M. bovis rep-
resented less than 1% of all cases in the infectivity data set. In the
clustering data set, both M. africanum and M. bovis represented
only 2% of all cases (Tables 1 and 2).
Infectivity by mycobacterial lineage. The proportion of cases
in which a contact investigation was performed in The Nether-
lands was approximately equal between lineages, though slightly
lower in the FB cohort for Beijing and EAI compared to the native
counterpart (Fig. 2). The average number of TST-positive con-
tacts declined significantly in the !65 years age category in the
native cohort and in the"20 years age category in the FB cohort.
Smear positivity was associated with an increased average number
of TST-positive contacts in both native and FB cohorts. There
were no significant differences in infectivity by gender, homeless-
ness, and alcohol use in the two cohorts, although use of intrave-
nous drugs in the native populations and rural residence in the FB
population were associated with a decreased average number of
TST-positive contacts. The mean number of TST-positive con-
tacts around an index casewas significantly lower forM.bovis than
for the Euro-American reference lineage in the native population
in multivariable analysis. In the FB population, M. africanum
and EAI presented a significantly lower number of TST-positive
contacts (Table 1).
Clustering by mycobacterial lineage. The number of second-
ary cases declined significantly with increasing age (!65 years) in
both the native and FB cohorts. Smear positivity was also associ-
FIG 1 Flow-diagram of exclusion criteria applied to data set.
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atedwith an increased number of secondary cases in both cohorts,
and female gender was associated with an increased number of
secondary cases only among the FB. Rural residence was associ-
ated with a decreased number of secondary cases only in the FB
cohort. Relative to the Euro-American reference in the multivari-
able analysis, the number of secondary cases was significantly
lower forM. bovis in the native-born population and forM. afri-
canum in the FB population (Table 2).
Estimatesof progression todiseasebymycobacterial lineage.
Estimates of progression to disease were significantly lower in
the !65 years age category in both ethnic cohorts and signifi-
cantly higher in the 0- to 19-years age category in the FB cohort.
Additionally, in the FB-born population, estimates of progres-
sion to disease were significantly lower in smear-negative pa-
tients. Both alcohol and drug abuse were significantly associ-
ated with higher estimates in the native population. No
TABLE 1 Risk factors among native and foreign-born index cases for infectivity (number of TST-positive contacts per index case)
Characteristic
Native cohort Foreign-born cohort
No. of
index
cases
Mean no. of
TST-positive
contacts/
index case
Univariate analysis
Multivariate
analysis,
relative no. (95%
CI)
No. of
index
cases
Mean no. of
TST-positive
contacts/
index case
Univariate analysis
Multivariate
analysis,
relative no.
(95% CI)
Relative no.
(95% CI) P
Relative no.
(95% CI) P
Age, yr 0.00 0.033
0–19 99 1.02 1.0 (0.68–1.6) 0.96 (0.65–1.4) 200 0.83 1.11 (0.83–1.5) 0.69 (0.53–0.89)
20–39 363 0.99 1 (Refa) 1 (Ref) 1024 0.75 1 (Ref) 1 (Ref)
40–64 339 0.82 0.83 (0.63–1.1) 0.91 (0.69–1.2) 459 0.60 0.81 (0.65–1.0) 0.96 (0.79–1.2)
!65 207 0.51 0.51 (0.37–0.72) 0.50 (0.36–0.70) 118 0.49 0.66 (0.45–0.97) 0.80 (0.57–1.1)
Sex 0.15 0.32
Male 635 0.78 1 (Ref) 1 (Ref) 1,125 0.73 1 (Ref)
Female 373 0.93 1.2 (0.93–1.5) 1.0 (0.82–1.3) 676 0.66 0.73 (0.65–0.82)
Smear positivity "0.001 "0.001
Negative 395 0.52 0.50 (0.39–0.65) 0.48 (0.38–0.62) 754 0.47 0.54 (0.45–0.65) 0.55 (0.46–0.65)
Positive 613 1.04 1 (Ref) 1 (Ref) 1,047 0.87 1 (Ref) 1 (Ref)
Lineage 0.00 0.006
Euro-American 786 0.91 1 (Ref) 1 (Ref) 1,157 0.75 1 (Ref) 1 (Ref)
Beijing 112 0.67 0.73 (0.50–1.1) 1.1 (0.77–1.6) 182 0.55 0.74 (0.54–1.0) 0.94 (0.71–1.2)
CAS 30 0.23 0.26 (0.11–0.61) 0.64 (0.27–1.5) 198 0.86 1.2 (0.86–1.5) 1.0 (0.79–1.3)
EAI 62 0.56 0.62 (0.37–1.04) 0.78 (0.47–1.3) 237 0.53 0.71 (0.54–0.94) 0.64 (0.49–0.83)
M. Africanum 5 0.40 0.44 (0.067–2.9) 0.44 (0.055–3.5) 15 0.27 0.36 (0.11–1.1) 0.30 (0.10–0.89)
M. bovis 13 0.23 0.25 (0.068–0.94) 0.23 (0.059–0.94) 12 0.17 0.22 (0.052–0.96) 0.51 (0.11–2.4)
Residency 0.07 0.002
Urban 690 0.90 1 (Ref) 1 (Ref) 1,067 0.79 1 (Ref) 1 (Ref)
Rural 318 0.70 0.78 (0.60–1.0) 0.78 (0.60–1.0) 734 0.58 0.74 (0.62–0.89) 0.71 (0.60–0.84)
Alcohol abuse 0.19 0.69
No 969 0.85 1 (Ref) 1 (Ref) 1,779 0.70 1 (Ref)
Yes 39 0.54 0.64 (0.33–1.2) 0.59 (0.30–1.2) 22 0.59 0.84 (0.36–1.9)
Drug abuse 0.01 0.97
No 953 0.86 1 (Ref) 1 (Ref) 1,722 0.70 1 (Ref)
Yes 55 0.40 0.47 (0.26–0.83) 0.43 (0.24–0.78) 79 0.71 1.0 (0.65–1.6)
Traveler to country
of endemicity
0.17 0.17
No 973 0.85 1 (Ref) 1 (Ref) 1,759 0.69 1 (Ref) 1 (Ref)
Yes 35 0.51 0.61 (0.30–1.2) 0.53 (0.25–1.1) 42 1.02 1.5 (0.83–2.6) 1.5 (0.88–2.4)
Homeless 0.72 0.94
No 978 0.84 1 (Ref) 1,753 0.70 1 (Ref)
Yes 30 0.73 0.88 (0.43–1.8) 48 0.69 0.98 (0.56–1.7)
Site of disease 0.21 0.099
Pulmonary 891 0.86 1 (Ref) 1 (Ref) 1,430 0.73 1 (Ref) 1 (Ref)
Pulmonary#
extrapulmonary
117 0.67 0.78 (0.53–1.1) 1.0 (0.70–1.5) 371 0.60 0.83 (0.66–1.0) 0.88 (0.71–1.1)
a Ref, reference.
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significant differences were found across phylogenetic lineages
(Table 3).
DISCUSSION
In this study, we observed variations between the infectivity and
clustering indices of different phylogenetic subgroups ofM. tuber-
culosis, M. bovis, and M. africanum after controlling for clinical
and demographic index host factors. M. africanum and M. bovis
showed both significantly lower infectivity and clustering indices
in the FB and native populations, respectively. A significantly
lower infectivity was also observed for the EAI lineage in the larger
FB population.
Our findings around M. africanum are consistent with previ-
ous experiments characterizing its reduced ESAT-6 (early secre-
tory antigenic target-6) immunogenicity and candidate genes be-
hind its attenuated phenotype (17). However, they are only
TABLE 2 Risk factors among native and foreign-born index cases for clustering (number of secondary cases within 2 years of an index case)
Characteristic
Native cohort Foreign-born cohort
No. of
index
cases
Mean no. of
second
cases per
index case
Univariate analysis
Multivariate
analysis,
relative no.
(95% CI)
No.
index
cases
Mean no. of
second
cases per
index case
Univariate analysis
Multivariate
analysis,
relative no.
(95% CI)
Relative no.
(95% CI) P
Relative no.
(95% CI) P
Age, yr
0–19 59 0.46 1.02 (0.53–1.90) 0.001 1.04 (0.56–1.93) 276 0.36 1.32 (0.92–1.92) 0.716 1.42 (0.99–2.03)
20–39 216 0.45 1 (Refa) 1 (Ref) 1,411 0.27 1 (Ref) 1 (Ref)
40–64 267 0.34 0.65 (0.41–0.98) 0.68 (0.46–1.02) 569 0.31 1.14 (0.86–1.51) 1.06 (0.80–1.42)
!65 495 0.1 0.22 (0.12–0.33) 0.21 (0.13–0.32) 195 0.08 0.30 (0.16–0.55) 0.30 (0.16–0.55)
Sex
Female 387 0.23 0.87 (0.61–1.23) 0.4255 975 0.23 0.51 (0.29–0.90) 0.019 1.29 (1.01–1.66)
Male 650 0.27 1 (Ref) 1,476 0.31 1 (Ref) 1 (Ref)
Smear positivity
Negative 393 0.18 0.58 (0.40–0.83) 0.0027 0.62 (0.44–0.88) 1,076 0.17 0.48 (0.38–0.61) !.0001 0.50 (0.39–0.65)
Positive 644 0.3 1 (Ref) 1 (Ref) 1,375 0.36 1 (Ref) 1 (Ref)
Lineage
Euro-American 756 0.25 1 (Ref) 0.1971 1 (Ref) 1,385 0.3 1 (Ref) 0.081 1 (Ref)
Beijing 73 0.36 1.44 (0.79–2.62) 1.20 (0.68–2.11) 354 0.28 0.93 (0.66–1.32) 1.07 (0.76–1.52)
CAS 28 0.29 1.15 (0.41–3.09) 0.79 (0.30–2.10) 290 0.28 0.93 (0.64–1.36) 0.87 (0.59–1.27)
EAI 118 0.33 1.34 (0.82–2.19) 0.90 (0.54–1.50) 335 0.22 0.74 (0.51–1.07) 0.80 (0.57–1.17)
M. Africanum 8 0.13 0.50 (0.04–5.22) 0.26 (0.03–2.53) 65 0.15 0.52 (0.22–1.21) 0.47 (0.31–0.94)
M. bovis 54 0.06 0.22 (0.06–0.78) 0.11 (0.006–0.56) 22 0.09 0.30 (0.06–1.67) 0.31 (0.06–1.67)
Residency
Urban 785 0.35 1 (Ref) 0.02 1 (Ref) 1,547 0.34 1 (Ref) 0.004 1 (Ref)
Rural 252 0.23 0.65 (0.45–0.94) 0.99 (0.69–1.43) 904 0.24 0.70 (0.55–0.89) 0.77 (0.61–0.99)
Alcohol abuse
No 1,009 0.24 1 (Ref) 0.02 1 (Ref) 2,430 0.28 1 (Ref) 0.964
Yes 28 0.68 2.8 (1.22–6.42) 1.88 (0.89–3.99) 21 0.29 1.93 (0.28–3.74)
Drug abuse
No 1,017 0.25 1 (Ref) 0.05 1 (Ref) 2,398 0.28 1 (Ref) 0.905
Yes 20 0.65 2.64 (0.98–7.03) 1.42 (0.58–3.49) 53 0.26 1.53 (0.42–2.18)
Traveler to country
of endemicity
No 988 0.26 1 (Ref) 0.07 1 (Ref) 2,391 0.28 1 (Ref) 0.167 1 (Ref)
Yes 49 0.10 0.39 (0.14–1.09) 0.26 (0.09–0.70) 60 0.15 0.53 (0.22–1.30) 0.47 (0.20–1.14)
Homeless
No 1,028 0.25 1 (Ref) 0.75 2,401 0.27 1 (Ref) 0.233 1 (Ref)
Yes 9 0.33 1.31 (0.25–6.99) 50 0.44 1.61 (0.74–3.49) 1.19 (0.5–2.56)
Site of disease
Pulmonary 883 0.26 1 (Ref) 0.22 1 (Ref) 1,949 0.29 1 (Ref) 0.129 1 (Ref)
Pulmonary"
extrapulmonary
154 0.19 0.94 (0.58–1.53) 502 0.23 0.79 (0.58–1.07) 0.92 (0.67–0.99)
a Ref, reference.
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partially consistent with those from a study conducted in the
Gambia, where M. africanum was shown to transmit equally well
to household contacts but less likely thanM. tuberculosis to prog-
ress to disease (9). While numbers in our native population were
too low to detect any associations in both indices, in the larger FB
cohort, our findings suggest that lower infectivity might also be a
component of the overall lower transmissibility of M. africanum.
Perhaps because of this lower infectivity, we did not observe the
previously reported lower estimate of progression to disease inM.
africanum. Possible explanations for this disparity may lie in the
slightly different definition of infectivity used in the Gambia,
where they used the incidence of TST conversion (using a fol-
low-up period of 3 months) specifically within households as the
outcome. In addition, we may not be comparing exactly the same
genotype; in our FB cohort, only 3 of 183 (1.7%) M. africanum
strains with a known birth country came from the Gambia.
In a cohort of native and FB TB cases in Montreal, the EAI
lineage was also significantly associated with lower number of
TST-positive contacts around index cases and with less clustering
(lower proportion of patients clustering, as defined by identical
RFLP or spoligotypes) inmultivariable analysis (18). It is interest-
ing to observe this trend in our study, which includes only pulmo-
nary cases of EAI, given the association this lineage has with the
extrapulmonary site of disease (16). In a secondary cohort of only
FB cases in the Montreal study, the EAI lineage was significantly
associated with less TST positivity but not with less clustering
(18). This again agrees with our study, where we observed a sig-
nificant association of EAI with lower infectivity but not with
lower clustering. These findings on the EAI genotype are hard to
explain using the molecular epidemiological data from Vietnam,
where approximately 40% of cases are caused by EAI strains and
another 40%, by the Beijing genotype strains (19). If EAI strains
are less successful at infecting, one would expect them to disap-
pear in a few generations and be replaced by other, more fit,
strains. This shift is perhaps occurring at the very moment, as
Beijing genotype isolates have been associated with a lower age of
patients and, hence, with active transmission.
Although M. bovis was spread significantly less in the native
FIG 2 Proportion of cases in which contact investigation was performed by phylogenetic lineage.
TABLE 3 Estimates of progression to disease by risk factor
Characteristic
Median of bootstrapped progression-to-disease
RR (95% CI)
Native cohort Foreign-born cohort
Age, yr
0–19 1.09 (0.54–2.39) 2.05 (1.25–3.74)
20–39 1 (Refa) 1 (Ref)
40–64 0.83 (0.56–1.25) 1.15 (0.79–1.74)
!65 0.76 (0.58–0.94) 0.60 (0.40–0.87)
Smear positivity
Negative 0.62 (0.27–1.52) 0.26 (0.17–0.38)
Positive 1 (Ref) 1 (Ref)
Lineage
Euro-American 1 (Ref) 1 (Ref)
Beijing 1.33 (0.60–3.48) 1.32 (0.64–2.35)
CAS 2.47 (0.73–11.26) 0.86 (0.54–1.43)
EAI 1.30 (0.57–3.30) 1.16 (0.82–1.68)
M. africanum 2.07 (0.96–2.11) 1.14 (0.70–2.11)
M. bovis 0.89 (0.66–1.31) 0.92 (0.45–2.00)
Residency
Urban 1 (Ref) 1 (Ref)
Rural 1.67 (1.01–3.01) 1.65 (0.91–2.42)
Alcohol abuse
No 1 (Ref)
Yes 9.78 (1.52–159.85)
Drug abuse
No 1 (Ref)
Yes 3.79 (1.20–22.68)
Traveler to country
with endemicity
No 1 (Ref) 1 (Ref)
Yes 0.77 (0.41–1.30) 0.39 (0.13–0.95)
a Ref, reference.
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population and although the estimates of average number of sec-
ondary cases were lower than other lineages, the fact that there
were three documented secondary cases (from three different in-
dex cases with unique fingerprints) does not rule out the possible
occurrence of transmission ofM. bovis in The Netherlands, where
pasteurization practices have been in place for decades. Ingestion
of unpasteurized dairy products has been suggested as the likely
route of infection in extrapulmonary cases in second-generation
immigrants in The Netherlands who may have traveled back to
their country of origin (20). Yet, all threeM. bovis index cases with
secondary cases in our clustering cohort also hadpulmonaryman-
ifestations; two of these index cases were FB but had no indication
of recent travel to a country of M. bovis endemicity. Indeed, in-
stances of human-to-human transmission of M. bovis have been
documented in other settings (21, 22). Together these observa-
tions suggest that, from a public health perspective, contact inves-
tigation and treatment of pulmonaryM. bovis patients should not
altogether differ from those ofM. tuberculosis patients.
Unlike studies conducted in other populations, where the Bei-
jing strain was associatedwith greater virulence and transmissibil-
ity, we did not find that the Beijing strain had higher indices of
infectivity, clustering, or progression to disease in The Nether-
lands (23, 24). This is concordant with other recent studies con-
ducted in similarly low-incidence, immigrant-receiving settings,
such as the United States and Canada, which concluded that Bei-
jing strains are nomore of a public health threat than non-Beijing
strains (25, 26). The observed higher success rate of Beijing strains
may therefore result from circumstances characteristic of high-
prevalence settings, such as mass use of BCG vaccination, devel-
opment of resistance, crowding of the human population, and
other unknown factors.
Other clinical and demographic factors positively associated
with either infectivity or clustering indices, such as smear positiv-
ity, a lower age, and residing in an urban area, have been similarly
described in previous studies (27–29). The significantly lower es-
timate of progression to disease given an elderly source likely re-
flects a lower dose of infection (due to a less close contact) and
propensity for older patients to have older contacts themselves, as
well as the higher proportion of long, latent infections (possibly
associated with lower virulence) in this age category (30). Like-
wise, the significant association between alcohol and drug abuse
with higher estimates of progression to disease can be linked to the
direct effects of both substances on immunity, the indirect effects
of substance-related disorders (i.e., malnutrition), and other po-
tential confounding factors, such as homelessness (31, 32). There
are two possible reasons behind the less-expected association be-
tween use of intravenous drugs and the lower average number of
TST-positive contacts in the native cohort. Contacts of drug abus-
ers are often intravenous drug users themselves, a scenario in
which the accurate definition of a first-ring contact is prone to
misclassification (contacts could bemisclassified as first-ring con-
tacts while they actually do not have much contact with an index
case and, therefore, do not become TST positive). It has also been
described that drug use can comprise cellular immunity (even in
the absence of HIV infection) so that TST sensitivity in drug users
is lower (33, 34).
The low prevalence setting of this study means that the inves-
tigation of the role of theM. tuberculosis genotype on transmission
is less likely to be confounded by a high background infection
pressure, where a TST result is more likely to fail at distinguishing
recent frompast infection. Furthermore, inTheNetherlands there
is no routine BCG vaccination program that could affect the in-
terpretation of TST results, making TST a suitable tool for the
detection of recent M. tuberculosis infection in contact investiga-
tions. This advantage applies solely to the native cohort, however,
as patients in the FB cohort are far more likely to have been BCG
vaccinated than native patients (40% versus 8%, respectively) and
have had higher exposure to TB in their country of origin; both of
these factors might lead to an overestimation of infectivity. It is
encouraging, however, to observe the same trend of lower infec-
tivity in EAI result in another study which did adjust for the prob-
ability of previous latent TB (18). On the other hand, the facts that
FB patients often have FB contacts and that contact tracing in this
group is less efficient imply that we might have also underesti-
mated infectivity (and, by implication, biased the progression to
disease index upward) in this group. The same reasoning applies
to cases of addiction to alcohol and drugs, where an increased
likelihood of homelessness means infected contacts are less likely
to be found.
It is important to remember the potential shortcomings from
the molecular epidemiology data underpinning these findings. A
lack of clinical follow-up data of infected contacts meant that we
were unable to link infected contacts to secondary cases and, thus,
to estimate the proportion of secondary cases infected by a specific
index case. In this low-burden country, however, there is likely a
large overlap in the number of infected contacts around an index
case and the number of secondary cases occurring within 2 years
of that index case. It nevertheless meant that we could not control
for risk factors across the transmission chain, such as rates of la-
tent TB treatment and existing medical risk factors in secondary
cases, which could influence the likelihood of progression to dis-
ease or the susceptibility to infection of the host, respectively.
Studies using a prospective cohort approach (i.e., with access to
household contacts and TST conversion data) that can bypass
some of these issues are warranted to confirm these findings.
In sum, the lower infectivity or overall transmissibility ob-
served in this study for M. bovis, M. africanum, and EAI—all,
ancient lineages—matches the hypothesis that modern strains, as
a consequence of their access to rapidly increasing numbers of
susceptible hosts, have been selected for more rapid disease pro-
gression and transmission (35). Validation of this scenario via
future experimental studies could have important implications on
how TB control efforts may be determined not only by index case
host characteristics, but also by a bacterial signature, such as phy-
logenetic lineage.
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Abstract
Tuberculosis presents a myriad of symptoms, progression routes and propagation patterns
not yet fully understood. Whereas for a long time research has focused solely on the patient
immunity and overall susceptibility, it is nowadays widely accepted that the genetic diversity
of its causative agent,Mycobacterium tuberculosis, plays a key role in this dynamic. This
study focuses on a particular family of genes, themclxs (Mycobacterium cyclase/LuxR-like
genes), which codify for a particular and nearly mycobacterial-exclusive combination of pro-
tein domains.mclxs genes were found to be pseudogenized by frameshift-causing insertion
(s)/deletion(s) in a considerable number ofM. tuberculosis complex strains and clinical iso-
lates. To discern the functional implications of the pseudogenization, we have analysed the
pattern of frameshift-causing mutations in a group ofM. tuberculosis isolates while taking
into account their microbial-, patient- and disease-related traits. Our logistic regression-
based analyses have revealed disparate effects associated with the transcriptional inactiva-
tion of twomclx genes. In fact,mclx2 (Rv1358) pseudogenization appears to be primarily
driven by the microbial phylogenetic background, being mainly related to the Euro-Ameri-
can (EAm) lineage; on the other hand,mclx3 (Rv2488c) presents a higher tendency for
pseudogenization among isolates from patients born on the Western Pacific area, and from
isolates causing extra-pulmonary infections. These results contribute to the overall knowl-
edge on the biology ofM. tuberculosis infection, whereas at the same time launch the nec-
essary basis for the functional assessment of these so far overlooked genes.
PLOS ONE | DOI:10.1371/journal.pone.0128983 June 2, 2015 1 / 20
OPEN ACCESS
Citation: Santos CL, Nebenzahl-Guimaraes H,
Mendes MV, van Soolingen D, Correia-Neves M
(2015) To Be or Not to Be a Pseudogene: A
Molecular Epidemiological Approach to the mclx
Genes and Its Impact in Tuberculosis. PLoS ONE
10(6): e0128983. doi:10.1371/journal.pone.0128983
Academic Editor: Igor Mokrousov, St. Petersburg
Pasteur Institute, RUSSIAN FEDERATION
Received: January 23, 2015
Accepted: May 4, 2015
Published: June 2, 2015
Copyright: © 2015 Santos et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Fundação
para a Ciência e Tecnologia (FCT), Portugal, and
cofunded by Programa Operacional Regional do
Norte (ON.2—O Novo Norte), Quadro de Referência
Estratégico Nacional (QREN), through the Fundo
Europeu de Desenvolvimento Regional (FEDER),
and from Projeto Estratégico – LA 26 – 2013–2014
(PEst-C/SAU/LA0026/2013). H.N.-G. received a
personal FCT Grant (SFRH/BD/33902/2209). The
funders had no role in study design, data collection
47
To be or not to be a pseudogene- a molecular epidemiological approach to the mclx genes
RESEARCH ARTICLE
To Be or Not to Be a Pseudogene: A
Molecular Epidemiological Approach to the
mclx Genes and Its Impact in Tuberculosis
Catarina Lopes Santos1,2☯*, Hanna Nebenzahl-Guimaraes1,2,3☯, Marta Vaz Mendes4,
Dick van Soolingen3,5, Margarida Correia-Neves1,2
1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho,
Braga, Portugal, 2 ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal,
3 National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands, 4 IBMC—Instituto
de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal, 5 Department of Medical
Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
☯ These authors contributed equally to this work.
* catarinasantos@ecsaude.uminho.pt
Abstract
Tuberculosis presents a myriad of symptoms, progression routes and propagation patterns
not yet fully understood. Whereas for a long time research has focused solely on the patient
immunity and overall susceptibility, it is nowadays widely accepted that the genetic diversity
of its causative agent,Mycobacterium tuberculosis, plays a key role in this dynamic. This
study focuses on a particular family of genes, themclxs (Mycobacterium cyclase/LuxR-like
genes), which codify for a particular and nearly mycobacterial-exclusive combination of pro-
tein domains.mclxs genes were found to be pseudogenized by frameshift-causing insertion
(s)/deletion(s) in a considerable number ofM. tuberculosis complex strains and clinical iso-
lates. To discern the functional implications of the pseudogenization, we have analysed the
pattern of frameshift-causing mutations in a group ofM. tuberculosis isolates while taking
into account their microbial-, patient- and disease-related traits. Our logistic regression-
based analyses have revealed disparate effects associated with the transcriptional inactiva-
tion of twomclx genes. In fact,mclx2 (Rv1358) pseudogenization appears to be primarily
driven by the microbial phylogenetic background, being mainly related to the Euro-Ameri-
can (EAm) lineage; on the other hand,mclx3 (Rv2488c) presents a higher tendency for
pseudogenization among isolates from patients born on the Western Pacific area, and from
isolates causing extra-pulmonary infections. These results contribute to the overall knowl-
edge on the biology ofM. tuberculosis infection, whereas at the same time launch the nec-
essary basis for the functional assessment of these so far overlooked genes.
PLOS ONE | DOI:10.1371/journal.pone.0128983 June 2, 2015 1 / 20
OPEN ACCESS
Citation: Santos CL, Nebenzahl-Guimaraes H,
Mendes MV, van Soolingen D, Correia-Neves M
(2015) To Be or Not to Be a Pseudogene: A
Molecular Epidemiological Approach to the mclx
Genes and Its Impact in Tuberculosis. PLoS ONE
10(6): e0128983. doi:10.1371/journal.pone.0128983
Academic Editor: Igor Mokrousov, St. Petersburg
Pasteur Institute, RUSSIAN FEDERATION
Received: January 23, 2015
Accepted: May 4, 2015
Published: June 2, 2015
Copyright: © 2015 Santos et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Fundação
para a Ciência e Tecnologia (FCT), Portugal, and
cofunded by Programa Operacional Regional do
Norte (ON.2—O Novo Norte), Quadro de Referência
Estratégico Nacional (QREN), through the Fundo
Europeu de Desenvolvimento Regional (FEDER),
and from Projeto Estratégico – LA 26 – 2013–2014
(PEst-C/SAU/LA0026/2013). H.N.-G. received a
personal FCT Grant (SFRH/BD/33902/2209). The
funders had no role in study design, data collection
48
Chapter IV
Introduction
Tuberculosis (TB) is an air-borne contagious disease that remains responsible for high rates of
morbidity and mortality worldwide: it is estimated that in 2013, nine million people fell ill with
TB and 1.5 million died from it [1]. TB's rate of incidence is declining slowly (1.5% per year in
average between 2000 and 2013) [1], which is somehow counter-intuitive given the financial ef-
fort put into research and prevention frameworks aiming towards its eradication. The reasons
for this halting TB twilight, besides those related with health policies, are the still missing links
in the understanding of the disease establishment on its latent or active form and TB transmis-
sion. TB has many different facets—from a life-lasting silent infection to an active and poten-
tially deathly disease—and classically most of this variability has been attributed to the hosts’
immune competence. However, and more recently, the role of the etiological agent—Mycobac-
terium tuberculosis (Mtb)—genotype has been gaining more relevance, as several studies came
up demonstrating that small genetic variations in clinical isolates or laboratory strains have a
significant impact not only in strict microbial characteristics, such as antibiotic resistance (for
instance, [2]), but also in factors related with the host-microorganism relationship dynamics,
such as disease progression and/or ability to modulate the host's immune response ([3] and ref-
erences therein).
This work presented here is focused on a family of genes that is almost exclusive ofMyco-
bacterium spp. and particularly abundant in members of theM. tuberculosis complex. Al-
though they have been seldom addressed from a functional point of view, their structure
suggests they might be involved in transcriptional regulation and response to quorum sensing
(sensu lato) stimuli (i.e., communication within bacterial cells or between bacteria and their
hosts) [4]. Its uniqueness relies on codifying for a particular combination of domains: an N-ter-
minal CHD (cyclase homology domain) and a C-terminal LuxR HTH (helix turn helix) do-
main; depending on the domain identification algorithm, an AAA (ATPases associated with
several cellular activities)/NB-ARC domain may also be identified between the other two [4–
6]. Whereas the AAA/NB-ARC domain has the general function of binding and hydrolysing
ATP and/or participating in the protein oligomerization ([5] and references therein), the CHD
is the catalytic domain of the class III nucleotidyl (adenylyl/guanylyl) cyclases [5,6], and the
LuxR is a DNA-binding domain mostly (but not exclusively) known to be associated with quo-
rum sensing transcription modulation [4,7,8]. In the genome of the reference strain Mtb
H37Rv, one can find three genes that codify for proteins with this particular domain composi-
tion: Rv0386, Rv1358 and Rv2488c [4–6]. For practical reasons, these genes will be referred to
asmclx1,mclx2 andmclx3 (fromMycobacterium cyclase/LuxR-like genes), respectively, in the
remainder of this manuscript.
Taking into account the overall lack of physiological and functional studies on Mclx pro-
teins, they can either be viewed as putative cyclase proteins with additional non-cyclase do-
main(s) attached [5,6], or as putative transcriptional regulators from the LuxR family that may
respond to, or be modulated by, ATP or cAMP [4]. Interestingly, the genome of the reference
strain Mtb H37Rv codifies for 16 genes with a CHD domain, some of which are predicted to be
transmembranar and others (including those from the Mclx family) predicted to be soluble
[5,6]. Both their frequency and their unique diversity in terms of domains composition suggest
that the cyclase activity may be a key point in Mtb fitness. In order to complete their function
—bind ATP (or, less commonly, GTP) and convert it to the secondary signal cAMP (or
cGMP)—nucleotidyl cyclases require a series of conserved residues that have been previously
characterized and that are responsible for binding a divalent metal, for stabilizing the transition
state species and for selecting and/or attaching the substrate (either ATP or GTP) [5,6]. Inter-
estingly, only the Mclx1 has all the necessary residues for cyclase activity, as Mclx2 lacks one of
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the residues necessary for the metal binding and a transition-stabilizing asparagine, Mclx3
lacks a transition-stabilizing asparagine. Moreover, both Mclx2 and Mclx3 seem to lack the
substrate selectivity residues [5]. Additionally, the Mclx1 is the only family member that has
been functionally characterized: not only was this protein found to have a significant (20%)
guanylyl cyclase side activity, besides its adenylyl activity [9], but was also found to have a role
in virulence [10]. In fact, Mclx1 was found to be required for a cAMP burst in macrophages
upon infection that destabilizes the macrophage immune response: loss of Mclx1 resulted in a
reduction in the production of tumor necrosis factor (TNF), and a decrease in the bacterial sur-
vival and in the immunopathology in the animal tissues [10].
The general association between the LuxR domain and quorum-sensing mechanisms, to-
gether with the lack of some canonical residues for the cyclase activity in the Mclx2 and Mclx3,
suggest that these proteins may indeed be quorum-sensing-like transcriptional regulators that
respond to or bind to ATP and/or cAMP in an allosteric modulatory fashion. A possible rela-
tion between cyclic nucleotides and quorum-sensing (sensu lato) is not new: a dynamic rela-
tionship between cyclic nucleotides as signals and quorum-sensing regulatory mechanisms has
been observed before, either directly or through CRP (cAMP-binding proteins), in organisms
such as Vibrio vulnificus [11], Vibrio fischeri [12], and Vibrio cholerae [13], among others.
The study presented here describes an integrative analysis combining genomics and epide-
miology and is focused on the clinical consequences ofmclx variation. Interestingly, we have
found a scattered pattern of pseudogenization amongmlcx2 andmclx3 genes, with implications
at the level of patients' demographic characteristics and TB clinical manifestations. As so, this
report establishes a link between the functionality of the proteins encoded by these two genes
and the virulence-related fitness and host adaptation ability of the Mtb.
Materials and Methods
Screening and alignment of themclx genes from public available
genomes
The presence and transcriptional integrity of themclx genes was analysed in a panel of Mtb
complex strains and clinical isolates which genome had been completely sequenced. These or-
ganisms were selected from the Genome database of the National Center for Biotechnology In-
formation (NCBI), limiting the search by organism—Mycobacterium tuberculosis complex
(taxid: 77643)—and including only genomes with the status "Complete" or "Scaffolds or con-
tigs". This search was performed on the 20th of March 2014 and yielded 187 organisms. To re-
trieve themclx gene sequences from these organisms, each genome or set of scaffolds was used
as a reference against which themclx sequences from the reference strain Mtb H37Rv (Rv0386,
Rv1358 and Rv2488c) were mapped, using the assembling tools from Geneious R7.1.4 (Bio-
matters) [14]. Instances when the putativemclx orthologue spanned more than one scaffold/
contig lead to the elimination of the respective organism from the analyses, as to avoid se-
quencing misreads potentially attributed to scaffolds/contigs junctions. One hundred and fifty
strains/clinical isolates were retained for further analyses: two ofMycobacterium africanum, 12
ofMycobacterium bovis, eight ofMycobacterium cannetti, and 128 of Mtb (Table 1). Themclx
genes were identified and individually aligned against their reference orthologue fromMtb
H37Rv to identify nucleotide substitutions, insertions and deletions, using the ClustalW algo-
rithm [15] available in the Geneious software [14] (S1A Fig).
For most Mtb strains/clinical isolates, the information on the lineage could be retrieved
from the literature and/or information on the genome. For the few cases in which this informa-
tion could not be found, each genome or set of scaffolds was used as a reference against which
the regions of difference (RD) from the reference strain Mtb H37Rv, described by Gagneux
AMolecular Epidemiological Approach to themclxGenes
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Table 1. Pairwise identity and indels in themclx genes in a panel of 150 Mtb complex strains/clinical isolates1.
Organism Lineage mclx 1 mclx 2 mclx 3
Maf GM041182 WA-2 99.97%—del -1406 (T) 99.90% 99.90%
Maf K85 WA-2 99.90%—del -1406 (T); del—2481 C) 99.90% 99.97%
Mbv 04–303 - 99.97% 99.90% 100.00%
Mbv AF2122/97 - 99.90% 99.90% 100.00%
Mbv AN5 - 100.00% 99.90% 100.00%
Mbv BCG ATCC 35733 - 100.00% 99.90% 99.97%
Mbv BCG ATCC 35740 - 99.90% 99.90% 99.97%
Mbv BCG China - 100.00% 99.90% 99.80%—ins—2198–2202 (GGCGG)
Mbv BCG Frappier - 100.00% 99.90% 99.97%
Mbv BCG Korea 1168P - 100.00% 99.90% 99.97%
Mbv BCG Mexico - 100.00% 99.90% 99.97%
Mbv BCG Moreau - 100.00% 99.90% 99.97%
Mbv BCG Pasteur
1173P2
- 100.00% 99.90% 99.90%
Mbv BCG Tokyo 172 - 100.00% 99.90% 99.97%
Mcn CIPT 140010059 - 99.90% 99.90% 93.40%—ins—2519–2521 (CCA)
Mcn CIPT 140060008 - 99.80% 99.60% 93.50%—ins—2521–2523 (ACC)
Mcn CIPT 140070002 - 99.90% 99.90% 98.90%
Mcn CIPT 140070005 - 99.70% 99.60% 98.60%
Mcn CIPT 140070007 - 99.30% 99.50% 99.00%
Mcn CIPT 140070008 - 99.70% 99.90% 99.10%
Mcn CIPT 140070013 - 99.30% 98.50% 98.80%
Mcn CIPT 140070017 - 99.00% 99.20% 97.00%—ins—2531–2533 (GCC)
Mtb '98-R604
INH-RIF-EM'
EAm 100.00% 99.90%—ins—840 (T) 99.97%—del—2716 (A)
Mtb 02_1987 EAs 99.90% 99.97% 100.00%
Mtb 1034 EAs 99.97% 99.97% 100.00%
Mtb 210 EAs 99.97% 99.97% 99.97%
Mtb 43–16836 IO 100.00% 99.97% 99.90%—ins—1393–1394 (TA)
Mtb 7199–99 EAm 100.00% 99.90% 100.00%
Mtb BT1 EAs 99.97% 99.97% 99.97%
Mtb BT2 EAs 99.97% 99.97% 99.97%
Mtb BTB05-552 EAm 100.00% 99.97% 100.00%
Mtb BTB05-559 EAm 100.00% 99.97% 100.00%
Mtb C EAm 99.50%—ins—3195 (T); ins—3211 (G);
ins—3218 (G)
99.90% 99.90%—ins—2919 (G); ins—2992 (G)
Mtb CAS/NITR204 EAI 98.90%- 15 del/ 1 ins 99.20%- 13 del 98.70%- 19 del/ 2 ins
Mtb CCDC5079 EAs 99.97% 99.90%—del—2523–2525
(CGA)
99.97%
Mtb CCDC5180 EAs 99.97% 99.97% 99.97%
Mtb CDC1551 EAm 100.00% 99.96% 100.00%
Mtb CDC1551A 100.00% 99.97% 100.00%
Mtb CTRI-2 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb EAI5 100.00% 99.90% 99.90%—del—1388–1392 (TTGCG)
Mtb EAI5/NITR206 IO 99.90% 99.97% 100.00%
Mtb EAS054 IO 99.97% 99.97% 99.80%—del—1388–1392 (TTGCG)
Mtb F11 EAm 99.97% 99.90%—ins—840 (T) 100.00%
Mtb FJ05194 EAs 100.00% 99.90% 100.00%
(Continued)
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Table 1. (Continued)
Organism Lineage mclx 1 mclx 2 mclx 3
Mtb GuangZ0019 EAm 100.00% 99.97% 100.00%
Mtb H37Ra EAm 100.00% 100.00% 100.00%
Mtb H37RvCO EAm 100.00% 100.00% 100.00%
Mtb HKBS1 EAs 99.97% 99.97% 99.97%
Mtb HM EAm* 99.97% 99.90%—ins—840 (T) 99.00%—ins—1921–1953 (TG...TG)
Mtb HN878 EAs 99.97% 99.97% 99.97%
Mtb INS_MDR EAm 100.00% 99.97% 100.00%
Mtb INS_SEN EAm 100.00% 99.97% 100.00%
Mtb INS_XDR EAm 100.00% 99.97% 100.00%
Mtb KZN 1435 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb KZN 4207 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb KZN 605 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb KZN R506 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb KZN V2475 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb MTB-489 ? 99.97% 100.00% 99.97%
Mtb NA-A0008 ? 99.97%—del—871 (C) 99.90% 99.80%—del—1388–1392 (TTGCG); del
—2044 (C)
Mtb NA-A0009 ? 99.90%—del—871 (C); ins—2308–
2310 (AG); del—2901 (C)
99.97% 99.80%—del—1388–1392 (TTGCG); del
—2104 (G)
Mtb NCGM2209 EAs 99.97% 99.97% 100.00%
Mtb OSDD071 EAI 100.00% 99.97% 99.90%
Mtb OSDD105 EAm 100.00% 99.90% 99.97%—del—900 (C)
Mtb OSDD493 EAm 99.97%—del—352 (C) 99.97% 100.00%
Mtb PanR0201 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0202 EAm 100.00% 99.97% 100.00%
Mtb PanR0205 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0206 EAm 100.00% 99.90% 100.00%
Mtb PanR0207 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0208 EAm 100.00% 99.97% 100.00%
Mtb PanR0209 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0304 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0305 EAm 100.00% 99.97% 100.00%
Mtb PanR0306 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0307 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0308 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0309 EAm 100.00% 99.97% 100.00%
Mtb PanR0313 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0314 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0315 EAm 100.00% 99.90% 100.00%
Mtb PanR0316 EAm 100.00% 99.97% 99.97%
Mtb PanR0317 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0401 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0402 EAm 100.00% 99.10%—ins—840 (T);
del—3466 (G)
99.97%
Mtb PanR0403 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0404 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0405 EAm 100.00% 99.90%—ins—840 (T) 99.97%
(Continued)
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Table 1. (Continued)
Organism Lineage mclx 1 mclx 2 mclx 3
Mtb PanR0409 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0410 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0411 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0412 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0501 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0503 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0505 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0602 EAm 100.00% 96.50%- 5 del/ 4 ins 100.00%
Mtb PanR0603 EAm 100.00% 99.90%-ins—840 (T) 99.97%
Mtb PanR0604 EAm 100.00% 99.90%-ins—840 (T) 99.97%
Mtb PanR0605 EAs 99.97% 99.97% 99.97%
Mtb PanR0606 EAs 99.97% 99.97% 99.97%
Mtb PanR0607 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0609 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0610 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0611 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0702 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0703 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0704 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0707 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0708 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0801 EAm 100.00% 99.90% 100.00%
Mtb PanR0802 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0803 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0804 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0805 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0902 EAm 100.00% 99.90% 100.00%
Mtb PanR0903 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PanR0904 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR0906 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR0907 EAm 100.00% 99.90% 100.00%
Mtb PanR0909 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR1005 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR1006 EAm 100.00% 99.90%—ins—840 (T) 99.97%
Mtb PanR1007 EAm 99.97% 99.90%—ins—840 (T) 99.97%
Mtb PanR1101 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb PR05 ? 100.00% 99.97% 99.80%—del—1388–1392 (TTGCG)
Mtb R1207 EAs 99.90% 99.97% 100.00%
Mtb RGTB327 EAm* 99.90%—ins—454 (G); ins—684 (A) 99.90%—ins—840 (T);
ins—1331 (C)
99.90%—ins—766 (G); ins—2844–2845
(GG)
Mtb RGTB423 IO* 99.97%—ins—2821 (C) 99.90%—ins—390 (A) 99.70%—ins—1121 (A); ins—2160–2162
(GCC); ins—3017 (G)
Mtb S96-129 EAm 100.00% 99.97% 100.00%
Mtb Beijing/NITR203 EAs 99.90% 99.90% 99.97%
Mtb Erdman = ATCC
35801
EAm 100.00% 99.90% 100.00%
Mtb Haarlem EAm 99.10%- 7 ins 99.90% 99.90%—del—2264 (G);del—2362 (G)
(Continued)
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et al. [16] in the definition of the six phylogeographical lineages, were mapped, and the occur-
rence of the described long sequence polymorphisms was used for the definition of the lineage
(marked with an "!" in Table 1). In a few cases the RDs fell in scaffolds/contigs junctions, and
therefore the presence of polymorphisms could not be accurately determined, precluding the
determination of the lineage (marked with a "?" in Table 1).
Screening and alignment of themclx genes from clinical isolates of an
epidemiologically characterized cohort
To get an insight into the epidemiological/clinical features that may be associated with the oc-
currence of themclx pseudogenization, themclx transcriptional integrity was analysed in a di-
versified panel of Mtb clinical isolates. This panel is composed of 140 organisms collected and
isolated in the Netherlands from 1993 to 2011, which are fully characterized from an epidemio-
logical and clinical point of view (S1 Table) [17]. Demographic and clinical information, pro-
vided by the Registration Committee of the Netherlands Tuberculosis Register (NTR) that
approved this retrospective study, were linked to the isolates on the basis of gender, date of
birth, year of diagnosis and postal code. For 100 of these clinical isolates, whole-genome se-
quencing was performed ([17] and Nebenzahl-Guimaraes et al., unpublished data) and the sin-
gle nucleotide polymorphisms and INDELs (insertions or deletions) were called against the
Table 1. (Continued)
Organism Lineage mclx 1 mclx 2 mclx 3
Mtb OSDD515 EAm 100.00% 99.97% 99.97%—del—938 (T)
Mtb SUMu001 ? 99.97%—del—952 (G) 100.00% 100.00%
Mtb SUMu002 ? 99.97%—del—952 (G) 99.97% 99.97%—ins—2487 (A)
Mtb SUMu003 ? 100.00% 99.97% 100.00%
Mtb SUMu004 ? 100.00% 99.97% 100.00%
Mtb SUMu005 ? 100.00% 99.97% 100.00%
Mtb SUMu006 ? 100.00% 99.97% 100.00%
Mtb SUMu008 ? 99.97%—del—952 (G) 99.97% 100.00%
Mtb SUMu010 ? 100.00% 100.00% 100.00%
Mtb SUMu011 ? 100.00% 100.00% 100.00%
Mtb SUMu012 ? 99.90%—del—2254 (G); del—2962 (G) 100.00% 100.00%
Mtb UM 1072388579 ? 100.00% 99.90% 100.00%
Mtb UT205 EAm 100.00% 99.90%—ins—840 (T) 100.00%
Mtb W-148 EAs 99.97% 99.90%—del—2523–2525
(CGA)
99.97%
Mtb WX3 EAs 99.97% 99.97% 99.97%
Mtb X122 EAs 99.97% 99.90%—del—2523–2525
(CGA)
99.97%
Mtb XDR1219 EAs 99.97% 99.97% 99.97%
Mtb XDR1221 EAs 99.90% 99.97% 100.00%
1The pairwise identity refers to the % of conserved residues of each gene after aligning it with its orthologue from the reference strain M. tuberculosis
H37Rv; the putative pseudogenes are highlighted in bold; indel ocurrences are described by their type (ins, insertion; del, deletion) and by their location
(considering an alignment with the reference mclx genes from the Mtb H37Rv strain), except when the total number of isolated occurences exceeds 3, in
which case only their frequency is indicated; Maf, Mycobacterium africanum; Mvb, Mycobacterium bovis; Mcn, Mycobacterium cannetti; Mtb,
Mycobacterium tuberculosis; WA-2, West-African 2; EAm, Euro-American lineage; EAs, East-Asian lineage; IO, Indo-Oceanic; EAI, East-African
Indian lineage
*, indicates that the information on the lineage was obtained by aligning the H37Rv RD with the genome/scaffolds of the respective organism.
doi:10.1371/journal.pone.0128983.t001
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reference strain H37Rv using Breseq software (version 0.23) with a minimum depth of 15x
[18] (S1B Fig). SNPs with low-quality evidence (i.e. possible mixed read alignment) or within
5 bp of an INDEL were discarded. The presence of INDELs within themclx coding regions and
their potential to disrupt the open reading frame was evaluated. For the remaining 40 clinical
isolates, themclx genes were PCR-amplified in 3 overlapping fragments, each of 1200 to 1400
base pairs (see S2 Table for information on the primers and PCR conditions), and the purified
PCR products were sequenced (by GATC Biotech). Each gene fragment was amplified twice
and all fragments were sequenced in both directions. The final sequences were mapped against
and aligned with their orthologues from the Mtb H37Rv reference strain, using the Geneious
R7.1.4 (Biomatters) [14] software (S1C Fig). All alignments were visually inspected and a con-
servative approach was applied: whenever the sequencing results failed to converge to an obvi-
ous consensus, the gene status (functional/pseudogene) was considered to be unknown. For
that reason, a few clinical isolates were not considered in the final analyses (final n = 127).
Statistical analyses
To envisage the relationship between the clinical and epidemiological features of the TB infec-
tion and the status of themclx genes, a separate logistic regression-based analysis was carried
out formclx2 andmclx3. Firstly, simple binary logistic regressions were performed to identify
the significant predictors of eachmclx genes status. Afterwards, two multiple binary logistic re-
gressions were performed considering only those considered to be significant predictor vari-
ables (p<0.2 in the univariate analysis). Particularly in the case ofmclx3, a sequential binary
regression model was performed considering three sets of variables (patient-related, microor-
ganism-related and disease-related). All statistical analyses were performed using the IBM
SPSS Statistics, version 22 (IBM).
Phylogenetic tree construction
The FASTA files of publicly available NCBI strains were downloaded and pair aligned with the
H37Rv reference sequence (NC_000962.gbk) using MAUVE v2.4.0. Multiple sequence align-
ments (MSA) using 62 robust SNP markers that have been shown to construct high resolution
and reproducible phylogenies [19] were then made for 100 of the clinical isolates and 100 of
the publicly available NCBI strains. The MSAs were subsequently used to generate a parsimo-
ny-based tree using the DNA parsimony algorithm version 3.69 from the Phylip package.
Results
A number ofmclx genes among theM. tuberculosis complex species
are likely pseudogenized
Themclx genes were previously identified as a family of genes nearly exclusive to theMycobac-
terium genus and particularly abundant among the members of Mtb complex [4]. As a distinc-
tive feature, these genes encode proteins with a particular domain architecture, including a
CHD (cyclase homology domain) and a LuxR HTH domain. In order to acquire a better under-
standing of the distribution of this particular group of genes among the Mtb complex, an align-
ment-based screening was performed against a diversified panel of organisms with their
genome fully-sequenced, including elements from the speciesM. africanum,M. bovis,M. can-
netti and Mtb. Interestingly, this strategy revealed that even thoughmclx genes have in general
an overall high degree of sequence conservation, usually with more than 99% nucleotides iden-
tical to their orthologues from the reference strain Mtb H37Rv, in a number of them a few
INDELs were present, which caused a disruption in the open reading frame leading to the
AMolecular Epidemiological Approach to themclxGenes
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accumulation of stop codons and to the truncation of the respective sequence (Table 1). To
avoid misinterpretations, and keeping in mind that gene size can vary to a certain extent with-
out necessarily implying loss of function, the following criterion was established: any given
mclx gene was considered to be a pseudogene whenever its sequence was truncated in more
than 25% of the size of the corresponding Mtb H37Rv reference orthologue. While this criteri-
on would require further functional validation, we consider it appropriate for this initial
screening, as it likely minimizes the chance of false positives (i.e., genes that could be consid-
ered pseudogenes given a small size variation but that in fact retain their full functionality).
Overall, our analysis revealed that the pseudogenization is a rather common phenomenon
among themclx genes: 51.3% of the organisms in the analysed panel have at least one of their
mclx genes truncated (Table 1 and Fig 1). As shown in Fig 1, the occurrence of the pseudogenes
is not evenly distributed among the three different genes: the number of species with amclx2
pseudogene is much higher than that of species that suffered pseudogenization in themclx1
and/or themclx3. In fact, whereas 7.3% and 8.7% of the organisms in the analysed panel have a
pseudogenizedmclx1 andmclx3, respectively, 39.3% do so for themcx2. Accordingly, the per-
centage of organisms with more than 1mclx pseudogenized is relatively low (3.3%). Notwith-
standing, it should be highlighted that in three (out of the four) organisms with two
pseudogenes, the pseudogenization events occur in themclx1 andmclx3 (Table 1 and Fig 1),
the two genes with lower pseudogenization occurrence, suggesting that the simultaneous loss
ofmclx2 and any othermclxmay be somehow harmful to the microorganisms.
Epidemiological assessment of themclx pseudogenization
In order to evaluate whether there was a relationship between the inactivation of these genes in
certain bacterial isolates and the epidemiological and clinical characteristics of the disease
caused by those isolates, the presence and functionality of themclx genes was analysed in a
Fig 1. Relative frequency of the organisms harbouring pseudogenes in each of themclx genes. The
percentages are relative to the total number of strains/organisms listed in Table 1, and are stratified according
to the three main species: Mtb (Mycobacterium tuberculosis), Mbv (Mycobacterium bovis) and Maf
(Mycobacterium africanum).
doi:10.1371/journal.pone.0128983.g001
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panel of Mtb strains isolated in the Netherlands from 1993 to 2011 and fully characterized re-
garding their epidemiological and clinical features (S1 and S2 Tables). Even though all organ-
isms in this panel were isolated in the Netherlands, only a minority of them (22.0%) were from
native Dutch individuals. In fact, the patients' birth region is quite diversified: whereas 29.9%
of the patients were born in Europe, 18.1% were born in Africa, 18.1% in the Eastern Mediter-
ranean area, 13.4% in the South East Asia, 10.2% in the Western Pacific and 9.4% in the Ameri-
cas. Accordingly, and given the strong phylogeographical nature of the Mtb lineages, this panel
of isolates holds representatives of the EAm lineage (51.2%), Indo-Oceanic (IO) lineage
(24.4%), East-African Indian (EAI) lineage (14.2%), and East-Asian (EAs) lineage (7.9%).
From the classical risk factors commonly associated with active TB, the one that stands out in
this panel is the origin from an endemic region. As for the other frequently-mentioned risk fac-
tors, their occurrence is rather low: only 3.1% of the strains were known to be isolated from
homeless patients, 8.7% from known drug and/or alcohol users, and 14.2% from patients with
co-morbidities (10.2% were HIV-positive, 3.1% had diabetes mellitus, 0.8% reported a malig-
nancy and none were diagnosed with renal insufficiency or had been through organ transplan-
tation). Regarding the TB localization, 64.6% of the isolates were retrieved from patients
diagnosed with pulmonary TB, 18.9% from patients with extra-pulmonary TB, and 15.7%
from patients reported to have both pulmonary and extra-pulmonary TB. Microbial transmis-
sibility was defined following the work of Nebenzahl-Guimaraes et al. [17], and 61.4% of the
clinical isolates analysed were considered "transmissible". In what concerns the transcriptional
integrity of themclx genes, no pseudogenes were found amongmclx1 following the criteria de-
scribed in the material and methods, whereas 18.9% and 24.4% of themclx2 andmclx3, respec-
tively, had suffered pseudogenization (S1 Table).
To identify the significant predictors of eachmclx2 andmclx3 gene status, simple binary lo-
gistic regressions were performed (Table 2). Interestingly, the results were dissimilar for both
genes, i.e., the independent variables for which the different categories presented odd ratios
(ORs) for pseudogenization statistically different from the reference were not the same for
mclx2 andmclx3. The only variable that had a statistically significant association with the pseu-
dogenization for both genes was “transmissibility” (Table 2). However, the effect of this vari-
able had a different direction in each of the genes, i.e., non-transmissible isolates were around
four times more likely to carry a pseudogenized copy ofmclx2, but around two times more like-
ly to carry a non-pseudogenized copy ofmclx3.
The other variable revealing an association tomclx2 was ethnicity—being a native Dutch
represented a 4.5-fold increased risk of carrying a pseudogene (Table 2). The calculation of the
ORs for the different Mtb lineages did not yield significant results, as most of the isolates with
themclx2 pseudogenized belong to the EAm lineage (with a single exception—S1 Table), and
for a number of lineages the number of pseudogenizations is null. However, isolates belonging
to the EAI lineage did have a decreased risk for pseudogenization when compared to isolates
belonging to the EAm lineage. Among the completely sequenced and publicly available Mtb
complex genomes, there was also only one strain outside the EAm lineage that had a pseudo-
genizedmclx2 (Table 1).
Concerning themclx3 four other factors besides transmissibility were shown to have a sig-
nificant association with its pseudogenization: gender, birth region, house setting and localiza-
tion of the TB infection (Table 2). Being a female represented a 2.2-increased risk for having a
pseudogenized form ofmclx3, whereas living in an urban area represented a decrease of this
risk to 0.345. On the other hand, isolates from strictly extra-pulmonary infections had an in-
creased OR (more than five-fold higher) formclx3 pseudogenization when compared to strictly
pulmonary strains. Finally, birth region was strongly associated with themclx3 gene status,
with no pseudogenes identified in isolates from patients born in Africa, a decreased OR (0.886
AMolecular Epidemiological Approach to themclxGenes
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Table 2. Univariate ORs formclx2 andmclx3 pseudogenization (p values <0.2 are highlighted).
univariate ORs (95% CI)
independent variables n mclx2 pseudogenization mclx3 pseudogenization
patient-related
age 126 0.973 (0.942–1.006); p = 0.103 1.008 (0.983–1.033); p = 0.553
gender p = 0.624 p = 0.061
female 47 1.255 (0.507–3.106) 2.202 (0.965–5.024)
male 79 1 (ref) 1 (ref)
birth region p = 0.589 p = 0.005
Africa 23 0.679 (0.216–2.137); p = 0.508 0.000 (0.000-.); p = 0.998
The Americas 12 0.385 (0.073–2.022); p = 0.259 0.886 (0.158–4.974); p = 0.890
Eastern Mediterranean 23 0.288 (0.072–1.154); p = 0.079 0.664 (0.154–2.874); p = 0.584
Europe 38 1 (ref) 1 (ref)
South East Asia 17 0.000 (0.000-.); p = 0.998 3.100 (0.873–11.007); p = 0.080
Western Paciﬁc 13 0.000 (0.000-.); p = 0.999 53.143 (5.896–478.992); p<0.001
ethnicity p = 0.002 p = 0.391
native dutch 28 4.583 (1.738–12.088) 0.626 (0.215–1.823)
foreign-born 97 1 (ref) 1 (ref)
house setting p = 0.787 p = 0.033
rural 81 1 (ref) 1 (ref)
urban 45 0.878 (0.343–2.248) 0.345 (0.129–0.918)
BCG vaccination p = 0.668 p = 0.751
no 27 1.306 (0.385–4.431) 0.842 (0.291–2.433)
yes 39 1 (ref) 1 (ref)
co-morbidities p = 0.371 p = 0.414
no or unknown 109 1 (ref) 1 (ref)
yes 18 0.494 (0.106–2.312) 0.579 (0.156–2.148)
alcohol or drug use p = 0.949 p = 0.243
no or unknown 116 1 (ref) 1 (ref)
yes 11 0.949 (0.192–4.707) 0.287 (0.035–2.334)
homelessness p = 0.753 p = 0.978
no or unknown 123 1 (ref) 1 (ref)
yes 4 1.499 (0.144–14.573) 1.033 (0.104–10.310)
microorganism-related
lineage p = 0.220 -
EAI 18 0.107 (0.013–0.860); p = 0.036 -
EAm 65 1 (ref) -
EAs 10 0.000 (0.000-.); p = 0.999 -
IO 31 0.000 (0.000-.); p = 0.998 1
antibiotic resistance p = 0.659 p = 0.979
none or unknown 118 1 (ref) 1 (ref)
resistant 8 1.455 (0.275–7.696) 1.023 (0.196–5.349)
transmissibility p = 0.003 p = 0.097
no 49 4.242 (1.650–10.907) 0.467 (0.190–1.148)
yes 78 1 (ref) 1 (ref)
disease-related
disease localization p = 0.573 p = 0.002
pulmonary TB 82 1 (ref) 1 (ref)
extra-pulmonary TB 24 0.589 (0.156–2.222); p = 0.435 5.279 (1.983–14.049); p = 0.001
pulmonary and extra-pulmonary TB 20 1.375 (0.435–4.343); p = 0.587 0.788 (0.205–3.038); p = 0.730
doi:10.1371/journal.pone.0128983.t002
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and 0.664) for pseudogenization in patients born in the Americas and Eastern Mediterranean,
and an increased OR (3.100 and 53.143) for those born in South East Asia and Western Pacific,
when compared to Europe (Table 2).
To detect confounding and/or mediation factors in the relation between the different vari-
ables with a significant association, multivariate binary logistic regression analyses were per-
formed for the pseudogenization ofmclx2 andmclx3 (Tables 3 and 4). These analyses included,
for each case, all variables that presented a p below 0.200 in the univariate binary logistic re-
gression (Table 2). These variables were organized into three different blocks (patient-related,
microorganism-related and disease-related), which were sequentially added to each multivari-
ate model.
Formclx2, a single model was built including the microorganism-related variable transmis-
sibility, and the patient-related variables age and ethnicity (Table 3). Transmissibility was no
longer significant upon correcting for age and ethnicity. In fact, in the multivariate model only
ethnicity and age present significant associations: microorganisms isolated from native Dutch
have an increased tendency to be carriers ofmclx2 pseudogenes, as do microorganisms isolated
from younger people. However, it should be noticed that the p value for the microorganism
lineage is close to the cut-off (0.200), and one of its categories actually has a p value of 0.036.
Adding this variable to the multivariate model, both age and ethnicity lose its significance (S3
Table).
Formclx3, three different models were built: the first one using only the disease-related vari-
able TB localization, the second one including the microorganism-related variable transmissi-
bility, and the third one incorporating the patient-related variables gender, house setting and
birth region (Table 4). As for transmissibility, gender and house setting, their associations to
mclx3 status were no longer significant after correcting for the other variables in the model.
However, birth region remained as a significant variable, with patients born in the Western Pa-
cific having an increased (77-fold) probability of carrying a pseudogenized form of this gene
when compared to patients from Europe (Table 4). Since no pseudogenes were found among
strains isolated from African patients, it was not possible to perform the mathematical compu-
tation of the OR and confidence interval for this category (and for the-Log likelihood of the
Table 3. Multivariate logistic regression model formclx2 pseudogenization (p values < 0.05 are
highlighted).
multivariate ORs (95% CI)
mclx2 Model 1
patient-related
age 0.952 (0.909–0.997); p = 0.038; B = -0.049; S.E. = 0.024;Wald = 4.307
ethnicity native dutch 6.628 (1.708–25.714); p = 0.006; B = 1.891; S.E. = 0.692; Wald = 7.475
foreign-born 1 (ref)
microorganism-related
transmissibility no 1.918 (0.594–6.193); p = 0.276; B = 0.651; S.E. = 0.598; Wald = 1.186
yes 1 (ref)
Omnibus Test (chi-square/p) 20.039/ p<0.001
Cox & Snell R2 0.149
Nagelkerke R2 0.242
Hosmer and Lemeshow (chi-
square/p)
5.568/ p = 0.695
n 124
doi:10.1371/journal.pone.0128983.t003
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model no final solution could be found). However, excluding African individuals from the
sample had a negligible effect on the calculation of the parameters for the other categories/
variables and on the overall significance of this model (data not shown). Finally, disease locali-
zation remains as a significant variable even after correcting for the microorganism- and
Table 4. Multivariate logistic regression models formclx3 pseudogenization (p values < 0.05 are highlighted).
multivariate ORs (95% CI)
mclx3 Model 1 Model 2 Model 3
patient-related
gender female - - 0.532(0.149–1.893); p = 0.330; B =
-0.631; S.E. = 0.648;Wald = 0.950
male - - 1 (ref)
house setting rural - - 1 (ref)
urban - - 0.433 (0.118–1.593); p = 0.208; B
= -0.837; S.E. = 0.665;
Wald = 1.586
birth region - - p = 0.009; Wald = 15.307
Africa - - 0.000 (0.000-.); p = 0.998; B =
-20.087; S.E. = 8006.116;
Wald = 0.000
The Americas - - 0.929 (0.148–5.849); p = 0.938; B
= -0.074; S.E. = 0.939;
Wald = 0.006
Eastern
Mediterranean
- - 0.433 (0.077–2.446); p = 0.344; B
= -0.837; S.E. = 0.883;
Wald = 0.897
Europe - - 1 (ref)
South East Asia - - 3.479 (0.657–18.431); p = 0.143;
B = 1.247; S.E. = 0.851;
Wald = 2.149
Western Paciﬁc - - 77.372 (6.357–941.774);
p = 0.001; B = 4.349; S.E. = 1.275;
Wald = 11.631
microorganism-related
transmissibility no - 0.761 (0.280–2.070); p = 0.593;
B = -0.273; S.E. = 0.510;
Wald = 0.285
2.953 (0.648–13.458); p = 0.162;
B = 1.083; S.E. = 0.774;
Wald = 1.957
yes - 1 (ref) 1 (ref)
disease-related
disease
localization
p = 0.002; Wald = 12.466 p = 0.009; Wald = 9.447 p = 0.025; Wald = 7.342
pulmonary TB 1 (ref) 1 (ref) 1 (ref)
extra-pulmonary TB 5.279 (1.983–14.049); p = 0.001;
B = 1.664; S.E. = 0.499;
Wald = 11.097
4.702 (1.630–13.560); p = 0.004;
B = 1.548; S.E. = 0.540;
Wald = 8.206
9.894 (1.825–53.654); p = 0.008;
B = 2.292; S.E. = 0.863;
Wald = 7.060
pulmonary and extra-
pulmonary TB
0.788 (0.205–3.038); p = 0.730; B
= -0.238; S.E. = 0.688;
Wald = 0.120
0.769 (0.199–2.978); p = 0.704;
B = -0.262; S.E. = 0.691;
Wald = 0.144
3.609 (0.637–20.434); p = 0.147;
B = 1.283; S.E. = 0.885;
Wald = 2.105
Omnibus Test (chi-square/p) 12.555/ p = 0.002 12.843/ p = 0.005 56.253/ p<0.001
Cox & Snell R2 0.095 0.097 0.360
Nagelkerke R2 0.141 0.144 0.536
Hosmer and Lemeshow (chi-square/p) 0.000/ p = 1.000 0.081/ p = 0.994 6.225/ p = 0.514
n 126
doi:10.1371/journal.pone.0128983.t004
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patient-related variables. Clinical isolates from strictly extra-pulmonary infections have a near-
ly 10-fold increased probability of carrying a pseudogenized form ofmclx3 when compared to
isolates from strictly pulmonary forms of the disease (Model 3, Table 4). This increased pro-
pensity formclx3 pseudogenized forms is maintained for isolates from disseminated (pulmo-
nary and extra-pulmonary) infections, although in a non-significant way (Model 3, Table 4).
To avoid phylogenetic redundancy, i.e., to ensure that the observed results were due to actu-
al relations observed in the sample and not to the relative abundance of certain genotypes, the
analyses were repeated using a single representative for each VNTR and RFLP type (the exclud-
ed isolates are annotated in the S1 Table). The results were similar to the previous ones in both
the univariate (S4 Table) and multivariate (S5 and S6 Tables) analyses, supporting the initial
deductions.
To gain some phylogenetic insight into the distribution of these pseudogenization events, a
phylogenetic tree encompassing a number of genomes analysed in this article was constructed
and the position of putative pseudogene-causing INDELS annotated (Fig 2). The frameshift-
causing INDEL events in the differentmclx genes are not unique in each organism, but are
often found repeated across different strains/clinical isolates. On the other hand, although
most pseudogenes in a given gene are concentrated in the same part of the tree, a few others ap-
pear scattered throughout the organisms, preventing a clear phylogenetic signal. Particularly,
although most strains with pseudogenization events amongmclx genes belong to Mtb, twoM.
africanum representatives have pseudogenized forms of themclx1 and there is oneM. bovis
BCG with a pseudogenizedmclx3 (Table 1, Figs 1 and 2). This somewhat dispersed distribution
of pseudogenization events, together with the fact that different INDELs occur in different
strains/clinical isolates but result in the pseudogenization of the same gene, suggest that the
pseudogenization of eachmclxmay have occurred more than once in their phylogenetic histo-
ry. This is consistent with a scenario where strong selective pressures are at the basis of these
inactivation events, leading to the same overall result—the pseudogenization of a givenmclx,
although sometimes following different pathways (different INDELs), as opposed to a scenario
of random evolution, where the pseudogenization of a given gene would have likely occurred
once and dispersed throughout the lineage.
Discussion
The analysis of the genotypic variability of themclx genes revealed a scattered pattern of pseu-
dogenization among the Mtb complex strains and clinical Mtb isolates. The occurrence of
INDELs in the differentmclx genes was not homogenous between the two panels explored, the
most striking difference being thatmclx1 was pseudogenized in 7.3% of the publicly available
strains compared to none in the dataset of clinical isolates. The absence of West-African 2 rep-
resentatives in the latter may have contributed to this, as the pseudogenization ofmclx1 is par-
ticularly common in this lineage [20] and quite rare amongst others. Taking into account the
role played by its codified protein in the macrophages' initial immune response [10], one can
argue that its inactivation may be one significant aspect inM. africanum (West-African 2
members) virulence attenuation. The percentages of the pseudogenizedmclx2 andmclx3 dif-
fered between both panels, the former being more common amongst the publicly available
strains and the latter more so in the clinical isolate dataset. These differences are likely related
to the degree of clustering in both panels. Whereas the clustering is limited among the studied
clinical isolates, and could actually be controlled for without an impact in the main results, one
cannot access such information regarding the genome-sequenced and publicly available
strains. The fact that a few of them are laboratory strains, and a number of others have been
likely isolated from the same given TB outbreak (such as the SUMu or the PanR collections,
AMolecular Epidemiological Approach to themclxGenes
PLOS ONE | DOI:10.1371/journal.pone.0128983 June 2, 2015 14 / 20
61
To be or not to be a pseudogene- a molecular epidemiological approach to the mclx genes
representing 6.7% and 39.3% of this panel, respectively), hints at the existence of higher genetic
relatedness. In this context, certain genetic features may appear more common solely because
they occur in an overrepresented genotype.
The existence of threemclx genes in each genome raises the hypothesis of functional redun-
dancy among them. However, that would likely have as consequence a random pattern of inac-
tivation, resulting in similar pseudogenization ratios for each gene, which is not supported by
the data. Moreover, the disparate results in the logistic regression analysis in terms of
Fig 2. A parsimony-based phylogenetic tree depicting the distribution of pseudogenization events across the 3mclx genes in both
epidemiologically characterized clinical isolates (n = 100; denoted in black) and publicly available NCBI strains (n = 100; denoted in red). LSP-
defined MTBC lineages/sublineages are colour-coded and indicated in the outer arc (Purple –Mycobacterium africanum; Brown—Mycobacterium bovis;
blue—Euro-American lineage; red—East-Asian lineage; orange—Indo-Oceanic; green—East-African Indian lineage).
doi:10.1371/journal.pone.0128983.g002
AMolecular Epidemiological Approach to themclxGenes
PLOS ONE | DOI:10.1371/journal.pone.0128983 June 2, 2015 15 / 20
62
Chapter IV
significant variables buttresses the hypothesis that selective pressures and/or the clinical conse-
quences of inactivatingmclx2 ormclx3 are dissimilar. This is in agreement with the previously
published functional analysis of themclx1—Agarwall et al. mutated other adenylyl cyclases be-
sidesmclx1, namelymclx3, and for none of them significant effects were noticed in survival
upon competing at mouse lungs, nor differences in macrophage cAMP levels compared to the
wild-type, as it was for themclx1, strongly suggesting that they have different functions [10].
The univariate and multivariate binary logistic regression analyses uncovered a number of
statistically significant relationships that highlight the potential impact of themclx genes func-
tionality in aspects related with the microorganism biology and fitness, TB development and
patients' demography. Inmclx2, the main factor associated with pseudogenization appears to
be the microorganism lineage, with all but one organism carrying a pseudogenized gene be-
longing to the EAm lineage among the panel of strains used for this analysis. Accordingly, in
the publicly available genomes there is only one pseudogenization ofmclx2 outside the EAm
lineage. Age and ethnicity might be significant factors as well, with the multivariate model
showing that native Dutch patients present an approximately 6.6-fold higher risk of carrying a
pseudogenizedmclx2, and younger patients having a decreased OR for these forms. Although
this could suggest some degree of adaptation it is also true that 78.6% of the native Dutch iso-
lates actually belong to the EAm lineage, and both age and ethnicity lose significance in the
multivariate model controling for lineage. As such, even if age and ethnicity do play a role in
the pseudogenization ofmclx2, this should be a rather limited one.
Formclx3, the results were quite dissimilar from those ofmclx2. Significant variables in the
multivariate model formclx3 include patient birth region and disease localization. Given the
strong phylogeographical structure of Mtb lineages, the relation between the patients' birth re-
gion andmclx3 pseudogenization can either be interpreted as a reflection of a phylogenetic sig-
nal (the effect of the microorganisms' lineage by itself cannot be evaluated for this gene, as all
pseudogenes are found among strains belonging to the IO lineage in the analysed panel) or due
to differences in the individuals from different regions (either genetic or socially/culturally- im-
plemented). The relationship with disease localization remains consistently significant after
correcting for all the other variables with a statistically significant signal in the univariate analy-
sis. This suggests thatmclx3 plays a key role in the establishment of a pulmonary infection—
and therefore its absence causes an adjustment of the infection to the extra-pulmonary space—
or, conversely, that Mclx3 function prevents the infection from spreading.
Several risk factors for extra-pulmonary forms of TB have been addressed and characterized
previously, both in what comes to the microbial influence [21–23], and also regarding host fac-
tors [24]. Concerning genetic microbial features, large INDEL polymorphisms in a phospholi-
pase C gene, plcD, have been significantly associated with extra-pulmonary forms of TB when
compared to strains without a plcD interruption [22]. On the other hand, the study of the same
kind of mutations occurring in other genes from the same family, plcA, plcB and plcC, failed to
show such a correlation [23]. This present study parallels this:mclx3 is strongly and significant-
ly associated with extra-pulmonary TB, but such is not the case for its paraloguemclx2. In what
concerns host features, gender, ethnicity and HIV-status have all been found to be significant
risk factors for extra-pulmonary forms of TB [24]. Whereas in this study we could not access
the patients' ethnicity (concerning race/skin colour), both gender and birth region (a possible
proxy) were accounted for in the multivariate model. As a precaution, the data was re-analysed
integrating themclx3 pseudogenization status as a putative risk factor for extra-pulmonary in-
fections (as opposed to strictly pulmonary and/or disseminated infections) and correcting for
all host factors previously associated with this form of the disease: age, gender, HIV serological
status, birth region and ethnicity. In accordance the pseudogenization ofmclx3 appears as an
independent and highly significant risk factor for extra-pulmonary TB (S7 Table). Finally,
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another microbial factor that should be taken into consideration is the microbial lineage. A pre-
vious report has demonstrated that, compared to the EAs lineage, the EAm, IO and the EAI lin-
eages are significantly associated with extra-pulmonary forms, even after correcting for
relevant host factors [21]. This is particularly important in the context of this study, as almost
allmclx3 pseudogenes are found among members of the IO lineage (and actually all of them in
the panel used for the regression analysis) and therefore could suggest that themclx3 pseudo-
genization is a mere phylogenetic signal. Since the occurrence ofmclx3 pseudogenes in the ana-
lysed sample is restricted to IO strains, it is not possible to correct for the lineage in the
multivariate models. However, previous reports support that the EAI lineage represents a fairly
similar risk for extra-pulmonary infections as the IO one [21]. Notwithstanding, in the ana-
lysed sample and among the EAI lineage there is only one case (5.6%) of strictly extra-pulmo-
nary infection, a value that deviates significantly from the 13 cases (41.9%) observed for the IO
lineage (S8 Table). Although it is not possible to completely disregard the phylogenetic hypoth-
esis, our results suggest that themclx3 pseudogenization is one of the factors that favor extra-
pulmonary forms of TB, and its prevalence among the IO lineage justifies that same tendency
in this lineage. Conversely, the lack ofmclx3 pseudogenes among the studied EAI could help to
justify the missing tendency for extra-pulmonary infections in this particular sample.
In the context of this manuscript, pseudogene is referred to as any gene whose coding se-
quence has been abruptly terminated by a large or small INDEL event, leading to the accumula-
tion of stop codons and the precocious ending of the putatively codified peptide. It does not, by
any means, reflect a status of overall non-functionality. Pseudogenes can have a number of dif-
ferent functions in the cell. In this context, it is important to highlight theMycobacterium
leprae. AlthoughM. leprae holds a large collection of pseudogenes in its genome (approximate-
ly 50%), an interestingly high number of them are actually expressed (43%), and some even
vary their expression patterns upon infection or in different leprosy patients, suggesting that
they can play a role in the virulence of this microorganism [25–28]. More often than not, this
expression occurs from pseudogenes that have stop codons in their reading frames, as is the
case of themclx addressed in this study. Therefore, themclx pseudogenes should be regarded
as potentially functional genes, although codifying smaller proteins/peptides than their ortho-
logues or displaying non-codifying functions. Supporting this hypothesis, one study has previ-
ously referred an over-expression of themclx2 after the induction of an alternative sigma factor
(sigF) [29]. Interestingly, the SigF binding site was located within themclx2 coding region, re-
sulting in a 250 residues-shorter protein. This suggests that shorter versions of at least thismclx
may hold an important role under defined conditions.
Gene pseudogenization has been often associated with the absence of purifying selective
pressures, which allow the accumulation of nucleotide substitutions and INDELs. However,
in this case, the high degree of sequence conservation at a nucleotide level suggests otherwise.
Frameshift-causing INDELs are sometimes the only difference in the sequences when com-
pared with their orthologues from the reference genome Mtb H37Rv. Conversely, themclx
genes from the closely relatedM. cannetti hold a much higher degree of sequence divergence
but are not pseudogenized. This suggests that the pseudogenization of themclx genes is
either recent and/or the result of defined selective pressures, as opposed to a longer process
of genome erosion in the absence of selection. This work, by describing a family of genes
selectively pseudogenized in certain isolates, reinforces the recent trend to complement im-
munological data with the study of bacterial evolution in order to fully understand—and
control—TB.
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gene	   primers'	  sequence	   localization	  in	  the	  genome	  (nt)	  
m
clx
1	  
(4
63
41
1-­‐
46
66
68
)	  
1.1Fw	   CGGTGGCGTCGCTTCGACAT	   463328-­‐463347	  
1.3Rev	   CACCGAGGCCCACAGCGTC	   464700-­‐464682	  
1.2	  Fw	   GGCCGGACTTTCGCCTCACC	   464486-­‐464505	  
1.2Rev	   CTGGTAGGCGAGCGCGAAGG	   465780-­‐465761	  
1.3Fw	   CCCAAGAGGCACGCGAGCTG	   465569-­‐465588	  
1.1Rev	   CCGTCCCCGAACGCCAATCA	   466695-­‐466676	  
m
clx
2	  
(1
52
66
12
-­‐1
53
00
91
)	   2.1Fw	   CCAGCGGTTTCCTACGGGCG	   1526542-­‐1526561	  
2.3Rev	   CGCCGGCAGATCTCGCTCAC	   1527960-­‐1527941	  
2.2Fw	   TGGGTGCCTGCCCGGAGTTA	   1527762-­‐1527781	  
2.2Rev	   TCTGCGCCAGGCAGGCAAAC	   1529081-­‐1529062	  
2.3Fw	   CCGAGGCGATCGAGCTGGC	   1528881-­‐1528899	  
2.1Rev	   GCGACAACGCGCAGAAGAGC	   1530170-­‐1530151	  
m
clx
3	  
(2
79
74
67
-­‐2
80
08
80
)	   3.1Fw	   ACCTTTGGTCGCTGGCTGGC	   2797439-­‐2797458	  
3.3Rev	   GGATCTGGCGCGACCGTGG	   2798733-­‐2798715	  
3.2Fw	   CCCTGCCAGAGATTCGCCGC	   2798497-­‐2798516	  
3.2Rev	   GCGGCTCTGATCGTCGCGTT	   2799830-­‐2799811	  
3.3Fw	   CAGGGCGAGGTTGTCGGCAG	   2799633-­‐2799652	  
3.1Rev	   CACGGGCACTGTAGGTCCGC	   2800950-­‐2800931	  
	  
mclx#2	   multivariate	  ORs	  (95%	  CI)	  Model	  2	  
pa
tie
nt
-­‐re
la
te
d	   age	  
0.958	  (0.912-­‐1.007)	  
p=0.089	  
B=-­‐0.043;	  S.E.=0.025	  	  
Wald=2.897	  
ethnicity	  
	   3.702	  (0.811-­‐16.898)	  
p=0.091	  
B=1.309;	  S.E.=0.775	  	  
Wald=2.854	  
native	  dutch	  
foreign-­‐born	   1	  (ref)	  
m
icr
oo
rg
an
ism
-­‐re
la
te
d	  
transmissibility	  
	   1.754	  (0.439-­‐7.000)	  
p=0.426	  
B=0.562;	  S.E.=0.706	  	  
Wald=0.632	  
no	  
yes	   1	  (ref)	  
lineage	  
	   p=0.357	  
Wald=	  3.237	  
EAI	   0.136	  (0.015-­‐1.196)	  
p=0.072	  
B=-­‐1.998;	  S.E.=1.111	  	  
Wald=3.237	  
EAm	   1	  (ref)	  
EAs	   p=0.999	  
0.000	  (0.000-­‐.)	  
B=-­‐20.230;	  S.E.=12299.315	  	  
Wald=0.000	  
IO	   p=0.998	  
0.000	  (0.000-­‐.)	  
B=-­‐20.251;	  S.E.=7120.660	  	  
Wald=0.000	  
Omnibus	  Test	  	  (chi-­‐square/p)	   40.620/	  p<0.001	  
Cox	  &	  Snell	  R2	   0.285	  
Nagelkerke	  R2	   0.459	  
Hosmer	  and	  Lemeshow	  (chi-­‐square/p)	   0.792/	  p=0.999	  
n	   121	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Supporting	  table	  4	  
independent	  variables	   n	   univariate	  ORs	  (95%	  CI)	  mclx#2	  pseudogenization	   mclx#3	  pseudogenization	  
pa
tie
nt
-­‐re
la
te
d	  
age	   105	   .970	  (0.937-­‐1.004)	  p=0.080	  
1.016	  (0.988-­‐1.045)	  
p=0.264	  
gender	  
	   	   p=0.463	   p=0.178	  
female	   36	   1.436	  (0.546-­‐3.773)	   1.895	  (0.747-­‐4.809)	  
male	   69	   1	  (ref)	   1	  (ref)	  
birth	  region	  
	   	   p=0.558	   p=0.020	  
Africa	   19	   0.885	  (0.268-­‐2.916)	  p=0.840	  
.000	  (.000-­‐.)	  
p=0.998	  
The	  Americas	   10	   0.479	  (0.088-­‐2.621)	  p=0.396	  
0.444	  (0.048-­‐4.116)	  
p=0.475	  
Eastern	  
Mediterranean	   20	  
0.213	  (0.042-­‐1.075)	  
p=0.061	  
0.706	  (0.161-­‐3.103)	  
p=0.645	  
Europe	   35	   1	  (ref)	  	  
1	  (ref)	  
	  
South	   East	  
Asia	   13	  
0.000	  (0.000-­‐.)	  
p=0.999	  
3.429	  (0.872-­‐13.483)	  
p=0.078	  
Western	  
Pacific	   8	  
0.000	  (0.000-­‐.)	  
p=0.999	  
28.000	  (2.942-­‐266.467)	  
p=0.004	  
ethnicity	  
	   	   p=0.003	   p=0.602	  
native	  dutch	   27	   4.606	  (1.669-­‐12.714)	   0.745	  (0.247-­‐2.250)	  
foreign-­‐born	   77	   1	  (ref)	   1	  (ref)	  
house	  setting	  
	   	   p=0.632	   p=0.030	  
rural	   67	   1	  (ref)	   1	  (ref)	  
urban	   38	   0.783	  (0.288-­‐2.131)	   0.276	  (0.087-­‐0.883)	  
BCG	  vaccination	  
	   	   p=0.721	   p=0.873	  
no	   25	   1.263	  (0.351-­‐4.551)	   1.098	  (0.349-­‐3.458)	  
yes	   30	   1	  (ref)	   1	  (ref)	  
co-­‐morbidities	  
	   	   p=0.328	   p=0.255	  
no	  or	  unknown	   89	   1	  (ref)	   1	  (ref)	  
yes	   17	   0.460	  (0.097-­‐2.183)	   0.406	  (0.086-­‐1.917)	  
alcohol	  or	  drug	  use	  
	   	   p=0.824	   p=0.280	  
no	  or	  unknown	   95	   1	  (ref)	   1	  (ref)	  
yes	   11	   0.833	  (0.167-­‐4.167)	   0.313	  (0.038-­‐2.578)	  
homelessness	  
	   	   p=0.831	   p=0.909	  
no	  or	  unknown	   102	   1	  (ref)	   1	  (ref)	  
yes	   4	   1.286	  (0.127-­‐12.998)	   1.145	  (0.114-­‐11.538)	  
m
icr
ob
e-­‐
re
la
te
d	  
lineage	  
	   	   p=0.267	   -­‐	  
EAI	   15	   0.119	  (0.015-­‐0.972)	  p=0.047	  
-­‐	  
EAm	   56	   1	  (ref)	  	  
-­‐	  
EAs	   8	   0.000	  (0.000-­‐.)	  p=0.999	  
-­‐	  
IO	   24	   0.000	  (0.000-­‐.)	  p=0.998	  
1	  
antibiotic	  
resistance	  
	   	   p=0.770	   p=0.881	  
none	   or	  
unknown	   97	  
1	  (ref)	   1	  (ref)	  
resistant	   8	   1.283	  (0.241-­‐6.846)	   1.136	  (0.214-­‐6.033)	  
transmissibility	  
	   	   p=0.006	   p=0.076	  
no	   48	   4.333	  (1.537-­‐12.217)	   0.412	  (0.154-­‐1.098)	  
yes	   58	   1	  (ref)	   1	  (ref)	  
di
se
as
e-­‐
re
la
te
d	  
local	  of	  infection	  
	   	   p=0.559	   p=0.001	  
pulmonary	  TB	   71	   1	  (ref)	   1	  (ref)	  
extra-­‐
pulmonary	  TB	   16	  
0.533	  (0.109-­‐2.609)	  
p=0.438	  
9.091	  (2.741-­‐30.153)	  
p<0.001	  
pulmonary	  and	  
extra-­‐
pulmonary	  TB	  
18	  
1.436	  (0.442-­‐4.665)	  
p=0.547	  
1.091	  (0.270-­‐4.408)	  
p=0.903	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Supporting	  table	  5	  
mclx#2	   multivariate	  ORs	  (95%	  CI)	  Model	  1	  	  
pa
tie
nt
-­‐re
la
te
d	   age	  
0.950	  (0.903-­‐0.999)	  
p=0.047	  
B=-­‐0.051;	  S.E.=0.026	  
Wald=3.940	  
ethnicity	  
	   6.845	  (1.704-­‐27.502)	  
p=0.007	  
B=1.924;	  S.E.=0.710	  
Wald=7.349	  
native	  dutch	  
foreign-­‐born	   1	  (ref)	  
m
icr
ob
e-­‐
re
la
te
d	  
transmissibility	  
	   1.790	  (0.485-­‐6.606)	  
p=0.382	  
B=0.582;	  S.E.=0.666	  
Wald=0.764	  
no	  
yes	   1	  (ref)	  
Omnibus	  Test	  	  (chi-­‐square/p)	   18.640/	  p<0.001	  
Cox	  &	  Snell	  R2	   0.166	  
Nagelkerke	  R2	   0.260	  
Hosmer	  and	  Lemeshow	  (chi-­‐square/p)	   5.027/	  p=0.755	  
n	   103	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Supporting	  table	  6	  
mclx#3	   multivariate	  ORs	  (95%	  CI)	  Model	  1	  	   Model	  2	   Model	  3	  
pa
tie
nt
-­‐re
la
te
d	  
gender	  
	   -­‐	   -­‐	   0.632	  (0.162-­‐2.471)	  
p=0.510	  
B=-­‐0.458;	  S.E.=0.695	  
Wald=0.434	  
female	  
male	   -­‐	   -­‐	   1	  (ref)	  
house	  setting	  
rural	   -­‐	   -­‐	   1	  (ref)	  
urban	   -­‐	   -­‐	   0.287(0.061-­‐1.352)	  
p=0.114	  
B=-­‐1.248;	  S.E.=0.791	  
Wald=2.492	  
birth	  region	  
	   -­‐	   -­‐	   p=0.062	  
Wald=10.505	  
Africa	   -­‐	   -­‐	   0.000	  (0.000-­‐.)	  
p=0.998	  
B=-­‐20.135;	  
S.E.=8708.272	  
Wald=0.000	  
The	  Americas	   -­‐	   -­‐	   0.547	  (0.053-­‐5.636)	  
p=0.612	  
B=-­‐0.604;	  S.E.=1.190	  
Wald=0.257	  
Eastern	  
Mediterranean	  
-­‐	   -­‐	   0.320	  (0.049-­‐2.087)	  
p=0.233	  
B=-­‐1.141;	  S.E.=0.957	  
Wald=1.420	  
Europe	   -­‐	   -­‐	   1	  (ref)	  
	  
South	  East	  Asia	   -­‐	   -­‐	   3.025	  (0.470-­‐19.483)	  
p=0.244	  
B=1.107;	  S.E.=0.950	  
Wald=1.357	  
Western	  Pacific	   -­‐	   -­‐	   24.851	  (1.933-­‐319.528)	  
p=0.014	  
B=3.213;	  S.E.=1.303	  
Wald=6.080	  
m
icr
ob
e-­‐
re
la
te
d	  
transmissibility	  
no	   -­‐	   0.728	  (0.241-­‐2.199)	  
p=0.573	  
B=-­‐0.318;	  S.E.=0.564	  	  
Wald=0.317	  
2.079	  (0.421-­‐10.259)	  
p=0.369	  
B=0.732;	  S.E.=0.815	  
Wald=0.807	  
yes	   -­‐	   1	  (ref)	   1	  (ref)	  
di
se
as
e-­‐
re
la
te
d	  
local	  of	  infection	  
	   p=0.001	  
Wald=	  13.647	  
p=0.006	  
Wald=10.383	  
p=0.025	  
Wald=7.345	  
pulmonary	  TB	   1	  (ref)	   1	  (ref)	   1	  (ref)	  
extra-­‐pulmonary	  TB	   9.091	  (2.741-­‐30.153)	  
p<0.001	  
B=2.207;	  S.E.=0.612	  
Wald=13.018	  
7.860	  (2.163-­‐28.569)	  
p=0.002	  
B=2.062;	  S.E.=0.658	  
Wald=9.806	  
13.464(1.951-­‐92.939)	  
p=0.008	  
B=2.600;	  S.E.=0.986	  
Wald=6.958	  
pulmonary	   and	  
extra-­‐pulmonary	  TB	  
1.091	  (0.270-­‐4.408)	  
p=0.903	  
B=0.087;	  S.E.=0.712	  
Wald=0.015	  
1.056	  (0.259-­‐4.294)	  
p=0.940	  
B=0.054;	  S.E.=	  0.716	  
Wald=0.006	  
4.571	  (0.691-­‐30.246)	  
p=	  0.115	  
B=1.520;	  S.E.=0.964	  
Wald=2.484	  
Omnibus	  Test	  	  (chi-­‐square/p)	   14,269/	  p=0.001	   14.587/	  p=0.002	   42.240/	  p<0.001	  
Cox	  &	  Snell	  R2	   0.127	   0.130	   0.331	  
Nagelkerke	  R2	   0.193	   0.197	   0.503	  
Hosmer	  and	  Lemeshow	  (chi-­‐square/p)	   0.000/	  p=1.000	   0.301/	  p=0.960	   6.527/	  p=0.480	  
n	   105	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Supporting	  Table	  7	  
independent	  variables	   n	  
univariate	  ORs	  (95%	  CI)	  
exclusively	  extrapulmonary	  	  
(vs.	  pulmonary	  and	  
disseminated)	  
extrapulmonary	  or	  both	  
(vs.	  	  exclusivetly	  pulmonary)	  
age	   124	  
1.059	  (1.019-­‐1.102)	  
p=0.004	  
B=0.058;	  S.E.=	  0.020	  	  
Wald=	  8.420	  
1.020	  (0.990-­‐1.051)	  
p=0.186	  
B=0.020;	  S.E.=0.015	  
Wald=1.749	  
gender	  
female	   46	  
6.575	  (1.896-­‐22.802)	  
p=0.003	  
B=1.883;	  S.E.=0.634	  
Wald=	  8.810	  
5.708	  (2.216-­‐14.701)	  
p<0.001	  
B=1.742;	  S.E.=0.483	  
Wald=13.021	  
male	   78	   1	  (ref)	   1	  (ref)	  
birth	  region	  
	   	   p=0.900	  Wald=1.608	  
p=0.179	  
Wald=7.610	  
Africa	  
23	  
6.883x108	  (0.000-­‐.)	  
p=0.999	  
B=20.350;	  S.E.=11556.217	  
Wald=0.000	  
11.220	  (0.710-­‐177.347)	  
p=0.086	  
B=2.418;	  S.E.=1.408	  
Wald=	  2.947	  
The	  Americas	  
12	  
1.307x108	  (0.000-­‐.)	  
p=0.999	  
B=18.689;	  S.E.=11556.217	  
Wald=0.000	  
1.874	  (0.104-­‐33.760)	  
p=0.670	  
B=0.628;	  S.E.=1.475	  
Wald=0.181	  
Eastern	  
Mediterranean	   23	  
5.254x108	  (0.000-­‐.)	  
p=0.999	  
B=20.080;	  S.E.=	  11556.217	  
Wald=0.000	  
6.247	  (0.429-­‐90.932)	  
p=0.180	  
B=1.832;	  S.E.=1.366	  
Wald=	  1.798	  
Europe	   36	   1	  (ref)	  	  
1	  (ref)	  
	  
South	  East	  Asia	  
17	  
4.683x108	  (0.000-­‐.)	  
p=0.999	  
B=19.965;	  S.E.=	  11556.217	  
Wald=0.000	  
3.314	  (0.213-­‐51.496)	  
p=0.392	  
B=1.198;	  S.E.=1.400	  
Wald=0.733	  
Western	  Pacific	  
13	  
3.313x108	  (0.000-­‐.)	  
p=0.999	  
B=19.619;	  S.E.=11556.217	  
Wald=0.000	  
1.077	  (0.058-­‐19.930)	  
p=0.960	  
B=0.075;	  S.E.=1.489	  
Wald=0.003	  
ethnicity	  
native	  dutch	  
27	  
9.348x107	  (0.000-­‐.)	  
p=0.999	  
B=18.353;	  S.E.=11556.217	  
Wald=0.000	  
0.995	  (0.064-­‐15.571)	  
p=0.997	  
B=-­‐0.005;	  S.E.=1.403	  
Wald=0.000	  
foreign-­‐born	   97	   1	  (ref)	   1	  (ref)	  
HIV	  
negative	   111	   1	  (ref)	   1	  (ref)	  
positive	  
13	  
0.497	  (0.044-­‐5.627)	  
p=0.572	  
B=-­‐0.700;	  S.E.=	  1.239	  
Wald=0.319	  
1.195	  (0.279-­‐5.114)	  
p=0.810	  
B=0.178;	  S.E.=0.742	  
Wald=0.058	  
mclx3	  status	  
pseudogene	  
30	  
8.259	  (1.674-­‐40.761)	  
p=0.010	  
B=2.111;	  S.E.=0.814	  
Wald=6.720	  
4.994	  (1.430-­‐17.436)	  
p=0.012	  
B=1.608;	  S.E.=0.638	  
Wald=6.354	  
functional	   94	   1	  (ref)	   1	  (ref)	  
Omnibus	  Test	  	  (chi-­‐square/p)	   	   41.614/	  p<0.001	   33.355/	  p<0.001	  
Cox	  &	  Snell	  R2	   	   0.285	   0.236	  
Nagelkerke	  R2	   	   0.456	   0.324	  
Hosmer	  and	  Lemeshow	  (chi-­‐square/p)	   	   5.289/	  p=0.726	   5.420/	  p=0.712	  
n	   	   124	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Supporting	  Table	  8	  
	  
Lineage	  
Total	  EAI	   EAm	   EAs	   IO	  
local	  of	  infection	   pumonary	  TB	   Count	   12a	   43a	   9a	   15a	   79	  
%	  within	  Lineage	   66,7%	   67,2%	   90,0%	   48,4%	   64,2%	  
extra-­‐pulmonary	  TB	   Count	   1a	   10a	   0a,	  b	   13b	   24	  
%	  within	  Lineage	   5,6%	   15,6%	   0,0%	   41,9%	   19,5%	  
pulmonary+extra-­‐
pulmonary	  TB	  
Count	   5a	   11a	   1a	   3a	   20	  
%	  within	  Lineage	   27,8%	   17,2%	   10,0%	   9,7%	   16,3%	  
Total	   Count	   18	   64	   10	   31	   123	  
%	  within	  Lineage	   100,0%	   100,0%	   100,0%	   100,0%	   100,0%	  
Each	  subscript	  letter	  denotes	  a	  subset	  of	  LSP_lineage	  categories	  whose	  column	  proportions	  do	  not	  differ	  significantly	  from	  each	  
other	  at	  the	  0.05	  level	  (collumn	  proportions	  compared	  by	  the	  z-­‐test	  with	  p-­‐values	  adjusted	  by	  the	  Bonferroni	  method).	  
	  
Supporting Table 8


77
Chapter V
Convergent genetic markers in Mycobacterium 
tuberculosis are associated with transmissibility and 
altered immune responses
78
Chapter V
79
Convergent genetic markers in Mycobacterium tuberculosis
Convergent genetic markers in Mycobacterium 
tuberculosis are associated with transmissibility 
and altered immune responses
 
Hanna Nebenzahl-Guimaraes1,2,3 ¶ , Arjan van Laarhoven4 ¶, Maha R. Farhat5 ¶, Valerie A.C.M. 
Koeken4, Jornt J. Mandemakers6, Mihai G. Netea4, Megan Murray7,8 †,*, Reinout van Crevel4 †,*,  
Dick van Soolingen1,9 †
AFFILIATIONS:
National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. 
ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical 
Center, Nijmegen, the Netherlands 
Pulmonary and Critical Care Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 
02114 Massachusetts, USA. 
University of Wageningen, 6706 KN, Wageningen, the Netherlands
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, Massachusetts, USA. 
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA 
Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
¶ Joint first authors 
† Joint last authors 
Abstract
Successful transmission of tuberculosis (TB) depends on human behavior, host immune responses and 
Mycobacterium tuberculosis virulence factors. We sought to identify mycobacterial genetic markers associated 
with increased transmissibility, and examined whether these markers lead to altered in vitro immune responses. 
Using a comprehensive TB registry and strain collection in the Netherlands, we identified M. tuberculosis strains 
either least or most likely to be transmitted after controlling for host associated behavioral factors. Through whole 
genome sequencing of 100 strains, we identified the loci espE, PE-PGRS33, PE-PGRS56, Rv0197, Rv2813-2814c 
and Rv2815-2816c as targets of convergent evolution among transmissible strains. We validated four of these 
regions in an independent set of strains, and demonstrated that mutations in these targets affected in vitro 
monocyte and T-cell cytokine production, reactive oxygen species release and neutrophil apoptosis. These findings 
suggest that M. tuberculosis shows convergent evolution associated with enhanced transmissibility in vivo and 
altered immune responses in vitro.
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Author summary
Tuberculosis is a highly contagious airborne disease 
that is transmitted from one person to the next through 
coughing, sneezing, or talking. There are several factors 
that determine the likelihood of transmission and 
these include the severity of infection and other patient 
related factors as well as factors related to the bacteria 
itself. To study bacterial genetic factors associated with 
tuberculosis transmission, we used the Dutch National 
TB registry that contains data on all TB patients, their 
infecting bacteria and the size of the associated circle 
of transmission. After adjustment for patient factors, we 
selected 100 bacterial samples that were either highly 
or poorly transmissible and studied them with whole 
genome sequencing. We identified six bacterial DNA 
regions to be associated with TB transmission. In the 
laboratory, we validated these regions by studying the 
response of human white blood cells to extracts from 
a subset of the tuberculosis bacteria that carried or 
did not carry mutations in these DNA regions. We show 
that there are differences in the immune response that 
associate with these genetic changes. In conclusion, 
we identified novel genetic regions that appear to be 
important for transmission of M. tuberculosis and 
maybe relevant targets for disease surveillance. 
Introduction
When patients with active pulmonary TB cough, they 
generate small droplet nuclei containing the pathogen 
M. tuberculosis, which can then be transmitted to others 
through the respiratory route. Successful transmission 
requires that viable bacteria enter the lungs, evade 
killing by the innate immune system, and replicate 
intracellularly. If a series of transmission events 
occurs over a relatively short time, one can identify a 
group of patients with M. tuberculosis strains that are 
genotypically highly similar. Epidemiologists often use 
molecular fingerprinting to characterize the genetic 
similarity among a group of strains; strains that share a 
molecular fingerprint are described as “clustered”[1-3] 
and are inferred to be the result of recent transmission 
rather than the reactivation of a previous infection. 
Host factors affect tuberculosis (TB) transmission 
and disease progression[4,5], but recent molecular 
epidemiologic studies have shown that M. tuberculosis 
strains also differ in their ability to cause pulmonary 
disease[6-8], their proclivity to infect contacts[9,10] 
or cause secondary cases[11-13]. This variability may 
reflect the strains’ ability to subvert innate[14-17] and/
or adaptive[1-3,6-8] immunity, or their ability to exploit 
the host immune system by inducing a detrimental 
inflammatory response[4,5,9,10] leading to tissue 
damage[1-3,6-8] and the formation of cavities that 
enable disease spread[4,5,9,10]. Cytokines play a 
pivotal role in these events; insufficient production of 
pro-inflammatory cytokines may lead to uncontrolled 
mycobacterial growth, while overproduction may lead to 
tissue damage[11-13]. 
Phylogenetic differences in cytokine response[14-17] 
suggest that specific microbial genetic determinants 
may underlie transmission related phenotypes. 
Several studies have used M. tuberculosis mutants 
in vitro and experimental models to identify the role 
of a few individual genes on transmission-associated 
phenotypes[18,19]. However, further elucidation of 
the full spectrum of genes affecting transmission 
could improve our understanding of the host-pathogen 
relationship in TB. 
To control for host factors and isolate mycobacterial 
factors of transmissibility, we used the Netherlands’ 
country-wide TB registry that stores patient data and 
M. tuberculosis isolates for all new culture positive 
cases of TB since 1993. We performed whole genome 
sequencing of 100 strains that were either more or less 
clustered than would be expected from their patient 
risk factors like sputum bacterial load, history of drug 
use or homelessness etcetera. We identified loci under 
positive selection for clustering by analyzing whole M. 
tuberculosis genomes from clustered and unclustered 
isolates for evidence of convergence. Following the 
hypothesis that clustered strains have consistent 
genetic differences compared to unclustered ones, 
and that the genes or intergenic regions implicated in 
these differences affect the host immune response, we 
performed a functional validation of the newly identified 
targets of independent mutation (TIMs) by measuring 
in vitro cytokine production and neutrophil responses.
Results 
STRAIN SELECTION FOR SEQUENCING
We aimed to compare strains that caused clusters of 
tuberculosis in the absence of obvious patient-related 
risk factors for clustering with unique (non-clustered) 
strains isolated from patients with a high likelihood 
of being part of a cluster (e.g. a homeless man with 
grade 3 sputum smear-positivity). The National Institute 
for Public Health and the Environment (RIVM) in the 
Netherlands stores all M. tuberculosis complex strains 
(>13,000) isolated in the Netherlands and their DNA 
fingerprints since 1993, and also has accompanying 
information on risk factors for clustering. Using this 
data, we calculated the Cluster Propensity to Propagate 
(CPP) as a summary measure of risk for transmission 
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of the patients belonging to that particular tuberculosis 
cluster (Table S1) [20]. This CPP was calculated for 
10,389 patient isolates. Following current practice, 
DNA fingerprinting by RFLP and MIRU-VNTR was used 
to define molecular clustering as a proxy for the relative 
transmissibility of a M. tuberculosis strain[21,22]. For 
whole genome sequencing, we selected 100 strains 
aiming for maximum contrast of the transmissibility 
phenotype: 66 clustered strains with low CPPs and 34 
unclustered strains with a high CPP (Fig. S1). Strains for 
the clustered phenotype were picked at random from 
56 unique cluster fingerprints (5 pairs of strains came 
from within the same cluster). To increase our power 
we matched the number and type of strain lineages in 
the clustered and unclustered group[23,24]. The 100 
selected strains were all drug sensitive, belonged to 
patients originating from 44 different countries, and 
were representative of the four major M. tuberculosis 
lineages.
TARGETS OF INDEPENDENT MUTATIONS (TIMS)
To identify genetic markers of clustering, we performed 
next generation whole genome sequencing. We 
constructed a Bayesian phylogenetic tree of the 100 
sequenced strains, based on a Multiple Sequence 
Alignment of single nucleotide substitutions (SNPs) 
called against reference strain H37Rv (Fig. 1). We 
conducted two parallel phylogenetic evolutionary 
convergence tests (PhyC) to identify either individual 
nucleotide positions, or genes and intergenic regions 
where cluster-associated mutations occur frequently 
and along disparate locations in the phylogenetic 
tree. Region-level PhyC detected four genes and two 
intergenic regions as significant targets of independent 
mutation (TIMs) (p < 0.05) (Table 1). A total of 12 SNPs, 
2 insertions and 31 deletions were found in these 
TIMs, including 1 SNP and 2 deletions that were also 
significant by the site-level phyC test (Table S2). TIMs 
in the two PE-PGRS genes occurred solely in clustered 
branches, while those in espE, Rv0197, Rv2813-2814c 
and Rv2815-2816c were also found in unclustered 
branches, but at a lower rate than in clustered branches 
(depicted for espE in Fig. S2). 
We validated these results in an independent public 
dataset of whole genome sequences of clustered (n=96) 
and unclustered (n=47) M. tuberculosis strains[23,24]. 
These strains were collected from patients of different 
geographical backgrounds and were predominantly 
drug resistant (Table S3). PhyC confirmed four out of six 
genes or intergenic regions (Table 1) including Rv0197, 
in which it detected the same nonsynonymous coding 
site (234,477TG). The TIMs occurring in the two PE-
PGRS genes could not be validated, as their occurrence 
in the original dataset was restricted to lineage 1, which 
only made up 3.4% of the validation dataset.
DELETERIOUS EFFECT OF TIMS ON PROTEINS
We used two protein prediction algorithms, I-Mutant 
v2.0 and PolyPhen-2[25], to predict the functional 
impact of the significant SNPs on the structure and 
function of their respective proteins. All 12 SNPs in 
genes Rv0197 and espE are predicted to adversely 
affect the respective proteins (Table S4). Two TIMs in 
Rv0197 (234,265GT and 234,477TG) result in a STOP 
codon and truncation of the protein, whilst two TIMs in 
PE-PGRS33 and PE-PGRS56 are frameshift mutations 
likely to have functional consequences.
ASSOCIATION BETWEEN TIMS AND INDUCTION 
OF CYTOKINE RESPONSES 
Genetic variation associated with transmissibility is likely 
to influence the initial host response. Next, we therefore 
examined in vitro cytokine responses in strains with 
and without convergent changes. Since mycobacterial 
lineages are known to induce differential cytokine 
responses[26], we only used strains of two lineages (1 
and 4), both of which had strains with mutations in at 
least four out of six genes or intergenic regions (Table 
S5). Nineteen clinical strains were selected. H37Rv was 
added for quality control of the experiments, but not 
included in the analysis. Peripheral blood mononuclear 
cells (PBMCs) from 12 healthy donors were stimulated 
with 3 μg/mL of heat-killed, bead-disrupted M. 
tuberculosis lysate from all 20 strains for 4 hours (for 
TNF-α) and 24 hours (TNF-α and other monocyte-derived 
cytokines) and 7 days (T cell-derived cytokines) using a 
previously established method[16,27]. We used a mixed 
effects regression model that accounts for between-
donor variation and lineage effects. This model exploits 
within-donor variation and covariance between cytokine 
concentrations to maximize statistical power. We first 
tested whether the six respective genes or intergenic 
regions were associated with an immunological 
phenotype for three sets of assays (monocyte cytokines, 
T-cell cytokines, and PMN responses). In secondary 
analyses, we compared levels of individual cytokines 
and PMN assays. In both analyses, significance was 
determined at α = 0.05/6, Bonferroni corrected for the 
six genes or intergenic regions tested.
Mutations in three of the targets we identified, espE, 
PE-PGRS33 and Rv2813-2814, were associated with 
alterations in monocyte cytokine production (p < 10-4, 
Table 2, Fig. 2). In the secondary analysis (see Table 
S6), mutations in espE were associated with decreased 
production of IL-10 (- 26%, p = 1.7 x 10-8, Fig. 3A) and to a 
lesser extent early TNF-α (- 18% p = 8.0 x 10-3); mutations 
in PE-PGRS33 were associated with decreased IL-10 (- 
18%, p = 1.9 x 10-3); and mutations in Rv2813-2814c 
were associated with increased production of early (+ 
29%, p = 6.2 x 10-3) and late (+ 33%, p = 2.5 x 10-3) 
TNF-α, IL-1β (+ 30%, p = 7.7 x 10-3) and IL-10 (+ 19%, 
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Fig. 1: Consensus Bayesian phylogenetic tree.  
Legend: Clustered strains and M. tuberculosis lineages are highlighted.
Original dataset (n = 100) Validation dataset (n = 143)
Strains with mutations, 
deletions and insertions 
(N)
Strains with mutations, 
deletions and insertions (N)
Gene/region 
[Rv number] Clustering
Non-
clustering p-value
Lineages 
with cases Clustering
Non-
clustering p-value
Lineages with 
cases
espE 
[Rv3864] 10 1 0.0377 1, 3, 4 10 2 0.0232 1, 3, 4
PE-PGRS33 
[Rv1818c] 16 0 0.0006 1 8 2 0.0779 1, 4
PE-PGRS56 
[Rv3512] 13 0 0.0052 1, 4 1 0 1 4
unnamed 
[Rv0197] 20 12 0.0214 1, 2, 3, 4 26 12 0.0362 1, 2, 3, 4
unnamed 
[Rv2813-2814c] 20 6 0.0458 1, 3, 4 22 3 0.0001 1, 3, 4
unnamed 
[Rv2815-2816c] 18 4 0.0178 1, 4 22 5 0.0105 1, 4
Table 1: Significant genes or intergenic regions by PhyC.
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Table 2: Overall response to M. tuberculosis strain with or without mutations in the six genes or intergenic 
regions for each of the assay groups. 
Gene or intergenic 
region
monocyte cytokines 
(df=6)
T-cell cytokines 
(df=3)
PMNs 
(df=3)
espE 1.33 x 10-6 0.961 0.077
PE-PGRS33 2.83 x 10-5 0.345 3.99 x 10-5
PE-PGRS56 0.039 5.35 x 10-3 0.021
Rv0197 0.017 0.224 0.343
Rv2813-2814c 7.47 x 10-6 0.309 5.79 x 10-8
Rv2815-2816c 0.025 0.027 0.151
 
Legend: Significance (in bold) is determined at α = 0.05/6 = 0.0083, corrected for the six genes or intergenic 
regions tested.
Fig. 2: Response to M. tuberculosis strain with or without mutations in the four TIMs that showed an effect 
in primary analysis. Relative differences for individual assays in the secondary analysis are indicated by the 
difference between the thick black line (mutation present) and the thin reference line (no mutation) for each of 
the TIMs (a) espE, (b) PE-PGRS33, (c) PE-PGRS56, or (d) Rv2813-2814c that significantly influenced at least one 
assay group. Shaded area: 95% confidence interval, corrected for the fact that six genes or intergenic regions 
were tested for each assay (z = 2.64). Legend: *  p < 0.05/6 = 0.0083. ** significant after further correcting 
for number of assays per group, i.e. 0.05/(6*6) for monocyte cytokines and p < 0.05/(6*3) for T-cell cytokines 
and PMN assays. Significance in the primary analysis is indicated by a colored confidence interval for monocyte 
cytokines (blue), T-cell cytokines (red) and PMN assays (green).
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p = 1.9 x 10-3). Of the six genes or intergenic regions, 
only PE-PGRS56 affected T-cell cytokine responses (p 
= 5.4 x 10-3), and in our secondary analysis, this was 
associated with lower IFN-γ production (- 34%, p = 1.6 x 
10-3, Fig. 3B). 
ASSOCIATION BETWEEN TIMS AND RESPONSE 
OF NEUTROPHILS 
We next examined the effect of TIMs on in vitro 
responses of neutrophils, given their putative role in 
transmission and clinical manifestation of TB[28]. 
We stimulated isolated polymorphonuclear cells 
(PMNs, largely consisting of neutrophils) with the 20 
M. tuberculosis strains, measuring the induction of 
reactive oxygen species (ROS) using luminol-enhanced 
chemiluminescence for one hour (6 donors), and 
neutrophil apoptosis and cell death with flow cytometry 
after six hours (8 donors). In the mixed effects model, 
we found that the TIMs PE-PGRS33 and Rv2813-2814c 
affected PMN responses (both p < 10-4). In secondary 
analysis, ROS production was lower (- 31%, p = 4.8 x 10-
4, Fig. 3C) and early apoptosis higher (+ 15%, p = 3.6 x 
10-3) for Rv2813-2814c, while ROS production was also 
lower for PE-PGRS33 (- 24%, p = 4.1 x 10-3).
Fig. 3: In vitro responses of selected assays TIMs. Stimulation was performed with lysate of M. tuberculosis 
strains from lineage 1 (filled) and lineage 4 (open) that did not harbor (blue) or harbored (red) a mutation in 
(A) espE or (B) PE-PGRS56 or (c) Rv2813-2814c. PBMCs of twelve healthy donors (A-L) were stimulated and 
(A) IL-10 was measured after 24h, (B) IFN-γ after 7 days. Because no mutations occurred in PE-PGRS genes in 
strains from lineage 4, only lineage 1 strains were used in the analysis for PE-PGRS33 genes and subsequently 
displayed here. (C) PMNs of six healthy donors (1-6) were stimulated with lysate of strains from lineage 1 (filled) 
and lineage 4 (open) that did not harbor (blue) or harbored (red) a mutation in Rv2813-2814c. Reactive oxygen 
species were measured by luminol-enhanced chemiluminescence and plotted in arbitrary units of the area 
under the curve (AUC) of the measurement over the first hour after stimulation.
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Discussion 
We identified six genes and intergenic regions (espE, 
PE-PGRS33, PE-PGRS56, Rv0197, Rv2813-14c and 
Rv2815-16c) as targets of independent mutation (TIMs) 
in clustered M. tuberculosis strains. We confirmed four 
out of six genes and intergenic regions in a second 
dataset despite differences in lineages and drug 
resistance profiles between the original and validation 
datasets. The TIMs we identified are predicted to alter 
the function of their respective proteins, supporting 
the hypothesis that they confer a selective advantage 
for transmission. Finally, four of six identified genes or 
intergenic regions were associated with altered cytokine 
production or PMN responses.
Experimental studies on the identified genes or 
intergenic regions support their potential roles in 
increasing the transmissibility of M. tuberculosis (Table 
S7). In addition, other genomic epidemiological studies 
may support the role of the genes we identified in 
mycobacterial transmission. Non-synonymous SNPs 
(albeit different from the ones identified in this study) 
and a frameshift mutation in espE were found to be 
more common in M. africanum strains relative to H37Rv 
[29], and to be implied in their reduced ability to induce 
a CD4-cell ESAT-6 induced IFN-γ host response[30,31]. 
Similarly, a previous study identified a Large Sequence 
Polymorphism (LSP) associated with clustering in a gene 
(MT1801) encoding Molybdopterin oxidoreductase, 
which is also encoded by Rv0197[32]. Another study 
reported that a M. tuberculosis strain responsible 
for a large outbreak in the UK harbored an insertion 
in position 3,121,877 of intergenic region Rv2815-
16c[33], adjacent to the 2bp deletion in 3,121,879 
observed in our own study. Finally, clinical strains with 
large insertions or deletions (INDELs) and frameshift 
mutations in the PE-PGRS33 protein have been linked 
to both the clustered phenotype and absence of lung 
cavitation[34]. 
Four out of six genes or intergenic regions with TIMs 
associated with clustering of TB showed a clear and 
statistically significant effect on monocyte or T-cell 
cytokine production or PMN responses at the group level. 
M. tuberculosis strains with TIMs in PE-PGRS56 induced 
lower production of IFN-γ, which is unequivocally seen as 
a key factor in protection against TB[11,35]. Some of the 
monocyte cytokines, however, can act as a double-edged 
sword, and may have different roles in different parts of 
the TB life cycle that all contribute to clustering. A lower 
IL-10 for example, found in association with TIMs in espE 
and PE-PGRS33 in our study, may prevent its inhibiting 
effect on tissue damage, while a higher amount, as 
associated with TIMs in Rv2813-2814c could also 
decrease intracellular killing of M. tuberculosis[11]. 
In zebrafish models, a high TNF-α as we observed in 
Rv2813-2814c, has been shown to lead to ‘necroptosis’ 
which favors bacterial outgrowth[36], while a low TNF-α 
as we observed in PE-PGRS33 might favor breakthrough 
to disease as in patients treated with TNF-α blocking 
therapy[37]. In line with a previous comparison of in vitro 
cytokine responses to different M. tuberculosis lineage 
strains [14], TNF-α and IL-6 induction in our study was 
higher in lineage 4 (ancient) compared to lineage 1 
(modern) strains. These lineage effects may depend on 
strain selection, as shown by another study by Reiling et 
al.[38] that found opposite results. The aim of our study 
was not to discern lineage effects, but we corrected for 
these effects in our statistical model. 
With regard to neutrophils, strains harboring cluster-
associated mutations in Rv2813-2814c induced 
lower ROS production and early apoptosis, and strains 
with mutations in PE-PGRS33 lower ROS production. 
Neutrophils are considered protective during early 
infection, when they are recruited to the site of infection, 
phagocytose mycobacteria[28] or mycobacteria infected 
macrophages[39], and resist mycobacterial growth using 
reactive oxygen species (ROS)[39]. Children with chronic 
granulomatous disease (CGD) have a reduced oxidative 
burst and are more susceptible to TB[40]. Neutrophil 
ROS also correlates with apoptosis[15], which is thought 
to contain mycobacterial growth and facilitate antigen 
presentation but may also contribute to mycobacterial 
spread[41]. 
This study was limited by several factors. The inclusion 
of additional key host factors that may influence 
disease transmissibility, such as exposure time (i.e. via 
prospective household contact data) and pulmonary 
cavitation, could improve our ability to isolate bacterial 
factors influencing transmissibility in the future. The 
difference in drug resistance profiles, and possibly 
other related parameters, such as treatment efficacy 
between the original and validation cohort of strains 
for the phyC test, could have introduced bias in 
measurement of the transmissibility phenotype (Table 
S3). However, validation of genetic markers associated 
with transmission in this separate dataset reduces the 
risk of false positive findings.
Of note, we performed in vitro cellular stimulations 
aiming to find biological support for the epidemiological 
associations identified through convergent evolutionary 
analysis, and not to identify specific effects of individual 
TIMs on in vitro cellular responses. Such effects cannot 
be identified in this study, as multiple TIMs were present 
in single strains in this dataset (Table S4). For this, 
additional studies using mutagenesis or recombineering 
to isolate the mutational effects should be performed. 
It is no surprise that no single pattern of cytokine 
production or PMN response was found for the six genes 
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or intergenic region, as M. tuberculosis has different 
strategies to subvert or resist the host immune system 
or use it to its advantage.
In summary, we present evidence from an evolutionary 
convergence analysis that six M. tuberculosis genes 
or intergenic regions confer a selective advantage 
promoting the transmission of M. tuberculosis and/or TB 
disease progression, and that these genetic elements 
influence the response of the host to the mycobacteria. 
These findings serve as an important step forward in the 
quest for an improved understanding of the microbial 
genetic determinants of TB transmission. 
Materials and Methods
STUDY DESIGN
Strains were selected taking into account their cluster 
size and cluster propensity to propagate (CPP), a 
summary measure of the contribution of the hosts’ risk 
factors towards clustering. In the overall RIVM dataset 
of 10,389 strains, we found CPP to be significantly 
higher in clustered versus unclustered strains, although 
the CPP rapidly plateaus with increasing cluster size 
(Fig. S1) [38]. As to our knowledge there are no power 
calculators to guide the design of studies associating 
genomic variants with the transmissibility phenotype 
[23,42]. We arbitrarily chose 100 strains for whole 
genome sequencing: 66 unclustered strains with an 
average CPP of 1.02 (sd=0.3) that was higher than the 
overall average of 0.84 (sd=0.12). We also chose 34 
clustered strains with an average CPP of 0.75 (sd=0.006) 
that was lower than the overall average above (Fig. 
S1). After variant calling and phylogeny reconstruction, 
PhyC[43] was used to identify genetic loci that displayed 
significantly higher variation in the clustered group. 
Second, these loci were validated by repeating the PhyC 
analysis in an independent dataset that comprised of 
96 clustered strains and 47 unclustered strains. Third, 
out of the first dataset, 19 strains were recultured, 
and heat-killed and bead-beated to perform functional 
experiments. After stimulation of PBMCs, cytokine 
responses were measured (6 experiments of two 
healthy donors each), and after stimulation of PMNs 
reactive oxygen species (3 x 2 donors) and apoptosis (4 
x 2 donors) was measured. Multivariate mixed models 
were applied to exploit covariance between assays and 
to control for inter-donor variability.
ACCESSION CODES 
All sequences have been rendered publically available 
through NCBI. The complete genome sequence for 
reference strain H37Rv was accessed from GenBank 
accession NC_000962.3. Raw sequences for the 200 
strains from Bryant et al. are available at the European 
Nucleotide Archive (ENA) under accession ERP000111.
RIVM DATASET OF STRAINS 
The National Institute for Public Health and the 
Environment (RIVM) in Bilthoven, The Netherlands, 
serves as a reference laboratory for the secondary 
laboratory diagnosis of all TB cases in The Netherlands, 
offering identification, drug susceptibility testing, and 
molecular typing. Strains recovered from patients 
between 1993 and 2009 underwent IS6110 and 
polymorphic GC-rich sequence (PGRS) restriction 
fragment length polymorphism (RFLP) typing and those 
from 2004 onwards to variable number of tandem 
repeat (VNTR) typing. Clusters were defined as groups 
of patients who shared TB strains with identical RFLP 
or VNTR patterns or, if strains had fewer than five 
IS6110 copies, identical PGRS RFLP patterns[44]. DNA 
fingerprints of all nationwide M. tuberculosis complex 
strains and their cluster status have been stored in 
a database since 1993. Demographic and clinical 
information, provided by the Registration Committee 
of the Netherlands Tuberculosis Register (NTR), were 
linked to the strains on the basis of gender, date of 
birth, year of diagnosis and postal code. Phylogenetic 
lineages were ascertained based on a combination of 
spoligotyping, MIRU-typing and Restriction Fragment 
Length Polymorphisms (RFLP)-pattern similarity, as 
previously described[20].
SEQUENCING, ALIGNMENT AND VARIANT 
CALLING
DNA was extracted from all strains using standard 
methods and was sequenced on an Illumina HiSeq 
2500 instrument using reads of 50bp in length in the 
paired-end modus. The average genome coverage was 
approximately 100x. The FASTQ sequence reads were 
generated using the Illumina Casava pipeline version 
1.8.3. Initial quality assessment was based on data 
passing the Illumina Chastity filtering. Subsequently, 
reads containing adapters and/or PhiX control signal 
were removed using an in-house filtering protocol. 
The second quality assessment was based on the 
remaining reads using the FASTQC quality control tool 
version 0.10.0. The quality of the FASTQ sequences 
was enhanced by trimming off low-quality bases using 
the “Trim sequences” option of the CLC Genomics 
Workbench version 6.5. The quality-filtered sequence 
reads were then puzzled into a number of contig 
sequences using the previously mentioned software. 
SNPs were called against reference strain H37Rv 
using Breseq software (version 0.23) using a minimum 
threshold of 15x coverage [45]. Mutations with low-
quality evidence (i.e. possible mixed read alignment) 
or within 5 bp of an INDEL (insertion or deletion) were 
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discarded. Due to the higher likelihood of false-positive 
calls in PE-PGRS genes, the two site-specific deletions in 
PE-PGRS33 and PE-PGRS56 significantly associated to 
transmissibility were manually checked to confirm that 
they did not fall within repetitive regions (Fig. S3).
PHYLOGENY CONSTRUCTION
The phylogeny was constructed on the basis of multiple-
sequence alignment of the M. tuberculosis whole-
genome sequences. Single nucleotide polymorphisms 
(SNPs) occurring in repetitive elements, including PE/
PPE and PGRS genes, were excluded to avoid any concern 
about inaccuracies in read alignment in those portions 
of the genome. The final concatenate of SNPs was used 
to construct phylogenetic trees using three different 
methods: parsimony (PHYLIP dnapars algorithm v3.68), 
Bayesian Markov chain Monte Carlo (MCMC) (MrBayes 
v3.2) and maximum-likelihood (PhyML v3.0) using the 
GTR model with eight categories for the gamma model. 
One hundred bootstrap re-samplings were performed for 
each tree, except for the Bayesian tree, where posterior 
probabilities on the branches were used as a measure 
of confidence. The three trees were fully consistent 
between each other, and we used the Bayesian tree for 
all subsequent analyses.
PHYLOGENETIC CONVERGENCE TEST FOR 
SELECTION (PHYC) 
PhyC is a test for positive natural selection based on 
homoplasy or parallel evolution, and is well suited for 
the study of clonal pathogens such as Mycobacterium 
tuberculosis . It has been shown in prior work on drug 
resistance to have a higher sensitivity (and likely also 
specificity) than the dN/dS method [43]. The PhyC 
test was conducted here as previously described[43] 
with two modifications: (1) We used Carmin-sokal 
parsimony for reconstruction of the phenotypic states 
as we thought this better mirrors our assumption that 
transmissibility evolves unidirectionally (i.e. from less to 
more transmissible); (2) We also performed ancestral 
reconstruction of INDELs using FASTML and maximum-
likelihood criteria[46]. For each nucleotide position in 
the genome, we counted the number of convergent 
SNPs and INDELs in clustered and unclustered 
branches. We controlled for the occurrence of SNPs 
or INDELs in strains belonging to the same cluster 
(as defined by MIRU- or RFLP-typing) by counting only 
one strain per cluster. Given that some background 
convergence is expected owing to neutral mutation 
and sequence error, even without positive selection, 
we assessed the significance of each convergent 
SNP or INDEL compared to the empirical background 
distribution using a permutation test, as previously 
described[23]. As this was a permutation test based 
on the observed frequency distribution for all variants 
across the genome, a 0.05 P-value threshold was used. 
In parallel we ran the convergence test grouping SNPs 
and INDELs by the gene or intergenic region in which 
they occurred. We used the same empirical resampling 
strategy a list of significant regions.
PHYC VALIDATION DATASET
Strains in the validation dataset were assigned two 
phenotypes: clustered (belonging to a cluster of 
minimum size of 3, n=96) and unclustered (having a 
unique fingerprint and no epidemiologic links reported 
from contact investigation, n=47). All clustered strains 
belong to clusters of different fingerprints, in order to 
eliminate redundant results caused by highly similar (or 
effectively clonal) strains. Since epidemiological data 
(host risk factors) was not available for these strains, 
we could not take the strain’s CPP into account, and 
hence the phenotype was defined solely using clustering 
status. For 19 clustered strains, single end 36bp read 
sequencing was previously performed which made 
calling INDELs unreliable (Table S5). 
STRAIN SELECTION FOR IMMUNOLOGICAL 
EXPERIMENTS 
Mycobacterial lineage is known to influence host immune 
response[26]. We therefore only selected strains from the 
WGS dataset belonging to lineages 1 and 4, both of which 
had four to six TIMs represented, and could therefore 
include lineage as a factor in the statistical model. 
Nineteen out of twenty-one strains could be re-cultured, 
fifteen of lineage 1 and four of lineage 4. Fifteen of the 
strains were of the clustered phenotype, four unclustered. 
The unclustered strains had a maximum of one mutation 
in the genes or intergenic regions associated to increased 
transmissibility, whilst all clustered strains had at least one 
TIM in the genes of interest (range 1–6), with the exception 
of strain F6 which had zero (Fig. S4, Table S3). H37Rv, 
the most well characterized strain of M. tuberculosis, was 
included as a reference strain.
MYCOBACTERIAL CULTURE AND 
STANDARDIZATION 
Strains were grown on a shaking platform to determine 
the growth curve, and then regrown to harvest mid-log 
(OD600 0.6-0.8 for all strains). Strains were heat-killed, 
washed in PBS, lysed mechanically by bead-beating and 
divided in two aliquots. The first was used for stimulation 
experiments and to measure protein concentration 
by bicinchoninic acid (BCA) protein, and the second 
was freeze-dried to determine dry weight and after 
resuspension used for the ROS experiments. Protein-
to-dryweight ratio did not differ substantially for one of 
the isolates (Fig. S5). Prior to this study, standardization 
experiments were performed to determine the optimal 
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moment of harvesting (mid-log phase) and processing 
method (bead-beating), and confirm the reproducibility 
of cellular responses. PBMCs of six donors were 
stimulated with three batches of H37Rv. Mean standard 
deviation over six donors was 0.33 for TNF-α (coefficient 
of variation [CV] 5.5%) and 0.45 for IL-1β (CV 6.1%).
PBMC CYTOKINE STIMULATION EXPERIMENTS 
PBMCs from buffy coats obtained from 12 healthy 
volunteers (Sanquin Bloodbank, Nijmegen, the 
Netherlands) over a density gradient using Ficoll-paque 
were stimulated in duplicate in 96-well round-bottom 
plates with 3 ug/mL of the different strains in a total 
volume of 200 μl and incubated at 37°C in a 5% CO2 
environment (in the presence of 10% human pooled 
serum for 7 day stimulation). Cytokines were measured 
batch-wise using ELISA after 4h (TNF-α, using R&D 
Systems, Minneapolis, Minnesota, USA), 24h (TNF-α, 
IL-1β and IL-1Ra, R&D; IL-6 and IL-10 using Sanquin, 
Amsterdam, the Netherlands) or 7 days (IL-17 and IL-22, 
R&D; IFN-γ, Sanquin) stimulation. 
PMN REACTIVE OXYGEN SPECIES AND APOPTOSIS 
EXPERIMENTS
Polymorphonuclear cells (PMNs) were isolated from 
EDTA blood from 8 other healthy volunteers using ficoll-
paque, cleared from erythrocytes by hypotonic lysis 
(two times) buffer and washed two times in cold PBS. 
Reactive oxygen species were measured in 6 volunteers 
in white 96-well flat-bottom plates using luminol-
enhanced chemiluminescence (5-amino-2,3,dihydro-
1,4-phtalazinedione, Sigma-Aldrich, St. Louis, Missouri, 
USA). PMNs were stimulated in 240 μl at 1·106 cells/
mL in 0.5% BSA HBSS with culture medium alone, 
zymosan (final concentration: 833 μl/mL) or the 20 
different M. tuberculosis strains (10 µg/mL), and 
chemiluminescence was measured at 37°C for the 
next 60 min, after which the area under the curve for 
luminescence was calculated. For apoptosis, PMNs of 8 
volunteers were stimulated for 6 hours with the different 
strains (10 µg/mL), IL-1β as anti-apoptotic control and 
cyclohexamide as positive control, after which Annexin 
V-FITC conjugate (Av, BioVision, Milpitas, California, 
USA) and propium iodide (PI) were added. Annexin V 
stains phosphatidylserine translocating from the inner 
to the outer leaflet of the membrane, marking early 
apoptosis. PI stains nuclei from cells that are permeable, 
reflecting cell death, either from advanced apoptosis or 
necrosis[47]. Flow cytometric analysis using Cytomics 
FC50 was used to distinguish Av-/PI- (alive) Av+/PI- (early 
apoptotic) and Av+/PI+ (advanced apoptotic / necrotic) 
populations. Different concentrations and time-points 
were tested first for ROS and apoptosis assays (Fig. S5). 
DATA ANALYSIS AND STATISTICS 
To control for inter-donor variability and exploit 
covariance between outcome measures, results were 
analysed using a multivariate mixed model for each 
assay group (monocyte cytokines, T-cell cytokines and 
PMNs). Cytokine concentrations and ROS area under 
the curve (AUCs) were Ln-transformed. PBMC and PMN 
experiments were performed on different donors and 
therefore tested in different models that included a set 
of fixed effects for each combination of donor, assay, and 
lineage group (lineage 1 and 4) to account for variability 
between donors, assays, and between lineages and 
a random effect for strain to model the dependency 
structure in the data. For each strain, the absence/
presence of TIMs in a gene or intergenic region was 
tested using assay-specific dummy indicators. First, we 
tested whether the presence of TIMs was associated with 
differential response by comparing multivariate models 
with and without TIMs indicators using Likelihood Ratio 
tests (Table 2). Bonferroni correction was applied for 6 
tests. Secondly, we examined the predicted differences 
and further corrected for the number of assays in 
each group. All analyses were performed using Stata 
MP, version 12.1. Cytokine radar graphs show the 
percentage change for each of the assays, plotted on a 
logarithmic axis.
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Fig. S5: (a) M. tuberculosis H37Rv protein concentration versus dry weight for the nineteen strains (with 
sequence ID) used in the immunological experiments. (b) PMN reactive oxygen production with different 
concentrations of H37Rv M. tuberculosis lysate (3.2, 10 or 32 μg/mL).  (c) PMN apoptosis stimulation time and 
dose response optimisation after stimulation with IL-1β, cycloheximide or H37Rv M. tuberculosis lysate (0.1, 
1 or 10 μg/mL) at 3, 6, 18 or 48 hours. Combined results of two experiments with in total six donors. * = not 
measured. 
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Table S1: Summary of risk factors combined to calculate the Patient Propensity to Propagate (PPP)*.
Category Odds ratio Case group
Sex 
1
0.87
males 
females
Age at diagnosis 
1.05
1
0.86
0.77
0.49
0.19
0.12
0-15
16-30
31-45 
46-60 
61-75
76-90
 >90 years
Disease classification 
1
0.76
0.90
pulmonary
extrapulmonary
pulmonary + extrapulmonary
Smear-positivity 
1
1.17
no
yes
Alcohol consumption 
1
1.29
no
yes
Drug-use 
1
2.75
no
yes
Homelessness 
1
1.58
no
yes
Traveler to endemic areas 
1
0.58
no
yes
Origin
1
0.28
0.76
1.06
0.43
native Dutch
foreign-born (Asia)
foreign-born (Africa)
foreign-born (America)
foreign-born (Europe)
 
 * The geometric mean of the PPPs across the cluster was used to calculate the Cluster Propensity to Propagate (CPP).
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Table S2: Genomic positions of SNPs and indels associated with the clustering phenotype.
Mutations, deletions and insertions (N)
Genomic position: polymorphism In clustering strains In non-clustering strains p-value
espE 
4341369: T=>G 1 0 1
4341402: C=>T 1 0 1
4341402: T=>C 5 0 0.8
4340408: A=>G 1 0 1
4340330: G=>T 1 0 1
4341224: G=>C 1 0 1
PE-PGRS33 
2061661: Δ1bp 15 0 0.0002
2062105: Δ9bp 1 0 1
2062351: Δ1bp 1 0 1
PE-PGRS56 
3943650: Δ3bp, Δ1bp 12 0 0.0027
3944270: Δ9 bp 1 0 1
3943311: Δ9 bp 1 0 1
3941910: Δ9 bp 1 0 1
Rv0197
234082: G=>A 1 0 1
234242: C=>T 1 0 1
234265: G=>T 1 0 1
234477: T=>G 1 1 1
234477: G=>T 16 8 0.0179
Rv2813-2814c
3119737: Δ512 bp 1 0 1
3120432: +AGC, +AGCA 4 0 0.9998
3120031: Δ438 bp, Δ218 bp 12 3 0.2542
3120395: Δ2 bp 1 0 1
3119592: Δ292 bp 1 0 1
3120321: Δ74 bp 5 1 1
3119913: Δ1 bp 2 1 1
3119663: Δ221 bp, Δ74 bp 2 1 1
3119957: Δ438 bp 1 0 1
3120469: Δ1,725 bp 1 0 1
Rv2815-2816c
3122774: Δ144bp 1 0 1
3122549: Δ72bp 2 1 1
3122847: Δ144bp 3 0 1
3123209: Δ75bp 1 1 1
3122122: Δ72bp, Δ350bp 4 0 0.9998
3121879: Δ2bp 1 1 1
3123284: Δ70bp, Δ142bp 8 1 0.4468
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Table S3: Description of validation set of strains including host risk factors.
Original dataset Validation dataset
Clustered strains (n=66) Unclustered strains (n=34) Clustered strains (n=96) Unclustered strains (n=47)
Publication source
Farhat et al.1 - - 50 (52%) 47 (100%)
Bryant et al.2 - - 46 (48%) -
Mutations called
SNPs & indels 66 (100%) 34 (100%) 77 (80%) 47 (100%)
SNPs only - - 19 (20%) -
Lineage
1 (EAI) 22 (34%) 6 (18%) 4 (4%) 1 (2%)
2 (Beijing) 8 (12%) 1 (3%) 21 (22%) 12 (26%)
3 (CAS) 10 (15%) 8 (23%) 3 (3%) 11 (23%)
4 (EAM) 26 (39%) 19 (56%) 62 (65%) 18 (38%)
M. bovis - - 1 (1%) -
Unclassified/T - - 5 (5%) 5 (11%)
Patient origin
Europe 10 (15%) 16 (47%) 12 (13%) 12 (26%)
Africa 13 (20%) 8 (23.5%) 22 (23%) 12 (26%)
Asia 40 (61%) 2 (6%) 4 (4%) 18 (38%)
The Americas 3 (4%) 8 (23.5%) 9 (9%) 1 (2%)
Unknown - 49 (51%) 4 (8%)
Drug resistance profile
Susceptible 66 (100%) 34 (100%) 35 (36%) -
Mono-resistant - - 5 (5%) -
MDR - - 36 (38%) 37 (79%)
XDR - - 4 (4%) -
Unknown - - 16 (17%) 10 (21%)
Gender
Male 35 (53%) 23 (68%)
NA
Female 31 (47%) 11 (32%)
Age at diagnosis
0-15 - 1 (3%)
NA
16-30 25 (38%) 13 (38%)
31-45 12 (18%) 15 (44%)
46-60 15 (23%) 5 (15%)
61-75 10 (15%) -
76-90 4 (6%) -
>90 years -- - -
Disease classification
Pulmonary                36 (54.5%) 27 (79%)
NAExtrapulmonary                                     20 (30%) 1 (3%)
Pulmonary + Extrapulmonary      10 (15.5%) 6 (18%)
Smear positivity
No 38 (58%) 6 (18%)
NA
Yes               28 (42%) 28 (82%)
Alcohol consumption
No 66 (100%) 32 (94%)
NA
Yes - 2 (6%)
Drug-use
No 65 (98%) 29 (85%)
NA
Yes  1 (2%) 5 (15%)
Homelessness
No 66 (100%) 33 (97%)
NA
Yes 1 (3%)
Traveler to endemic areas
No 63 (95%) 34 (100%)
NA
Yes 3 (5%) -
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Table S4: Protein prediction for TIMs associated to an increased clustering phenotype.
Protein Prediction
Gene position Nucleotide change Amino acid change I-Mutant # PolyPhen &
espE
61 T=>G L21V Large Decrease of Stability NA
139 A=>G M47V Large Decrease of Stability NA
955 G=>C V319L Large Decrease of Stability NA
1100 T=>G L367R Large Decrease of Stability NA
1133 T=>C V378A Large Decrease of Stability NA
Rv0197
344 G=>T G115V No effect Probably damaging
1334 G=>T R445L No effect Probably damaging
1852 G=>A V618M Large Decrease of Stability Probably damaging
2012 C=>T A671V No effect Probably damaging
2035 G=>T E679 (STOP) Prediction not possible Prediction not possible
2038 G=>T V680F Large Decrease of Stability No effect
2247 T=>G Y749 (STOP) Prediction not possible Prediction not possible
NA: No homologs of espE were found therefore protein prediction was not possible. 
Entries in bold denote that backwards mutations of these polymorphisms also occurred. 
# I-mutant predicts free energy changes of protein stability upon a point mutation under different conditions 
& PolyPhen predicts the possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical 
and comparative considerations.
TIMs in individual genes or intergenic regions of interest (n)
Sequencing ID Lineage espE PE-PGRS33 PE-PGRS56 Rv0197 Rv2813-2814c
Rv2815-
2816c
Clustered
A4 1 1 1 1 0 0 0
B12 1 0 1 0 1 0 0
B6 1 1 0 0 0 0 0
C8 1 1 1 0 1 0 0
D11 1 0 1 0 2 1 0
D3 1 0 0 2 0 0 1
D4 1 1 1 0 1 0 0
D6 1 0 1 1 0 0 0
E2 1 0 0 0 0 2 0
E7 1 0 0 1 1 0 0
F6 1 0 0 0 0 0 0
F8 1 0 1 0 0 5 0
G11 1 1 1 1 1 0 1
X1 4 1 0 0 0 0 0
H4 4 1 0 0 1 0 0
Non-clustered
A12 1 0 0 0 0 0 0
C10 1 0 0 0 0 0 0
D5 4 0 0 0 0 1 0
F10 4 0 0 0 0 0 1
Table S5: Count of TIMs in the six genes or intergenic regions associated with clustering across the 19 strains 
selected for functional validation studies.
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Chapter V
Gene Experimental findings
Rv0197  
codes for a possible 
oxidoreductase.
Contains the binding motif for molybdenum cofactor, a key component in TB pathogenesis.3
Upregulated during higB expression in M. tuberculosis H37Rv (important for bacterial survival under 
stress conditions encountered during infection).4 
espE 
codes for an ESX-1 
secretion-asociated 
protein.
Essential for survival of M. tuberculosis in C57BL/6J mouse macrophage.5 
Rv3616c, a homologue of espE is essential for in vivo survival of M. tuberculosis in C57BL/6J mice.6
Homologue of Rv3864 (espA) is an Esx-1 substrate required for virulence of M. tuberculosis in C57BL/6J 
and BALB/C-SCID mice.7
PE-PGRS33 
encodes a suface exposed 
protein.
Enhances survival of M. smegmatis and induces induces necrosis in macrophages  of C57BL/6 mice.8
PE-PGRS33 protein co-localises to the host mitochondria of T-Rex cell lines and induces apoptosis and 
necrosis.9
Variations in the polymorphic repeats of the PGRS domain of M. smegmatis attenuate the gene’s TNF-α 
inducing ability.10
PE-PGRS56 
no data on function
One of the 10 most dominant M. tuberculosis H37Rv proteins found within both 30- and 90-day infected 
guinea pig lung samples.11
Rv2813-14c 
not coding, intergenic 
region.
No published data.
Rv2815-2816c 
contains promotor to both 
Rv2814c and Rv2815c
Rv2815 is implied in induction of PI-measured cell death.12
Table S7: Summary of relevant experimental findings on the functions of the six TIMs.
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6.1 SYNTHESIS OF STUDIES
Many of the studies to date on M. tuberculosis (Mtb) transmission have focused on host risk factors. 
The study of different Mtb lineages have revealed measurable differences in virulence and immune 
responses and suggested differences in patient-to-patient transmissibility independent of host factors 
(Reiling et al. 2013; Sarkar et al. 2012; Krishnan et al. 2011). However, to date there has not been a 
systematic study of the genetic determinants of differences in transmissibility.
This thesis begins with the description of a novel method - the Propensity to Propagate (PPP) - to adjust 
for host risk factors when quantifying transmissibility, as described in Chapter 2. An overall scoring of 
host risk factors behind a cluster of strains (CPP) was found to not be equal across four phylogenetic 
lineages in the Netherlands. This finding emphasizes the importance of controlling for host-related 
factors in order to attain comparability in measuring the ability of difference strains/lineages of Mtb 
to propagate. Many studies on investigating the relationship between phylogenetic lineages and 
transmissibility actually do not control for host risk factors (Table 1). 
Applying the PPP method to the large database of molecular-typed strains in the Netherlands revealed 
no significant differences in average cluster size of four different phylogenetic lineages, which 
goes against our hypothesis that a bacterial factor, such as phylogenetic lineage, also accounts for 
differences in transmissibility. However, we did find evidence of phylogenetic lineages influencing more 
specific indices of transmissibility, namely, a decreased ability to infect and a lower secondary case 
rate in ancient phylogenetic lineages (M. africanum and EAI) compared to their modern counterparts 
(Euro-American, Beijing, and CAS). An indication that phylogenetic lineages may be more transmissible 
via different mechanisms (increased ability to enter the lungs of hosts versus an ability to more rapidly 
progress to disease) is relevant in that each calls for different control strategies. A more physical 
method such as quarantining, for example, might be more effective for strains known to be more 
infective, while a greater focus on starting adequate therapy as early as possible is crucial for strains 
known to progress faster to disease.
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A survey of the literature shows no real consensus to date regarding potential differences in ability 
to transmit by phylogenetic lineage. As Table 1 demonstrates, studies greatly vary by time span of 
sample collection, sample size, lineages compared (including which lineage was used as the reference) 
and which host risk factors were adjusted for. Even within the same country (Canada), three studies 
produce conflicting findings regarding the transmissibility of lineage 2 (Beijing), although they do agree 
on the lower transmissibility of lineage 1. In general, the geographically widespread lineage 2 (whose 
emergence is hypothetically linked to enhanced pathogenicity, leading to increased transmissibility and 
rapid progression from infection to active disease) (Buu et al. 2009; M. Hanekom et al. 2007) shows 
increased clustering in higher prevalence settings rather than in lower prevalence ones. The association 
between lineage 2 strains and drug resistance could account for this, as compensatory mutations have 
been associated with transmission of MDR Beijing genotype strains in China (Li et al. 2016). The lower 
clustering observed for lineage 1, as was also found in our study in Chapter 3, seems to span across 
both settings.
A first step towards discovering more specific genetic regions behind a particular phenotype involves 
checking for the absence/presence of mutations in the genes of interest between the two phenotypes. 
In Chapter 4, we looked at the frequency of frameshift-causing indels in Mycobacterium cyclase/LuxR-
like genes (mclxs) across different phylogenetic lineages and, using a regression-based model, their 
association with patient-, disease- and microorganism-related factors, including transmissibility. While 
this approach is justified when functional studies strongly support the role of particular regions/genes 
behind a phenotype of interest, its main shortcoming is that it does not control for phylogeny (that is, 
distinguishing between having the same phenotype due to the repeated and independent emergence of 
recent mutations versus due to a more deep-rooted sharing of a common ancestor). 
To disentangle adaptive loci from other mutations fixed in the clonal background, one can look for 
loci that have an excess of functional changes, such as the ratio of non-synonymous to synonymous 
mutations (dN:dS), or other metrics that explicitly measure deviations from the expected pattern of 
amino acid substitution (Shapiro et al. 2009). Evolutionary convergence analysis is a solution that 
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has been shown to be well suited for the study of clonal pathogens such as Mtb (Read & Massey 
2014; Guerra-Assuncao et al. 2015). In a perfectly clonal population, genomes are related by a single 
phylogenetic tree, rather than a more complicated network structure that represents recombination. 
Alleles that arise independently multiple times in different branches (and are, thus, incongruous 
with the tree) stand out as candidate examples of convergent evolution. Thus after adjustment for 
patient factors using the PPP method, we selected 100 bacterial samples that were either highly or 
poorly transmissible and subjected them to whole genome sequencing and evolutionary convergence 
analysis. We identified 6 bacterial DNA regions - espE, PE-PGRS33, PE-PGRS56, Rv0197, Rv2813-14c 
and Rv2815-16c - to be associated with Mtb transmission and validated these regions by studying the 
response of human white blood cells to extracts from a subset of the Mtb that carried or did not carry 
mutations in these DNA regions. 
It is interesting to note that the mutations associated to increased transmissibility described in 
Chapter 5, with the exception of those in Rv0197, were not observed in the successful lineage 2 
strains. Since differences in dissemination and virulence of ancient versus modern Beijing lineages 
have been documented (Ribeiro et al. 2014), it is imperative that future phylogenetic studies looking 
into transmission distinguish between the two sub-lineages. A larger study allowing for a stratification 
of the analysis by phylogenetic lineages would be needed in order to assess targets of independent 
mutation (TIMs) that are universal across lineages and those that are specific. Since it is postulated 
that phylogenetic lineages have resulted from adaptation to hosts of the particular geographic location 
where they circulate (Gagneux et al. 2006), it is conceivable that mutations conferring increased 
transmissibility could also be lineage-specific. Quite recently, the presence of non-synonymous SNPs 
in putative genes coding for DNA repair enzymes mutT2, mutT4, ogt (postulated to confer a mutator 
phenotype to facilitate spreading of the pathogen) were detected with variable percentages in all of 
modern lineage 2 sublineages, but absent in ancient ones (Chang et al. 2011).
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6.2 LIMITATIONS
The described PPP method in Chapter 2 for adjustment for host risk factors and designation of a CPP 
scoring per cluster only does so approximately. The future inclusion of additional epidemiological 
and clinical factors, such as degree of exposure to index case (Bailey et al. 2002; Marks et al. 2000), 
or presence of pulmonary cavitation in the host (Jones-López et al. 2014), can further improve the 
calculation of CPP and hence more accurately pinpoint those strains that are more transmissible 
due to bacterial factors. It is however theoretically impossible to fully control for a host’s propensity 
to propagate, since genetic factors and biomarkers for susceptibility and progression to disease are 
still actively being discovered and tend to be controversial (Minchella et al. 2015; Elliott et al. 2015; 
Jiang et al. 2015; Salem & Gros 2013). In addition, the highly skewed distribution of genotypic cluster 
sizes found in the Netherlands has been suggested as a sign of superspreading (Ypma et al. 2013). 
This heterogeneity in the number of secondary cases caused per infectious individual is currently not 
accounted for in the calculation of CPPs using the geometric mean of PPPs. As such, the existence of 
one superspreader with a particularly high PPP can offset the overall CPP scoring of a cluster composed 
of hosts with otherwise relatively low PPPs.
The challenge of identifying bacterial factors responsible for increased transmissibility also stems 
from the ambiguity in the definition and quantification of the “transmissibility” phenotype itself. Unlike 
with drug resistance, where the endpoint to be measured is clearly defined (i.e. minimum inhibitory 
concentrations), the widely used clustering rates from molecular typing can be calculated at different 
resolutions (i.e. in Wada et al., a VNTR cluster is defined as two or more isolates sharing 19 identical 
VNTR alleles, while in our study we used a stricter definition of all 24 identical VNTR alleles) (Wada et 
al. 2009; Nebenzahl-Guimaraes et al. 2015). The rough quantification of “transmissibility” can also be 
broken down into further specific components, such as the ability of the bacteria to spread (infectivity) 
followed by the likelihood of breaking down to disease in the host (pathogenicity, or virulence), as 
described in Chapter 3. How exactly the latter is related to transmissibility is yet unclear. More virulent 
strains could lead to large clusters if virulence was associated with increased transmission rates or 
increased rates of disease after host infection (Valway et al. 1998). However, more virulent strains 
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could have less opportunity to transmit if the severity of symptoms leads to early treatment or death, 
thus reducing the duration of the infectious period.
There is also no “gold standard” “non-transmissible” strain to compare more transmissible strains to 
because it is currently unknown how transmissible the reference strain selected for the study in chapter 
5 (H37Rv) really is. For example, in a rabbit inhalation model evaluated by Lurie’s Pulmonary Tubercle 
Count Method, H37Rv tubercles were found to be larger and contain more bacilli than a CDC1551 
strain, a clinical isolate reported to be hypervirulent and to grow faster than other isolates (Bishai et al. 
1999).
It should be noted that the methods to quantify tuberculin-skin test (TST) conversion and number of 
secondary cases following the index case as applied in Chapter 3 are influenced by programmatic 
factors, such as the thoroughness of contact investigations, and the underlying proportion of the 
population that is BCG vaccinated (Menzies 2000). Whilst stratifying by ethnicity can certainly help 
reduce the latter bias, even in the Netherlands where a solid TB control program is in place, there is 
still room for improvement for contact investigation in particular risk factor groups, such as immigrant 
patients (Mulder et al. 2011; Mulder et al. 2012).
6.3 IMPLICATIONS FOR FURTHER RESEARCH
The study findings support the following research priorities:
Conduct a prospective validation study on cohort transmission phenotypes
A prospective household contact study including TST conversion data, which would be far more 
accurate at ascertaining instances of transmission, is warranted to confirm our findings on differences 
in transmissibility across phylogenetic lineages. In terms of improving the transmissibility phenotype 
by adjusting for host risk factors, more data not only on index but also secondary cases would allow 
us to adjust for patient risk factors across the transmission chain i.e. rates of latent TB treatment and 
existing medical risk factors in secondary cases (Kumari & Meena 2014; Ayele et al. 2015), which could 
influence the likelihood of progression to disease or susceptibility to infection of the host, respectively. 
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Expand evolutionary convergence analysis
Our study applying evolutionary convergence analysis on a limited set of 100 WGS strains can be built 
upon in various ways. To begin with, we could easily increase the statistical leverage by improving the 
selection of strains to compare (for example, by pairing closely related strains) (Farhat et al. 2014). 
Targeted sequencing, using molecular inversion probe technology, of the identified candidate TIMs 
instead of WGS of entire strains would also allow for a larger sample size.
Given increased statistical power, the analysis could also be repeated looking at more specific 
phenotypic outcomes, such as either infectivity or pathogenicity i.e. comparing strains from patients 
with a high number of positive TST contacts to those with none, regardless of the final cluster size to 
which they belong to. In this way we would be able to identify SNPs/genes specifically related to the 
bacteria’s ability to spread (infectivity).
Initiate validation experiments using mutant strains and animal models
The in vitro studies on cytokine and neutrophil responses in Chapter 5 were performed merely to 
provide some independent biological support for molecular-epidemiological associations. Due to the 
co-occurrence of TIMs in the strains used for the immunological validation experiments, we could not 
definitely discern what genetic variation was responsible for which effect. Demonstrating a causal 
association between the genes and transmissibility would involve directly manipulating the bacteria 
i.e. creating knockouts of one (or more) of the putative TIMs in a fixed reference strain and measuring 
the outcome in phenotype, much in the same way as has been done in allelic exchange experiments of 
mutations conferring drug resistance (Appendix 1).
Another avenue through which to validate the candidate TIMs is via experiments in animal models. 
Several reports have demonstrated that the severity and clinical manifestations of TB depend on 
differences in the immunogenicity and pathogenicity of the infecting strains of Mtb (Manca et al. 2001; 
Dormans et al. 2004; López et al. 2003; Malik & Godfrey-Faussett 2005). Progressive pulmonary TB 
by the intratracheal route or aerosol inhalation in different mouse strains have been used to examine 
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the course of infection in terms of strain virulence (mouse survival, lung bacillary load, histopathology) 
and immune responses (cytokine expression determined by real-time PCR). A newer mouse model of 
transmissibility consisting of prolonged cohousing (up to 60 days) of infected and naıve animals has 
been used to assess the ability of strains to be transmitted, measuring lung bacillus loads of the naıve 
animal and cutaneous delayed type hypersensitivity (DTH) against mycobacterial antigens as markers 
of disease and transmission (Marquina-Castillo et al. 2009). In this study they reassuringly found 
that rapid death, higher bacterial loads, more tissue damage, immunological responses consistent 
with a Th2 response and transmission of infection to contact animals correlated with indicators of 
transmission in the community, such as size of cluster and TST reactivity or rapid progression to 
disease among household contacts. Guinea pigs have also often been used in studies on infectivity 
because they are highly susceptible to infection by human Mtb, more so than mice and rabbits and 
perhaps as much as AIDS patients; in addition, their immunological response seems to be more similar 
to that of humans than mice (Young 2009). The big limitation around these models is that none of 
these animals transmit TB efficiently, unlike bovine strains and other animal adapted strains (such as 
Mycobacterium microti in voles) that are transmitted in the wild (Dharmadhikari & Nardell 2008). Thus, 
a small-animal model that can be used to study TB transmission has yet to be developed.
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Background: Improving our understanding of the relationship between the genotype and the drug resistance
phenotype of Mycobacterium tuberculosis will aid the development of more accurate molecular diagnostics for
drug-resistant tuberculosis. Studies that use direct genetic manipulation to identify the mutations that cause
M. tuberculosis drug resistance are superior to associational studies in elucidating an individual mutation’s contri-
bution to the drug resistance phenotype.
Methods:We systematically reviewed the literature for publications reporting allelic exchange experiments in any
of the resistance-associated M. tuberculosis genes. We included studies that introduced single point mutations
using specialized linkage transduction or site-directed/in vitro mutagenesis and documented a change in the
resistance phenotype.
Results:Wesummarize evidence supporting the causal relationship of 54differentmutations in eight genes (katG,
inhA, kasA, embB, embC, rpoB, gyrAand gyrB) andone intergenic region (furA-katG)with resistance to isoniazid, the
rifamycins, ethambutol and fluoroquinolones.We observed a significant role for the strain genomic background in
modulating the resistance phenotype of 21 of these mutations and found examples of where the same drug
resistance mutations caused varying levels of resistance to different members of the same drug class.
Conclusions: This systematic review highlights thosemutations that have been shown to causally change pheno-
typic resistance inM. tuberculosis and brings attention to a notable lack of allelic exchange data for several of the
genes known to be associated with drug resistance.
Keywords: M. tuberculosis, microbial susceptibility tests, genetics, SNPs, in vitro resistance
Introduction
The 2012WHO report on global tuberculosis (TB) surveillance sug-
gests that only one in five patientswith drug-resistant TB are diag-
nosed and appropriately treated.1 Patientswith undiagnosed drug
resistance have higher morbidity andmortality than patients with
drug-susceptible disease, and may continue to spread drug-
resistant TB in their communities.2 The WHO has stated that a
major challenge for drug-resistant TB control is the lack of laboratory
capacity to diagnose resistance.1 Newer, molecular-based diagnos-
ticsdetectmutationsconferringdrugresistanceandofferadvantages
for the identificationof resistance inMycobacteriumtuberculosis (Mtb)
over traditional culture-based techniques, including a more rapid
turnaround time and a lower level of skill required to run the
tests.3–5 A thorough understanding of which mutations encode
drug resistance in Mtb will be helpful in focusing research aimed
atelucidating theunderlyingmechanismsof resistanceand in sup-
porting the development of more accurate molecular diagnostic
tests for patient care.
Epidemiological studies of Mtb drug resistance have largely
focused on the association of specific mutations with the drug
resistance phenotype, primarily through the comparison of
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resistance have higher morbidity andmortality than patients with
drug-susceptible disease, and may continue to spread drug-
resistant TB in their communities.2 The WHO has stated that a
major challenge for drug-resistant TB control is the lack of laboratory
capacity to diagnose resistance.1 Newer, molecular-based diagnos-
ticsdetectmutationsconferringdrugresistanceandofferadvantages
for the identificationof resistance inMycobacteriumtuberculosis (Mtb)
over traditional culture-based techniques, including a more rapid
turnaround time and a lower level of skill required to run the
tests.3–5 A thorough understanding of which mutations encode
drug resistance in Mtb will be helpful in focusing research aimed
atelucidating theunderlyingmechanismsof resistanceand in sup-
porting the development of more accurate molecular diagnostic
tests for patient care.
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Appendix
mutations in specific genes in resistant clinical strains with drug-
susceptible counterparts.6–8 This approach, however, cannot de-
finitively establish causality between the mutation and the
resistance phenotype. Studies using direct bacterial genetic ma-
nipulation to identify themutations that causeMtbdrug resistance
can better elucidate the individual mutation’s contribution to
the drug resistance phenotype and uncover whether additional
factors, likesynergy, strainbackgroundor interactionsbetweenmuta-
tions, modulate this relationship. The purpose of this systematic
review is to clarifymutation–phenotype relationships in Mtb by iden-
tifying whichmutations have been causally linked to Mtb drug resist-
anceand inwhatcontext thesecausalobservationshavebeenmade.
Methods
Definitions
Two types ofmutationwere included in this study: (i) non-synonymous nu-
cleotide substitutions, denoted by x#y, where x represents the wild-type
amino acid, # the codon number and y the variant amino acid; and (ii) non-
coding (ribosomal RNA, promoter, intergenic regions) nucleotide substitutions,
denoted by #xy, where # refers to the position relative to the start of the non-
coding region, x is thewild-type nucleotide base and y is the variant nucleotide
base. For phenotypemeasurements, we definedMICas the lowest concentra-
tionof drug that inhibits bacterial growthand IC50 as the concentrationof drug
required to inhibit supercoilingactivity by50%.Wedescribeamutation leading
to any increase in MIC as causative of resistance; mutations that increase the
MIC above the accepted critical concentration for medical diagnostic testing
is said to be causing clinical levels of resistance.9
Literature search
Using the search strategy described in Table 1, we identified peer-reviewed
primary research studies that reported the effect of creating specificmuta-
tions in resistance-associated genes on the drug resistance phenotypes of
Mtb strains.We searched thePubMedandEMBASEdatabases fromJanuary
1980 to June 2012, using combinations of the keywords listed in Table 1.
Bibliographies of articles selected for further review were hand-searched
andadditional references not previously identifiedwere addedas appropri-
ate. We performed full-text mining of keywords in search theme 4 ‘Intro-
duction of mutation’ on articles retrieved by PubMed and EMBASE using
search themes1–3. This additional stepwasundertaken to capture articles
that did not have these keywords in the title or abstract.
Study selection criteria
Methods to investigate phenotype causation have included (i) gene knock-
outs and complementation of the resulting null mutants; (ii) increasing
transcriptionof thegene, leading to itsoverexpression;and (iii) invitro selec-
tionofdrug-resistant clonesbyplating susceptible strainsonserial dilutions
of a drug.10–12While the formermethods shed light on whether the entire
gene is essential for resistance, spontaneous mutants with a resistance
phenotypemay include compensatorymutations. Allelic exchange techni-
ques, which introduce specific point mutations into a gene of interest, do
not have these limitations and directly define the causative role for muta-
tions in drug resistance, making it our method of choice for this review.
We included studies if they met the following criteria: (i) single point
mutations within a putative resistance gene were introduced into
Mtb strains using specialized linkage transduction or site-directed/in vitro
mutagenesis; and (ii) a change in the resistance phenotypewas documen-
ted. The resistance phenotypes were reported as MIC measurements
or IC50 results performed before and after the introduction of a
mutation. Researchers have demonstrated a quinolone structure–activity
relationship for the gyrA/B protein complex, in which inhibition of supercoil-
ing activity by 50% (IC50) correlates well (better than DNA cleavage) with
inhibition of Mtb growth by the fluoroquinolones (FQs).13 We included
studies thatused liquid-or solid-basedmedia fordrugsusceptibility testing.
We excluded manuscripts that (i) studied mycobacterial species other
than Mtb; (ii) created knockout or overexpression of a gene instead of a
single point mutation; (iii) did not specify the host strain used whenmeas-
uring the MIC effect; (iv) did not state how the unique transfer of the
intended point mutation was confirmed; or (v) did not have a phenotypic
result (MIC or IC50). We excluded in vitro selected mutations in order to
remove the potential effects of compensatory mutations.
Data extraction
Foreverystudy thatmetoureligibility criteria, twoof threeauthors (H.N.-G.,
K. R. J. and M. R. F.) independently reviewed the data and one additional
author (M. B. M.) adjudicated differences between the authors. From each
publication, the following information was extracted by two authors
(H. N.-G. and K. R. J.): authors; publication year; gene; amino acid and nu-
cleotide coordinates of themutation; host strain andmethodused to intro-
duce the mutation; method used to confirm introduction of the mutation;
resistance genotypic and phenotypic susceptibility methods; and pheno-
typic results. Additional details and clarifications were obtained via
personal correspondence by one of the authors (H. N.-G.).
Results
Of the 489publications thatwe identified, 444were excluded after
abstract review. We performed full-text reviews of the remaining
45 papers and excluded a further 25. We identified 433 more
papers through an additional text-mining step. Seventeen of these
were selected through titleandabstract review,but16wereexcluded
upon full-text review. In total, 21 articles were selected for inclusion
and final data extraction (Figure 1).
Isoniazid
We identified studies examining 11 different putative isoniazid re-
sistance mutations in four Mtb genes: katG, the furA-katG intergenic
region, inhA and kasA. Of these 11 mutations, 7 were shown to
confer resistance to isoniazid (Table 2). No two studies looked at the
same point mutation.
Mutations that caused isoniazid resistance
Pym et al.14 investigated two point mutations in katG using host
strain INH34, a clinical isolate with inherent up-regulation of
ahpC.15 The use of this strain ensured that any phenotypic differ-
ences detected among the INH34 transformants could not be
due to the emergenceof compensatorymutations in thepromoter
region of ahpC. Both katG S315Tand T275P caused isoniazid resist-
ance.Vilchezeetal.16 introducedmutationS94A into the inhAgene
of an H37Rv Mtb reference strain and found that it conferred a
.5-fold increase in resistance to both isoniazid and ethambutol.
Richardson et al.17 demonstrated that a katGW300GH37Rv trans-
formant caused a 1280-fold increase in isoniazid MIC, while Ando
et al.18 found that complementing mutations (27GA,210AC and
212GA) into a clinical isolate with a deleted furA-katG gene con-
ferred low-level isoniazid resistance (0.1–1 mg/L).
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Mutations that had no effect on isoniazid resistance
Pym et al.14 complemented a resistant furA-katG deletion Mtb
mutant with a katG gene carrying the A139V mutation and
found that it restored isoniazid susceptibility. This demonstrates
that A139V does not confer resistance in this strain. Vilcheze
et al.16 found that kasA G312S and F413L mutations in H37Rv
caused no detectable changes in isoniazid MIC. Ando et al.18
found that mutation C41T in furA resulted in no appreciable
change in MIC relative to the Mtb strain harbouring the wild-type
furA gene (Table 3).
Ethambutol
We identified six studies examining nine different putative etham-
butol resistance mutations in the gene embB. Four of these
Table 1. Search strategy to identify studies of mutations documented to confer resistance by evidence of genetic experiment
Search theme
1. organism 2. drug resistance 3. mutation
4. method of
introducing mutation
PubMed database
Medical Subject Headings
(MeSH) terms
1. ‘mycobacterium
tuberculosis’
1. ‘drug resistance’,
OR
1. ‘mutation’, OR NA
2. ‘microbial
sensitivity tests’
2. ‘amino acid
substitution’, OR
3. ‘mutagenesis,
site-directed’, OR
4. ‘codon’
text terms 1. ‘mycobacterium
tuberculosis’, OR
1. ‘resistance’, OR 1. ‘mutation*’, OR 1. ‘isogenic’, OR
2. ‘m tuberculosis’, OR 2. ‘mic’, OR 2. ‘mutagenesis’, OR 2. ‘engineered’, OR
3. ‘mtb’ 3. ‘inhibitory
concentration’, OR
3. ‘mutant*’, OR 3. ‘mutagenesis’, OR
4. ‘drug susceptibility’ 4. ‘nonsense’, OR 4. ‘recombinant’, OR
5. ‘missense’, OR 5. ‘site-directed’, OR
6. ‘frameshift’, OR 6. ‘allelic’, OR
7. ‘codon*’, OR 7. ‘transduction’, OR
8. ‘transduction’ 8. ‘wild-type’, OR
9. ‘induced’, OR
10. ‘introduced’
EMBASE
Emtree tool 1. ‘mycobacterium
tuberculosis’
1. ‘drug resistance’ 1. ‘mutation’, OR NA
2. ‘site-directed
mutagenesis’, OR
3. ‘amino acid
substitution’, OR
4. ‘codon’
text terms 1. ‘mycobacterium
tuberculosis’, OR
1. ‘resistance’, OR 1. ‘mutations*’ OR 1. ‘isogenic’, OR
2. ‘m tuberculosis’, OR 2. ‘mic’, OR 2. ‘mutagenesis’, OR 2. ‘engineered’, OR
3. ‘mtb’ 3. ‘mics’, OR 3. ‘mutant*’, OR 3. ‘mutagenesis’, OR
4. ‘inhibitory
concentration’, OR
4. ‘nonsense’, OR 4. ‘recombinant’, OR
5. ‘drug susceptibility’ 5. ‘missense’, OR 5. ‘site-directed’, OR
6. ‘dst’ 6. ‘frameshift’, OR 6. ‘allelic’, OR
7. ‘codon*’, OR 7. ‘linkage
transduction’, OR
8. ‘transduction’ 8. ‘wild-type’, OR
9. ‘induced’, OR
10. ‘introduced’
NA, not available.
Systematic review
3 of 12
JAC
126
Appendix
investigated the same three mutations [Met306Ile (ATA),
Met306Ile (ATC) and Met306Val]. We identified one additional
study that examined five putative ethambutol resistance muta-
tions in embC. All nine embB mutations and one embC mutation
were shown to confer resistance to ethambutol.
Mutations that caused ethambutol resistance
Two different clinical strains were chosen by Safi et al.19 as host
backgrounds for introducing embB gene mutations into codon
306: drug-susceptible 210 belonging to the W-Beijing family, the
embB sequence of which is identical to that of laboratory strain
H37Rv; and the ethambutol-resistant clinical isolate 5310 that
had been reverted back to wild-type embB sequence. Mutations
M306V, M306L, M306I (ATA) and M306I (ATC) all caused etham-
butol resistance (MIC.4 mg/L) when incorporated into wild-type
strain 210 and strain 5310.19
Starkset al.20 introduced theembBM306Vallele intoH37Rvand
Beijing F2, resulting in a 4-fold ethambutol MIC increase, while
M306I resulted in a 2-fold increase in both host strains. Plinke
et al.21 found a 4-fold increase in ethambutol MIC for mutations
M306V and M306I (ATA) and a 2-fold increase for mutation M306I
(ATC) when introduced into H37Rv. These, however, remained below
the critical clinical cut-off value. Goude et al.22 showed thatmutation
M70I introduced intoH37Rvpresentedasmall increase inethambutol
MIC (4 mg/L), insufficient to render it clinically resistant.
Safi et al.23 also looked at the role of commonmutations found
in clinical strains with high-level ethambutol resistance at the
embB 406 and 497 codons. They substituted the wild-type clinical
Mtb 210 strain embB G406 codon with G406A, G406D, G406C or
G406S, all of which led to ethambutol resistance. Replacing the
wild-type embB Q497 codon in strain 210 with the Q497R codon
also increased the ethambutol MIC (Table 2).
Mutations that potentiated susceptibility or had no effect
on ethambutol resistance
Goude et al.22 introducedapointmutationat the conservedaspar-
tateD294G that hadpreviously been shown toaffect theactivityof
embC inMycobacteriumsmegmatis todeterminewhethera similar
effect would be seen in Mtb. They found that D294G and a further
twomutations introduced into codon 300 of the embC arabinosyl-
transferase (M300LandM300V) increased susceptibility to etham-
butol. Mutation M300I had no resistance effect (Table 3).
Rifamycins
We identified four studies that examined five putative single rifa-
mycin resistance mutations and three double mutations in Mtb.
The most common rifamycin amino acid substitutions in clinical
strains (rpoB codons 531, 526 or 516) and two additional muta-
tions were shown to individually confer resistance to rifamycins.23
Mutations that caused resistance to rifamycins
Williams et al.24 investigated the causal relationship between spe-
cific amino acid changes and three rifamycins (rifampicin, rifapen-
tine and rifabutin) by incorporating mutations D516V, H526Y and
S531L into the rpoB gene of Mtb H37Rv. Mutant alleles S531L and
H526Y conferred high-level resistance to the three rifamycins
Partially relevant articles identified and
screened for retrieval (n = 922)
Potentially eligible articles (n = 62)
No abstract available (n = 2)
Reviews (n = 68)
Commentaries (n = 1)
Association studies (n = 125)
Immunology studies (n = 40)
Mathematical model /
    computational biology (n = 12)
Diagnostics (n = 173)
Vaccine / drug development (n = 29)
Molecular / structural /
    biomedical studies  (n = 160)
New methodologies (n = 32)
Deletion / KO / overexpression (n = 40)
Other species (n = 169)
Other endpoint (n = 11)
Resistance selected in vitro (n = 14)
Viability/growth studies (n = 17)
Excluded based on title / abstract
(n = 860)
Excluded upon full text review
(n = 41)
Association studies (n = 3)
Other species (n = 12)
Deletion / KO /
   overexpression (n = 7)
Host strain not specified (n = 1)
No method for confirming
   introduction of mutation (n = 2)
Other endpoints (n = 12)
DST / MICs not performed in
   standard / uniform way (n = 1)
Resistance selected in vitro (n = 3)
Eligible meta-analysis (n = 21)
Note: Papers may have been excluded on one or more
exclusion criteria.
Figure 1. Study selection process and reasons for exclusion of studies. KO,
knock-out.
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Table 2. Mutations shown to confer resistance to isoniazid, ethambutol or RIF
Drug Gene Host strain Substitution MIC (mg/L) Reference
Isoniazid katG INH34a WTb 0.1 Pym et al., 200214
S315T 5
T275P .10
H37Rv WT 0.1 Richardson et al., 200917
W300G 128
furA-katG intergenic
region
NCGM2836c WTb 0.1 Ando et al., 201118
G7A 0.4
A10C 0.4
G12A 0.15
inhA H37Rv WT 0.1 Vilcheze et al., 200616
S94A 0.5
Ethambutol embB 210d WT 2 Safi et al., 201023
G406S 6
G406A 7
G406D 7
G406C 7
Q497R 12
210d WT 2 Safi et al., 200819
M306I (ATA) 7
M306I (ATC) 7
M306L 8.5
M306V 14
5310e WT 3
M306I (ATA) 16
M306I (ATC) 16
M306L 20
M306V 28
H37Rv WT 1 Plinke et al., 201121
M306I (ATC) 2
M306I (ATA) 4
M306V 4
H37Rv WT 5 Starks et al., 200920
M306V 20
M306I (ATA) 10
Beijing F2 WT 5
M306V 20
M306I (ATA) 10
embC H37Rv WT 3 Goude et al., 200922
T270I 4
Rifampicin rpoB H37Rv WT 0.25 Williams et al., 199824
D516V 32
H526Y 64
S531L .64
WT ≤0.015f
H526Y 16f
S531L 16f
WT 0.03g
D516V 16g
H526Y 16g
S531L .64g
H37Ra WT 1.5 Zaczek et al., 200926
D516V 50
H526Y 25
Continued
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(Table 2). Clones containingmutation D516Vshowed resistance to
rifampicin and rifapentine but susceptibility to rifabutin. Gill and
Garcia25 also found that these threemutantalleles led toelevation
of IC50values for rifampicin, rifabutinandrifaximin. Theyfoundthat
the rifabutin IC50 was elevated less bymutations S531Land D516V
thanbyH526Y. Zaczeketal.26 exploredwhether thebackgroundMtb
strain affected the change in the rifampicin MIC. All strain
backgrounds (H37Ra, KL1936 and KL463) containing rpoB genes
withmutationsH526D,D516VorS531Lhadhigh-level rifampicin re-
sistance.
Noting that 5% of clinical strains with rifampicin resistance do
not have mutations in the 81 bp region of rpoB, Siu et al.27 aimed
to identify mutations located outside this rifampicin resistance-
determining region. They found that H37Ra transformants
Table 2. Continued
Drug Gene Host strain Substitution MIC (mg/L) Reference
S531L 50
S512I+D516G 6.2
Q513L 6.2
M515I+D516Y 6.2
D516Y 3.1
KL1936h WT 1.5
H526D 50
D516V 25
Q513L 12.5
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
M515I+D516Y 6.2
D516Y 6.2
KL463i WT 1.5
H526D 50
D516V 25
Q513L 50
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
M515I+D516Y 6.2
D516Y 3.1
H37Raj WT 1.5
H526D 50
D516V 25
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
Q513L 6.2
M515I+D516Y 6.2
D516Y 6.2
H37Ra WT ,0.1 Siu et al., 201127
S531L 64
V146F 64
I572F 8–16
WT, wild-type.
aDfurA-DkatG clinical isolate resistant to isoniazid and with inherent up-regulation of ahpC.
bComplemented with the wild-type katG gene.
cDfurA-DkatG clinical isolate resistant to isoniazid.
dDrug-susceptible clinical strain, member of the W-Beijing family.
eClinical isolate resistant to ethambutol.
fRifabutin.
gRifapentine.
hRifampicin-susceptible clinical strain containing PrpoB natural promoter.
iRifampicin-susceptible clinical strain.
jContaining a modified heat shock promoter (Phsp65).
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containingmutations S531Lor V146Fwere resistant to rifampicin.
Transformants containing mutation I572L had a rifampicin
MIC raised to 8–16 mg/L. Although V146F and I572L conferred
resistance, the authors noted that they are rarely seen in clinical
strains.
Zaczek et al.26 found that D516Yconferred low-level resistance
in strains KL453, KL1936 and H37Ra. The double mutations
Q510H+D516Y, S512I+D516G and M515I+D516Y all conferred
low-level resistance in these strains. Hence, the substitutions in
position 516 (D/Y; D/G), even when supported with Q510H, M515I
or S512I, did not result in a large increase in the rifampicin MIC.
The authors therefore concluded that a mutation D/Y or D/G at
516 is not sufficient to confer clinical rifampicin resistance in Mtb,
in contrast to D/V, which does confer clinical resistance.
Mutation(s) with an effect on resistance to rifamycins that
varied by host strain
Zaczek et al.26 found that mutation Q513L led to high-level rifam-
picin resistance in strain KL463, lower-level resistance in KL1936
and no significant increase in MIC in H37Ra (Table 2).
FQs
We identified nine articles that studied the causal relationship
between mutations in gyrA/B in Mtb and resistance to FQs. All
except one of these studies measured IC50 rather than MIC as
the resistance outcome. Not all FQs have the same effect on Mtb.
Ofloxacin and ciprofloxacin have bacteriostatic antimycobacterial
activity, whereas moxifloxacin shows high bactericidal activity.25
gyrA
Mutations that caused FQ resistance Onodera et al.28 found that
gyrAmutations A90Vand A90V+D94V greatly increased the IC50
of levofloxacin and ciprofloxacin compared with the wild-type
(Table 4). Aubry et al.29 reported that gyrAmutations A90V, D94G
and D94H led to increased IC50s of four FQs; in addition, mutation
A90V+D94G had an additive effect as a double mutant. Matrat
et al.30 found that transformants bearing gyrA G88A and G88C
were more resistant than wild-type gyrase to inhibition by FQs.
The increases in IC50 for G88C were higher than for G88A with
respect to gatifloxacin, levofloxacin and moxifloxacin and similar
for ofloxacin. Malik et al.31 reported that the A74S mutation
increased the MIC 2-fold to 4-fold for each FQ tested, which is
slightlyabove thecritical concentration.While the singleD94Gmu-
tation conferred resistance, the addition of A74S to D94G had a
synergistic effect, further increasing the MICs of all FQs tested by
2-fold to 8-fold over those for the single D94G mutation. Kim
et al.32 found that IC50 values of levofloxacin, ciprofloxacin and
gatifloxacin against DNA gyrase containing S95+D94G were
2-fold greater than those against DNA gyrase containing S95
with A74S+D94G, which was higher than the wild-type.
Mutations that increased susceptibility or had no effect on FQ
resistance Aubry et al.29 reported that gyrAmutations T80A and
T80A+A90G led to a reduced IC50; A90G alone did not affect the
FQ IC50 (Table S1, available as Supplementary data at JAC Online).
Malik et al.31 also found that the gyrA double mutation T80A+A90G
had no significant effect on MICs and actually decreased the MIC
for ofloxacin. Transformants with G247S and A384V, located outside
the gyrA quinolone resistance-determining region (QRDR), had
similar FQ MICs compared with negative controls.
Matrat et al.33 looked to identify theminimumnumberofmuta-
tions needed to increase FQ susceptibility in Mtb to levels similar to
those in Escherichia coli. An A83S mutation in gyrAwas sufficient
to decrease moxifloxacin IC50 to a susceptible range for E. coli. To
decrease the ofloxacin IC50 to a susceptible range similar to
E. coli, the A83Smutation had to be coupled with a second substi-
tution, either M74I in gyrA or R447K in gyrB. Modification of the
vicinity of A83 (residues 84 and 85) did not have any effect on FQ
susceptibility.
Kim et al.32 explored whether lineage-specific amino acid
residues affect FQ resistance. They conducted in vitro IC50
studies using recombinant DNA gyrase bearing an S95 residue
in gyrA. The wild-type (gyrA containing S95) and gyrA containing
A74S with the S95 demonstrated similar levels of in vitro FQ
susceptibility. The authors believed the reason that this muta-
tion did not show the higher FQ resistance described in previous
reports was because those earlier strains from China were
Table 3. Mutations shown not to confer resistance to isoniazid, ethambutol or rifampicin
Drug Gene Host strain Substitution MIC (mg/L) Reference
Isoniazid katG INH34a A139V 0.1 Pym et al., 200214
furA-katG intergenic region NCGM2836a C41T 0.1 Ando et al., 201118
kasA H37Rv G312S 0.1 Vilcheze et al., 200616
F413L 0.1
Ethambutol embC H37Rv M300L 0.5b Goude et al., 200922
M300I 3
M300V 0.5b
D294G 0.5b
Rifampicin rpoB H37Rv D516V ≤0.015c Williams et al., 199824
H37Ra Q510H+D516Y 1.5 Zaczek et al., 200926
aDfurA-DkatG clinical isolate resistant to isoniazid and with inherent up-regulation of ahpC.
bMutations shown to increase susceptibility to isoniazid, ethambutol or rifampicin.
cRifabutin.
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Beijing, which contains threonine at position 95, which may
already enhance resistance by altering interactions between
a4 and a3 helices.34,35
gyrB
MutationsthatcausedFQresistance Aubryetal.29 found that the
N510D mutation in gyrB led to an IC50 elevation (Table 4). Kim
et al.36 found that a gyrase bearing the E540Vamino acid substitu-
tion ingyrB,mimickingaclinical strain fromBangladesh,washighly
resistant to inhibition by four FQs. Pantel et al.37 reported that
D500A and N538T (located in the QRDR) and T539P (located
outside the QRDR) conferred low-level resistance, in contrast to
E540V (alsooutside theQRDR),which conferredhigher-level resist-
ance. In contrast to the findings of Kim et al.36 and Pantel et al.,37
Malik et al.31 found that the resistance pattern of the E540Vmuta-
tion was dependent on the genetic background of the mutated
strain. InH37Rv, E540Vconferred consistent susceptibility to cipro-
floxacin but conferred resistance to levofloxacin and ofloxacin and
low-level resistance to moxifloxacin. In the Erdman background,
E540V exhibited cross-resistance to all four FQs tested during one
round of testing but was susceptible to moxifloxacin on repeat
testing. In addition, Malik et al.31 found that transformants har-
bouring D500A had increased MICs for levofloxacin and ofloxacin
(at least 4-fold), which were still considered in the susceptible
range; theMICs for ciprofloxacin andmoxifloxacinwere unaffected.
Malik et al.31 report that transformants harbouring gyrB D500H
or D500N were resistant to levofloxacin and ofloxacin but suscep-
tible to ciprofloxacin and moxifloxacin. The N538D-containing
transformant exhibited resistance to all four FQs. The N538D+T546M
double mutation conferred resistance to all of the FQs tested
when introduced into Erdman but did not significantly increase the
MIC to a greater extent than N538D alone. The N538D+T546M
double mutation resulted in slightly different results in the H37Rv
genetic background, where it was resistant to ciprofloxacin, levo-
floxacin and moxifloxacin but susceptible to ofloxacin. Transfor-
mants carrying another variant at codon 538, N538T, plus T546M
were susceptible to all FQs tested. These data suggest that T546M
does not play a synergistic role in FQ resistance and N538T does
notconfer resistance. TheR485CandT539NgyrBmutationseach in-
dependently increased the MIC, but not to clinical resistance levels.
The T539Nmutation did confer low-level resistance tomoxifloxacin
in the Erdman strain. When introduced together into H37Rv, gyrB
R485C+T539N conferred resistance to ofloxacin, levofloxacin and
moxifloxacin; thesamedoublemutation inErdmanconferredresist-
ance toall four FQs tested.Basedon these results, R485CandT539N
individually increase the FQMIC slightly but in combination they act
synergistically to increasetheMICabovethecriticalconcentration to
confer clinical resistance.
Maliketal.31 found that theT539Pmutationalone increasedthe
levofloxacinMIC, but not above the critical concentration; thismu-
tation did not substantially affect the MIC for any other FQ. Both
A543TandA543V increased (2-fold to4-fold) theMICs for levofloxa-
cin, ciprofloxacinandofloxacinbuthadnoeffectonthemoxifloxacin
MIC. These were still below the accepted critical concentration for
clinical resistance. The N538K mutation exhibited low-level resist-
ance to moxifloxacin and increased the MICs (4-fold) of ciprofloxa-
cin, ofloxacin and levofloxacin, although these increases were not
sufficient to be considered resistant.
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Mutations that increased susceptibility or had no effect on FQ
resistance Pantel et al.38 studied eight substitutions in gyrB
(D473N, P478A, R485H, S486F, A506G, A547V, G551R and
G559A) and found that none of them was implicated in FQ resist-
ance (Table S1, available as Supplementary data at JAC Online).
Malik et al.31 found that gyrB M330I, V340L and T546M did not
confer resistance to any FQ tested. Transformants with D533A
werealsosusceptible toall four FQs. T546Mdidnotconfer FQ resist-
ance. Matrat et al.33 found that the R447K substitution conferred
increased susceptibility.
Discussion
In this systematic reviewwe identifiedpapers that introduceddrug
resistance-conferringmutations into eight genes (katG, inhA, kasA,
embB, embC, rpoB, gyrA and gyrB) and one intergenic region (furA-
katG).Within thesegenomic regions,25 individualmutationsplus3
doublemutations caused clinical resistance to first-line drugs, and
8 resulted in no change in inhibitory concentration. A further 18 in-
dividual mutations and 7 double mutations caused clinical resist-
ance to one or more FQs, with 26 individual mutations and 4
doublemutations conferring no change in FQ inhibitory concentra-
tions (Tables 2–4andTable S1, available as Supplementarydata at
JAC Online).
Several studies found thatmutations canhaveadifferent effect
onthedrugMIC,dependingonthebackgroundstrain intowhich it is
introduced. Forexample, the rpoBmutationQ513L led tohigh-level
resistance to rifampicin in strain KL463, lower-level resistance in
strain KL1936 and no significant increase in MIC in H37Ra. In
embB, mutation M306I (ATC) caused a moderately higher MIC in
strain 5310 compared with strain 210 and H37Rv. Similarly,
embB mutation M306I (ATA) resulted in varied levels of MIC:
7 mg/L in strain 210; 16 mg/L in strain 5310; 10 mg/L in a Beijing
F2 strain; and both 4 mg/L and 10 mg/L in two H37Rv-derived
strains in two different studies. Depending on what value is
chosen as the critical concentration cut-off, the latter H37Rv
could be considered ‘susceptible’ and the former ‘resistant’.9
Although all MICs consistently increased, such discrepancies
underline the limitations of the currently accepted critical concen-
tration cut-offs in determining clinical ‘resistance’, and suggest
that epistasis between the introduced mutations and other
genetic variation elsewhere in the genome plays an important
role in influencing the resistance phenotype. Mutation–mutation
interactions have been previously noted to influence the drug re-
sistance phenotype of other pathogens such as HIV.39 The obser-
vation of epistasis influencing the drug resistance phenotype in
Mtb challenges the reductionist view that one ‘correct’ mutation
is sufficient to result in resistance to aparticular drug, and supports
the more comprehensive study of additional genes in the Mtb
genome that canmodulate or contribute to the resistance pheno-
type in an alternative ‘multi-hit’ model.
This systematic review also demonstrates that the same drug
resistance mutations can cause varying levels of resistance to dif-
ferent members of the same drug class, For example, the D500H
mutation ingyrB led to resistance toearlier-generationFQs (ofloxa-
cin, levofloxacin) but notmoxifloxacin. Likewise, clones containing
the D516V mutation in rpoB showed resistance to rifampicin and
rifapentine but maintained susceptibility to rifabutin. This finding
is consistent with similar observations made in clinical strains
that exhibited rifampicin resistance with rifabutin susceptibility
by current cut-offs.40
It is possible that these observations may be overemphasized
by the current, arguably arbitrary, drug concentration cut-offs for
clinical resistance. However, the observation that in isogenic back-
grounds the same mutation leads to smaller increments in MIC
for some members of the same drug class, coupled with the
known higher pharmacological potency of some of these agents
seems likely to have treatment implications. To date, there are no
directclinicalorpharmacologicaldatatosupporttheclinicalefficacy
of treatingMtb resistant to onemember of the FQ or rifamycin drug
class with another member, but observations of improved treat-
ment outcomes for patients with extensively drug-resistant TB (by
definition resistant to a member of the FQ drug class) who were
treated with later-generation FQs (levofloxacin or moxifloxacin)
provide some indirect support for this notion.41–44 Evidence from
this review thus emphasizes the importance of further studying
FQs and alternative rifamycins to assess their clinical value in the
treatmentofMtbresistanttoothermembersof thesamedrugclass.
This systematic reviewhighlights somenotable lackofallelic ex-
change data for several of the genes known to be associated with
drug resistance. Notably, we found no studies that met our inclu-
sion criteria which studied pncA, rrs, inhA promoter region, or
ethAencoding resistance to thedrugspyrazinamide, streptomycin,
the aminoglycosides (amikacin, capreomycin, kanamycin) and
ethionamide. Even within the genes studied, only a subset of the
common mutations was studied in most cases. For example, we
found no report of allelic exchange experiments performed at
codon 91 of gyrA, or codons 446, 447, 461, 494, 501 and 504 of
gyrB, codons that have previously been associated with FQ resist-
ance in clinical strains.45,46
Rapid molecular assays for detecting drug resistance are cur-
rently limited, with GeneXpert (Cepheid) only testing for rifampicin
resistance, the sensitivity of the GenoType MTBDR test (Hain Life-
science) for the detection of isoniazid resistance reported to be in
the 80%–90% range47–49 and the GenoType MTBDRsl assay
showing a low level of performance for FQs, aminoglycosides and
ethambutol (reported sensitivities of 87%–89%, 21%–100%
and 39%–57%, respectively).50–53 Their accuracy is largely de-
pendent on the strength of the association between a specificmu-
tation and the resistance phenotype. These and further allelic
exchange studies may point towards recommendations for im-
proving the diagnostic accuracy of molecular-based resistance
assays, depending on their correlation with the frequency of
these mutations found in clinical strains. For example, including
embBmutations in codon 406, shown to increase the ethambutol
MICtoaclinicallysignificant level in this reviewandalsoobserved in
clinical isolates in India, Russia and the USA,54–56 could improve
the sensitivity for detecting resistance to ethambutol in those par-
ticular geographic settings. An updatable database on mutations
associated with resistance worldwide, such as TBDReaMDB, may
serve as a cross-check for the clinical relevance of including
newly identifiedmutations fromallelic exchange studies into diag-
nostic tests.46 Finally, the reviewed allelic exchange experiments
suggest thatmutationQ513L in rpoB, currentlyassayed in theGen-
eXpertpipeline,doesnot result inaconsistent increase in rifampicin
MIC, depending on the strain background genome. This may have
an impact on GeneXpert’s specificity.
It is critical to note that drug susceptibility testing, although the
gold standard, is not 100% accurate. A lack of concordance with
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resistance screening may therefore not necessarily imply that re-
sistance has been missed. It has been shown that in vitro data do
not necessarily correlate with in vivo data and vice versa. For
example, mutations leading to only slightly raised in vitro rifampi-
cin resistancemay indeed have clinical significance,57 whilemuta-
tions with dramatic in vitro effects may be unfit in vivo and hence
very rare in patient isolates.12Whole genomesequencingand con-
vergence analysis may be particularly useful in identifying poten-
tial mutations of interest requiring confirmation.58,59
This systematic review highlights the current understanding of
the causal relationships of different mutations on phenotypic re-
sistance in Mtb as studied via allelic exchange. Given increasing
reports of Mtb strains with higher levels of drug resistance world-
wide, this review provides new suggestions for drug resistance
diagnostics development and highlights some gaps in our knowl-
edge of genotype–phenotype relationships that are worth
further study.
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